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Chelsea Anderson: Noncancer mortality among adolescents and young adults with cancer 
(Under the direction of Hazel Nichols) 
 Background: As a result of cancer treatment-related exposures, cancer survivors may be 
at elevated risk for several noncancer conditions. We used data from the Surveillance, 
Epidemiology and End Results (SEER) program to examine patterns of noncancer mortality 
among adolescents and young adults (AYAs, ages 15-39 years) with cancer. Methods: In aim 1, 
we identified 235,542 patients diagnosed with cancer at ages 15-39 during 1973-2015 in the 
SEER 9 database. Rates of mortality from noncancer causes among AYAs with cancer were 
compared to rates in the general U.S. population using standardized mortality ratios (SMRs). In 
aim 2, we identified 242,940 women and 158,347 men diagnosed with AYA cancer during 1985-
2015 in the SEER 18 database. Multivariable-adjusted hazard ratios (HR) were used to examine 
disparities in mortality from all noncancer causes, cardiovascular diseases (CVD) and infectious 
diseases (ID) according to race/ethnicity, geographic region, and county-level socioeconomic 
characteristics; analyses were stratified by sex. Results: Aim 1: A total of 12,948 deaths from 
noncancer causes occurred over 3.1 million total person-years. Overall, noncancer mortality was 
significantly increased among AYAs with cancer relative to the general population (SMR=1.84; 
95% CI: 1.80-1.87). SMRs were particularly elevated for ID (SMR=5.13), CVD (SMR=1.55), 
and renal diseases (SMR=2.40). These associations persisted for more than 20 years after cancer 
diagnosis. Cancer types with the highest SMRs for all noncancer mortality included leukemias 
(SMR=5.26), Hodgkin lymphoma (SMR=3.12), non-Hodgkin lymphoma (SMR=6.33), central 
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nervous system tumors (SMR=3.38), head and neck cancers (SMR=2.09), and cervical/uterine 
cancers (SMR=2.03). Aim 2: All noncancer mortality was significantly increased among non-
Hispanic Black AYAs (HR vs non-Hispanic White: HRWomen=2.31; HRMen=2.17) and those in the 
South (HR vs. Northeast: HRWomen=1.18; HRMen=1.42) or in rural counties (HR vs metro: 
HRWomen=1.74; HRMen=1.57). Mortality from CVD (HRWomen=2.77; HRMen=2.44) and ID 
(HRWomen=5.24; HRMen=2.39) was also elevated among AYAs of Non-Hispanic Black 
race/ethnicity. Conclusions: AYAs with cancer have an elevated burden of mortality from 
noncancer causes that persists many years after cancer diagnosis, indicating the importance of 
comprehensive follow-up care for noncancer conditions throughout survivorship. Our analyses 
also highlight disparities among AYAs with cancer, and identify subgroups that may be targeted 
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CHAPTER 1. INTRODUCTION 
Adolescents and young adults (AYAs) with cancer represent an understudied patient 
group in the United States (U.S.), falling between the childhood and older adult cancer patients 
who are more often the focus of cancer survivorship research. The National Cancer Institute 
defines AYAs with cancer as those diagnosed between the ages of 15 and 39 years.[1] Though a 
heterogenous group within themselves, AYAs with cancer are distinguished from childhood and 
older adult cancer patients in their cancer type distribution, disease and host biology, patterns of 
treatment, and psychosocial and other patient characteristics,[2] all of which may contribute to a 
unique risk profile for both short- and long-term health outcomes among AYA cancer patients 
and survivors.   
A number of cancer treatments may increase risk of morbidity and mortality from 
noncancer causes among individuals with cancer relative to the general population. Perhaps most 
notoriously, many chemotherapeutic agents have immunosuppressive and/or cardiotoxic 
properties, predisposing patients to acute or chronic treatment-related complications from 
infection or heart disease. However, documented adverse effects of chemotherapy, as well as 
radiation and other anti-cancer therapies, are even more wide-ranging, with the potential to 
impact function of nearly all organ systems. While excess mortality from cardiovascular, 
infectious, and other noncancer causes has been well-studied in cancer patients diagnosed as 
children, there remains a paucity of evidence specific to those diagnosed as AYAs. For many 
AYAs, particularly those diagnosed at the older end of the age range, mortality estimates for 
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childhood cancer survivors are unlikely to adequately reflect their risk, making this a critical gap 
in the current evidence base. 
 The Surveillance, Epidemiology, and End Results (SEER) Program represents the largest 
source of population-based cancer information in the U.S. In addition to cancer incidence and 
cancer-specific mortality data, SEER registries also collect death certificate information to record 
noncancer causes of death among individuals with a cancer diagnosis. With active, long-term 
follow-up of patients diagnosed as early as 1973, the SEER database is the only existing data 
source in the U.S. with a sufficient sample size and length of follow-up to examine noncancer 
mortality among AYA cancer patients and survivors. This research utilized SEER data to 
compare mortality rates from noncancer causes between AYAs with cancer and the general 
population. Within the cohort of AYA cancer patients, we also estimated the cumulative 
incidence of noncancer mortality according to patient characteristics, with a focus on potential 
disparities related to race, sex, county-level socioeconomic indicators, rural-urban continuum, 
and geographic region. Ultimately this research may provide AYA-specific information on the 
risk of death from noncancer causes after a cancer diagnosis, and may aide patients and providers 





CHAPTER 2. REVIEW OF THE LITERATURE 
2.1. Background 
2.1.1. Descriptive epidemiology of cancer in AYAs 
More than 70,000 AYAs are diagnosed with invasive cancer each year in the U.S., 
representing about 4% of all new cases,[2] and approximately seven times as many diagnoses as 
in children younger than 15 years.[3, 4] In recent decades, overall cancer incidence in AYAs in 
the U.S. has been slowly increasing, though patterns vary by cancer type, and the increase 
overall is largely driven by recent increases in thyroid cancer diagnoses.[5] The most common 
cancer types diagnosed across the AYA age range differ markedly from those most commonly 
diagnosed among children and older adults. In AYAs, thyroid cancers are most common 
overall,[6] though leukemia and lymphoma are most frequent among 15-24 year-olds, and breast 
cancer and melanoma occur most often in 25-39 year-olds.[7] Testicular cancer and bone 
sarcomas, including osteosarcoma and Ewing sarcoma, peak in incidence among AYAs,[5] and 
thyroid cancer in females also starts to become more common in this age group.[7] In total, the 
incidence of cancer in AYAs is slightly higher among females than males,[2] largely due to 
breast and thyroid cancers at the upper end of the AYA age spectrum. Across racial/ethnic 
groups, cancer incidence in AYAs is highest in non-Hispanic whites, and lowest in American 
Indians/Alaska Natives.[1] 
Five-year relative survival among all AYAs diagnosed with cancer in the U.S. has been 
increasing steadily since the 1970s, from less than 70% among those diagnosed in 1975 to over 
80% in those diagnosed in 2008.[5] However, recent reports have indicated that these survival 
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gains in AYAs have lagged behind those observed in childhood and older adult cancer 
patients.[8] Among AYAs, there are notable differences in five-year relative survival across the 
more common cancer sites, ranging from approximately 56% among those with carcinomas of 
the gastrointestinal (GI) tract (70% for colon and rectum; <40% for stomach, pancreas, and liver) 
and 64% among those diagnosed with leukemia, to nearly 100% among those diagnosed with 
thyroid cancer.[9] Thus even for cancers with the poorest prognosis on average, many AYA 
patients will go on to survive at least five years beyond their original diagnosis. Consequently, 
the long-term health of AYA cancer survivors, including late effects of cancer treatment on 
noncancer morbidity and associated mortality, has become a priority area for research.  
2.1.2 Unique characteristics of the AYA cancer patient population 
AYAs have been defined as a distinct cancer patient population due to well-recognized 
differences from children and older adults in disease and host biology, patient characteristics and 
psychosocial aspects, and patterns of treatment. All of these factors have the potential to impact 
survival from both cancer and noncancer causes, supporting the study of long-term health 
outcomes in AYA cancer survivors as a group separate from childhood or older adult survivors. 
Disease and host biology 
It has been suggested that the slower progress in improving survival among AYAs with 
cancer relative to that in other age groups is partially attributable to a lack of appreciation for 
unique aspects of cancer biology in AYAs.[10] In addition to differences in the cancer type 
distribution compared to children and older adults, there may also be distinct biological features 
of AYA cancer within individual cancer types and within the host,[10] leading to distinct 
patterns of treatment, and potentially, distinct long-term health outcomes in survivors.  
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Noteworthy examples of cancers types with a potentially unique biology in AYAs 
include breast cancer, colorectal cancer, and acute lymphocytic leukemia. Breast cancers 
diagnosed among younger women, including AYAs, tend to be less-hormone sensitive, of a 
higher grade, and with greater lymph nodal involvement than those diagnosed among older 
women. Tumors lacking receptors for estrogen, progesterone, and HER2, known as triple-
negative tumors, are more common in younger women, and are associated with fewer treatment 
options and poorer prognosis than other tumor subtypes.[10-12] Other gene expression 
signatures, such as enriched growth factor signaling, are more common in younger women, when 
accounting for subtype distribution.[13, 14] Even within hormone-receptor positive tumor 
subtypes, younger women may have poorer survival than older women,[15] suggesting a more 
aggressive tumor biology. These differences contribute to the more aggressive treatment 
typically received by younger women, which may lead to different treatment-related sequelae 
and patterns of noncancer morbidity and mortality than those reported in older women. 
While the incidence of colorectal cancer in older adults has decreased in the past 20 
years, an increase in incidence has been observed in AYAs, with the obesity epidemic and lack 
of routine screening in younger adults likely contributing to this trend.[16] Distinguishing 
features of colorectal cancers in AYAs include microsatellite instability and a higher incidence 
of familial adenomatous polyposis and hereditary non-polyposis colon cancer, the heritable types 
of colorectal cancer. The non-inherited forms of sporadic colorectal cancer also tend to differ in 
AYAs, with a lower likelihood of KRAS mutations and other mutations more typically seen in 
older patients. The differences may affect the relative efficacy of specific anti-cancer therapies in 
younger patients compared to older adults.[10, 17] As described for breast cancer patients, the 
distinguishing characteristics of colorectal cancer biology in AYA patients may necessitate 
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different treatment strategies, which may in turn contribute to different long-term risk profiles for 
adverse late effects. 
Acute lymphocytic leukemia (ALL) is most common in children and AYAs, but may 
present with different biological characteristics in the two groups. Characteristics which are more 
common in AYAs, and associated with poorer prognosis, include L2 morphology, pro-T cell 
immunophenotype, the t(9,22) BCR-ABL translocation, and the Hox+ subtype. The TEL-AML1 
chromosomal translocation, associated with favorable prognosis,[18] is significantly less 
common in AYAs.[5, 10] On the other hand, certain growth-regulating kinase tumor suppressor 
genes are more methylated in adult patients than in children,[19] and a potential target for anti-
cancer drugs that act on hypermethylation sites. Newer therapies that are utilized more 
commonly in adults may have long-term health implications that differentiate AYA from 
childhood cancer patients. 
Along with these distinguishing features of cancer biology, various aspects of host 
biology may also distinguish AYAs from younger and older patient groups. Physiological 
changes, particularly those related to hormonal changes, are an important consideration in the 
treatment and outcomes of AYAs, with the potential to affect drug metabolism and clearance, 
toxicities, and treatment efficacy.[10] Other host biological differences, such as a higher 
prevalence of obesity in AYAs compared with younger patients, and changes in body 
composition, can also contribute to worse outcomes in AYAs,[20] including higher treatment-
related mortality.[21] In contrast, compared with older adults, AYAs have greater hematopoietic, 
renal, and hepatic capacity, and can therefore generally tolerate higher doses of therapies that 




Patterns of treatment 
 While children diagnosed with cancer in the U.S. are often treated in specialized pediatric 
cancer centers, AYAs are more likely to be treated in community-based settings than in 
academic centers, which can limit access to clinical trials and influence the treatment protocols 
used.[2, 22] For some cancers in AYAs, such as ALL and rhabdomyosarcoma, treatment with 
pediatric protocols has been associated with superior outcomes. For others, such as Hodgkin and 
non-Hodgkin lymphoma, the evidence does not suggest a benefit of pediatric over adult 
treatment protocols.[22] As noted previously, the distinctive biology of many cancers in AYAs 
may necessitate distinct treatment strategies from those used in other age groups. Consequently, 
it is critical that AYAs are seen by oncologists with specialized expertise and experience in 
treating cancers common in this age group. In general, AYAs have fewer comorbidities than 
older adult patients and can thus tolerate more intensive treatment regimens, and clinical 
guidelines from the National Comprehensive Cancer Network (NCCN) suggest that, though 
approaches will vary by diagnosis, most AYA without contraindications should be treated with 
aggressive therapy.[22] These aggressive treatment approaches may prove beneficial for 
improving survival from the original cancer diagnosis, but may also be associated with adverse 
early and late effects that contribute to mortality from noncancer causes.     
Patient characteristics and psychosocial aspects 
Individuals with cancer as AYAs may face special challenges related to insurance status 
and healthcare access, financial security before and after treatment, and the need for age-
appropriate mental health and supportive care services. Historically, health insurance rates are at 
their lowest during young adulthood,[23] and a lack of coverage may be especially concerning 
for individuals with a cancer history who require long-term medical surveillance. Among 
younger cancer survivors, a lack of health insurance has been associated with a lower likelihood 
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of receiving the recommended follow-up and survivorship care,[24-27] which may be critical for 
early detection of recurrences, second malignancies, and late effects of treatment. Being 
uninsured has also been associated with higher all-cause mortality in cancer patients diagnosed 
as AYAs.[28] Furthermore, findings from the Behavioral Risk Factor Surveillance System 
(BRFSS), a nationally representative survey, have suggested that, although the proportion 
uninsured may be similar between survivors of cancer and controls, cancer survivors in the AYA 
age group may be more likely to forgo medical care due to costs, even for those with health 
insurance.[29] This is likely attributable to greater care needs and the associated costs for 
individuals with a cancer history. It is unclear how recent healthcare legislation changes will 
affect care among young people with medical conditions such as a cancer diagnosis. However, it 
remains likely that loss of health insurance coverage, either through loss of employment or aging 
out of parents’ insurance, will be a critical issue for many young adults. For AYA cancer 
survivors, forgoing care due to costs, lack of insurance, or both, could negatively influence long-
term survival from both cancer and noncancer causes.  
In addition to insurance-related issues, AYAs with cancer may also experience greater 
concerns surrounding personal finances and employment. A cancer diagnosis and treatment can 
be an impediment in the transition to financial independence associated with young adulthood, 
presenting challenges in the pursuit of higher education and gainful employment. Those at the 
older end of the AYA age spectrum who have already established their career may face lost 
productivity if they become unable to work during or after cancer treatment, and cancer-related 
financial problems are reportedly more common among individuals diagnosed before age 40 than 
among those diagnosed at older ages.[30] Cancer-related financial problems have in turn been 
associated with a greater likelihood of delaying or forgoing medical care,[30] which may include 
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long-term surveillance for second cancer events and late effects of treatment. A 2012 online 
LIVESTRONG survey found that most AYA cancer patients had to take time off from work or 
school, switch to part-time work, or find a less demanding job, and many reported that their 
overall productivity at work was adversely affected by their cancer diagnosis.[3] Results from 
the 2009 BRFSS suggest that individuals with an AYA cancer history are more likely to be out 
of work or unable to work than their age-matched peers without a history of cancer.[31] Such 
interruptions or transitions in employment may strain personal finances, with the potential for 
long-lasting effects on health and well-being. 
Finally, having cancer as an AYA can be a major life stressor in other aspects of life, 
bringing with it the need for age-appropriate psychological and social support. Late adolescence 
and early adulthood are critical periods for establishment of personal identity and independence, 
which may be disrupted by the need to rely on others during cancer treatment and recovery.[32] 
Other possible life disruptions may include those related to peer relations, family dynamics, and 
self-esteem, as well as future plans.[3] Furthermore, emotional development may not yet be 
complete in some AYAs,[33] who may benefit from psychological services to learn adequate 
coping strategies. AYAs with cancer may also have unique information and service needs related 
to fertility, body-image, financial issues, and mental health, which may require additional 
intervention. Prior reports have shown that as many as two-thirds of AYAs have unmet 
information needs related to their cancer,[34, 35] and that greater unmet information need may 
be associated with poorer mental and physical health-related quality of life.[34] The life 
disruptions and unmet information needs that accompany an AYA cancer diagnosis may be 
barriers to receipt of recommended follow-up care,[36] and may continue to exert an influence 
on psychological and physical health in the years following treatment.  
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2.1.3. Potential adverse effects of cancer treatment in AYAs 
Established negative sequelae of cancer treatment include both short-term and long-term 
adverse effects, many of which may precipitate early death from noncancer causes. These effects 
include, among others, infectious, cardiovascular, pulmonary, renal, and gastrointestinal 
complications.[2] However, the preponderance of evidence to date on adverse effects has come 
from studies of cancer survivors diagnosed as children or older adults, rather than AYAs. For 
example, much of the evidence used to guide the assessment of long-term outcomes in AYAs 
comes from the reports from the Childhood Cancer Survivor Study (CCSS),[37] comprised of 
childhood and adolescent cancer survivors diagnosed before age 21. Given that age at treatment 
modifies the risk of several late effects,[22] there is a critical need to consider these outcomes 
among AYAs as a distinct group. A specific lack of evidence on long-term treatment-related 
effects in the AYA population has been noted in NCCN guidelines, particularly for cancers 
typically diagnosed at the upper end of the AYA age range.[22] The following sections describe 
possible adverse effects of cancer treatments on various organ systems that may be relevant for 
assessing noncancer mortality risk among AYAs with cancer.  
 Cardiovascular effects 
Though the precise incidence of any cardiac injury following cancer therapy remains 
unknown,[38] a number of modern cancer treatments have been linked to acute and/or chronic 
cardiotoxicities (Table 1). These toxicities range from asymptomatic, temporary left ventricular 
ejection fraction decline and electrocardiographic changes, to more serious conditions such as 
congestive heart failure.[39] Notably, the likelihood and severity of cardiotoxic effects after 
certain cancer therapies may be modified by age,[40] though little research has investigated long-
term cardiovascular outcomes specifically among AYA cancer survivors. 
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Systemic antineoplastic agents, including chemotherapeutic agents and molecular 
targeted therapies, can adversely impact cardiovascular function through either direct effects on 
the heart itself or peripheral effects on hemodynamics (i.e. hypertension or thrombotic 
events).[39] Metabolic abnormalities may also be an indirect effect of some systemic anticancer 
therapies, with a subsequent increase in risk for later cardiac events.[42] Anthracyclines, such as 
doxorubicin, epirubicin, and daunomycin, are the most common chemotherapeutic agents 
associated with cardiotoxicity. These drugs are often used in the treatment of several AYA 
cancers, including breast cancer, sarcomas, lymphomas, and leukemias, and are thought to act 
through direct damage to cardiac myocytes, leading to possible left ventricular dysfunction, 
Table 1.1 Cardiotoxicities associated with cancer therapies that may be used in AYA patients* 
Class Drugs Cardiac toxicity 
Associated cancer types 
common in AYAs 
Radiation -- 
Coronary artery disease, 
acute pericarditis, 
myocarditis, CHF, valvular 
disease, conduction disease 
Breast, cervix, colorectal, thyroid, 
leukemia, non-Hodgkin 
lymphoma, Hodgkin lymphoma 






Left ventricular dysfunction, 
CHF, pericarditis and/or 
myocarditis 
Leukemia, breast, Hodgkin 
lymphoma, Non-Hodgkin 
lymphoma, thyroid, soft tissue 
and bone sarcomas 
Taxanes Paclitaxel, Docetaxel 
Left ventricular dysfunction, 







Left ventricular dysfunction, 
CHF, thrombosis 















Left ventricular dysfunction, 
CHF, arterial thrombosis, 
angina, myocardial 
infarction, hypertension 
Breast, cervical, colorectal 






Left ventricular dysfunction, 




CHF: congestive heart failure 
*Adapted from refs [39-41] 
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congestive heart failure, pericarditis, or myocarditis.[42] Acute cardiotoxicity following 
anthracycline infusion is relatively rare (<1%) across age groups and is generally reversible.[39] 
Both early-onset (<1 year post-treatment) and late-onset (≥1 year post-treatment) chronic 
progressive anthracycline-induced cardiotoxicity are more common (~2-5% of patients) and are 
usually irreversible. Higher doses, co-administration with other cardiotoxic agents, pre-existing 
cardiovascular disease (CVD), and female sex are among the risk factors for cardiotoxicities 
caused by anthracyclines.[43, 44] Risk is also greater with increasing age, especially over 65 
years,[42] suggesting that studies of long-term cardiovascular outcomes among older adult 
patients may not adequately reflect the risk profile for individuals treated with anthracyclines as 
AYAs.  
Cyclophosphamide, an alkylating chemotherapeutic agent often used in the treatment of 
leukemia and breast cancer, has also been associated with acute toxicities such as left ventricular 
dysfunction[39] and congestive heart failure.[42] Cisplatin, another alkylating agent, has been 
linked to acute myocardial ischemia and diastolic heart failure in adults,[45] as well as in 
younger patients treated for testicular cancer,[46] a cancer type most common in AYAs. Other 
chemotherapy drugs which may be used in AYA patients and have been associated with 
cardiotoxicities include taxanes (e.g. paclitaxel), antimetabolites (e.g. 5-fluorouracil), and 
tyrosine kinase inhibitors (e.g. imatinib), with effects ranging from arrhythmias and left 
ventricular dysfunction to myocardial infarction, congestive heart failure, and sudden death.[39, 
42, 45] Finally, trastuzumab, a biologic therapy used to treat breast tumors that overexpress the 
cell surface receptor HER2, has also been shown to increase risk of left ventricular dysfunction 




 In addition to cardiovascular risk from systemic therapies, toxicities from chest radiation, 
often used to treat breast cancer or Hodgkin’s lymphoma, may include coronary artery disease, 
valvular disease, chronic pericardial disease, arrhythmias, cardiomyopathy, or carotid artery 
stenosis.[47, 48] Evidence also suggests a potential increased risk of stroke among those treated 
with radiation to the brain and/or neck.[48] Many of these effects may manifest long after 
treatment, with a latent period of up to 20 years until symptoms occur.[47] With modern 
radiation techniques, the incidence of cardiotoxicities is lower than that observed among patients 
treated in earlier eras.[47] 
Infectious complications 
Infections in cancer patients are a major cause of morbidity and mortality, often resulting 
from multiple complex factors which interact to cause disease. These factors may include 
treatment-induced immunosuppression, in addition to potential effects of the patient’s underlying 
immunodeficiencies and/or effects of the malignancy itself.[49-51] In patients with hematologic 
malignancies, the neoplasm can directly interfere with immune function as a consequence of its 
location within the immune system.[51] Similarly, in patients with solid malignancies, the 
location of the tumor itself may impede normal immune function, or may disrupt barriers that 
normally act to help prevent infection.[52]  
Cancer therapies that may increase risk of bacterial, fungal, parasitic, and/or viral 
infection include radiation, systemic therapies, and invasive procedures.[50] Extensive surgery, 
radiation therapy, and cytotoxic chemotherapies such as anthracyclines and 5-fluorouracil, for 
example, can weaken innate immunity by compromising anatomical barriers that are protective 
against most infectious agents. Chemotherapy, in particular, is also associated with bone marrow 
suppression and neutropenia, predisposing patients to potentially life-threatening infections.[50, 
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53, 54] For patients with solid tumors receiving conventional chemotherapies, the risk of serious 
infectious complications is fairly low. However, hematologic cancer patients are generally 
considered to be at higher risk, due to treatment protocols which tend to induce more extreme 
and protracted neutropenia.[55] While immune system function recovers in most patients by 6-
12 months after therapy, some may have infectious complications years later.[56-60] Those 
receiving allogenic hematopoietic stem cell transplantation are particularly at risk for infectious 
disease associated with chronic graft-versus-host disease and impaired immune 
reconstitution.[61] However, some evidence suggests that other therapies, such as total body 
irradiation, may also be associated with late morbidity and mortality from infectious causes.[62]  
Renal effects 
Several cancer therapies have been associated with renal impairment, increasing the risk 
of both acute toxicities and long-term dysfunction, and contributing to morbidity, reduced quality 
of life, and potentially even mortality. Adverse effects may include declines in glomerular 
filtration rate, tubular dysfunction, albuminuria, and hypertension.[63] Renal failure, though rare, 
may also result from exposure to cancer treatments. Among the more common causes of 
nephrotoxicity is treatment with alkylating agents such as ifosphamide and cisplatin, which may 
cause both glomerular and tubular damage.[64] While acute, subclinical manifestations of renal 
toxicities are often reversible, they may lead to more serious, persistent impairments in cases of 
more severe damage. In a study of children, adolescents, and young adult sarcoma patients 
treated with ifosphamide, more than one-fourth of all patients were found to have clinically 
significant nephrotoxicity up to 4 years after completing treatment.[65] Other studies have 
shown toxicities persisting up to 10 years after treatment with ifosphamide or platinum-based 
agents.[63, 66] In addition to these alkylating agents, other cancer treatments that may lead to 
acute and/or chronic nephrotoxicities include nitrosoureas, hematopoietic stem cell 
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transplantation, methotrexate, anti-infective drugs, immunosuppressive drugs, radiation to the 
kidneys, or nephrectomy.[64] 
Pulmonary effects 
 A number of studies have reported abnormal pulmonary function in children and adults 
with cancer, with effects observed acutely or several years after treatment completion. Lung 
injury following cancer treatment may involve the lung parenchyma, conducting airways, pleura, 
or pulmonary circulation,[64] depending on the treatment received. The most well-studied 
pulmonary effects are those induced by bleomycin, a chemotherapeutic agent, and mediastinal 
radiation. Bleomycin is often used to treat germ cell tumors and Hodgkin lymphoma, cancer 
types common in AYAs, and, depending on the patient population studied, the estimated 
incidence of bleomycin-induced pneumonitis is as high as 46%.[47] A minority of patients 
(<5%) may also develop pulmonary fibrosis following receipt of bleomycin, which may prove 
fatal in a small proportion of cases.[64] Mediastinal radiation may result in pneumonitis in 
patients treated for Hodgkin lymphoma or breast cancer, though it is less common in these 
patients than in those with lung cancer. Radiation-related pneumonitis usually occurs 1-3 months 
after completing therapy and is soon completely resolved, but in some cases it may develop into 
progressive pulmonary fibrosis at 6-24 months after treatment.[47] Patients with hematologic 
malignancies may also be subject to pulmonary complications following hematopoietic stem cell 
transplantation, with chronic dysfunction in the form of restrictive or obstructive lung 
disease.[64] 
Gastrointestinal and liver effects 
 Gastrointestinal toxicities are among the most common side effects reported by patients 
actively receiving antineoplastic therapy.[67] Some short-term effects, such as nausea and 
vomiting, are generally not life-threatening in themselves, and typically resolve soon after 
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treatment completion. However, others, such as diarrhea, can be severe enough to require 
hospitalization and, in some cases, may prove fatal.[67] In addition to acute effects, some 
therapies, particularly abdominal surgery and radiation, are also thought to have possible long-
term consequences for the gastrointestinal tract and the liver,[67] ranging from constipation, 
which may adversely impact quality of life,[68] to more severe conditions such as liver cirrhosis, 
which may contribute to mortality.[69] These late effects, and the potential for excess mortality 
from gastrointestinal and liver diseases, have not been well-studied among cancer survivors 
diagnosed as AYAs. 
2.2. Critical review of the literature 
The following sections summarize studies that have investigated excess morbidity and/or 
mortality from noncancer conditions among AYA cancer survivors, highlighting gaps in the 
current evidence base on noncancer mortality risk in this population. 
2.2.1. Cardiovascular outcomes 
Previous studies in the U.S., Canada, and Europe have reported an increased risk of CVD 
and its major risk factors among AYA cancer survivors compared to individuals without cancer, 
which is likely due, at least in part, to late effects of cardiotoxic cancer therapies. Self-reported 
data from the 2009 BRFSS suggested that, compared to age-matched respondents without a 
cancer history, those with a cancer diagnosis at ages 15-29 years had a higher prevalence of 
cardiovascular disease (14% vs 7%), hypertension (35% vs 29%), and diabetes (12% vs 9%).[31] 
Similarly, in a study of 5,673 two-year survivors of AYA cancer diagnosed between 1998 and 
2009 at Kaiser Permanente Southern California (KPSC), Chao et al. reported a greater than two-
fold risk of developing CVD relative to a comparison cohort of age-matched patients without 
cancer (incidence rate ratio [IRR]: 2.37; 95% CI: 1.93, 2.93).[70] For their study, CVD was 
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defined exclusively by clinical events, including myocardial infarction, congestive heart failure, 
and stroke. The excess risk was greatest among survivors of leukemia (IRR: 4.23; 95% CI: 1.73, 
10.31) and breast cancer (IRR: 3.63; 95% CI: 2.41, 5.47). AYA cancer survivors also had a 
higher incidence of diabetes (IRR: 1.48; 95% CI: 1.31, 1.66) and dyslipidemia (IRR: 1.17; 95% 
CI: 1.08, 1.27), but not hypertension, than the comparison group. The number of events was 
insufficient to report cancer site-specific estimates for sites other than breast, lymphoma, 
leukemia, melanoma, and thyroid, and relative risks for CVD-specific mortality for AYA cancer 
survivors versus the comparison group were not investigated. 
Recent studies from Denmark have similarly documented higher rates of hospitalization 
for cardiovascular disease among AYA cancer survivors identified from the national cancer 
registry compared to age-matched controls selected from a national population registry.[71, 72] 
Rugbjerg et al. reported a rate ratio (RR) of 1.30 (95% CI: 1.28, 1.33) for first hospitalization for 
cardiovascular disease for AYA cancer survivors versus comparisons, which corresponded to an 
absolute excess risk (AER) of 400 and 350 extra cases per 100,000 person-years among 
survivors for those with an age at discharge of 20 to 59 and 60 to 79 years, respectively.[72] In a 
separate report from Denmark, the hospitalization rate ratio for all diseases of the circulatory 
system, comparing five-year AYA cancer survivors to age-matched comparisons, was 1.28 (95% 
CI: 1.25, 1.31), and was of slightly greater magnitude among men (RR=1.34; 95% CI: 1.29, 
1.39) than among women (RR= 1.24; 95% CI: 1.21, 1.28). Subgroup analyses suggested that the 
rate ratio was greatest for AYAs diagnosed with Hodgkin lymphoma (RR=2.3; 95% CI: 2.1, 
2.5), corresponding to an AER of 1079 cases per 100,000 person-years.[71] As in the KPSC 
study,[70] these studies did not include estimates of cause-specific mortality, though they 
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suggest that the risk of life-threatening cardiovascular conditions, such as those requiring 
hospitalization, is elevated among AYA cancer survivors relative to individuals without cancer. 
In a study from Finland, Kero et al. compared rates of hospitalization for cardiovascular 
morbidities in five-year survivors of childhood and young adult cancers (diagnosed at ages 0-34 
years) with those of siblings.[73] In general, magnitudes of association were greater for those 
diagnosed at ages 0-19 years than for those diagnosed at ages 20-34 years. However, hazard 
ratios in the 20-34 year age group for survivors compared to siblings were significantly elevated 
for cardiomyopathy/cardiac insufficiency (HR=3.6; 95% CI: 2.8-4.6), atherosclerosis/brain 
vascular thrombosis (HR=1.7; 95% CI: 1.4-2.0), myocardial infarction/cardiac ischemia 
(HR=1.8; 95% CI: 1.5-2.1), and cardiac arrhythmia (HR=1.4; 95% CI: 1.2, 1.7). Though 
numbers were small within categories of cancer type, the excess of these outcomes seemed most 
pronounced among survivors of Hodgkin lymphoma, non-Hodgkin lymphoma, and testicular 
cancer. The differences in relative risk for those diagnosed at younger versus older ages in this 
study suggest the importance of quantifying long-term morbidity and mortality outcomes in 
AYA cancer survivors as a group distinct from childhood cancer survivors.  
A recent study from British Columbia focused on hospitalization rates for various 
morbidities among five-year AYA cancer survivors diagnosed between the ages of 20 and 24 
years from 1981 to 1999.[74] The most common cancer type in their sample was lymphoma, 
followed by carcinomas, melanoma, and germ cell tumors. Overall, the rate of hospitalization for 
diseases of the circulatory system among survivors was nearly twice that among age-matched 
controls (IRR= 1.90; 95% CI: 1.33, 2.72), with 4.1 and 2.1 events per 1000 person-years in 
survivors and controls, respectively.  
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Though lacking general population rates for comparison, Keegan et al. recently reported 
rates of CVD, defined as hospitalization or death from cardiovascular conditions, among 2-year 
AYA cancer survivors in California.[75] Cancer types with the highest cumulative incidence of 
CVD at 10 years post-diagnosis included central nervous system tumors (7.30%), acute 
lymphoid leukemia (6.85%), acute myeloid leukemia (6.84%), and non-Hodgkin lymphoma 
(4.12%). Other characteristics associated with higher CVD incidence included distant stage 
disease, receipt of chemotherapy or stem cell transplant, black race, low neighborhood 
socioeconomic status, and having either public or no health insurance, suggesting disparities in 
CVD outcomes among patients with an AYA cancer history.  
Studies of mortality from cardiovascular causes among AYA cancer survivors are more 
limited, and most have focused exclusively on deaths occurring at least 5 years after the initial 
cancer diagnosis. In the largest study to date, based in England and Wales, Henson et al. 
examined mortality from cardiac diseases among 200,945 five-year AYA cancer survivors 
diagnosed from 1971 to 2006 and followed through 2014.[76] For all cancer types and ages 
combined, the standardized mortality ratio (SMR) for all cardiac disease was 1.4 (95% CI: 1.3, 
1.4), corresponding to an absolute excess risk of 1.9 deaths per 10,000 person-years. The SMR 
was greatest for survivors diagnosed at ages 15 to 19 years, and for those diagnosed with 
Hodgkin lymphoma, acute myeloid leukemia, and genitourinary cancers other than bladder 
cancer. In a smaller study of 9,245 childhood and AYA cancer survivors in Finland, an excess of 
death from any circulatory disease was identified among survivors overall (SMR= 1.9; 95% CI: 
1.5-2.3), with a higher SMR for those diagnosed at ages 15 to 19 years (SMR=3.5; 95% CI: 2.0-
5.7) than at ages 0 to 14 (SMR= 2.7) or 20 to 34 years (SMR=1.6).[77] As in the study by 
Henson et al.,[76] the excess in circulatory disease deaths was greatest among patients with 
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Hodgkin lymphoma (SMR=6.6; 95% CI: 4.8-8.9), though the number of observed deaths was too 
small to produce stable estimates within strata of most other cancer types.[77] Kero et al. 
reported similar findings for excess cardiovascular disease deaths in another study of five-year 
childhood and AYA cancer survivors in Finland.[78] To our knowledge, no prior U.S.-based 
study has quantified the excess incidence of cardiovascular mortality among AYA survivors of 
all cancer types compared to the general population. 
2.2.2. Infectious disease outcomes 
Elevated rates of hospitalization for infectious and parasitic diseases among AYAs with 
cancer relative to age-matched noncancer controls have been reported in population-based 
studies from Denmark (RR=1.69; 95% CI: 1.61-1.77) and British Columbia (RR=1.98; 95% CI: 
1.14-3.43). However, studies of mortality from infectious causes in AYA cancer survivors are 
more limited. Among five-year cancer survivors in Finland, Kero et al. reported an SMR of 4.0 
(95% CI: 2.1-5.8) for infectious disease death for those diagnosed with cancer at ages 20-34 
years.[78] Though the number of deaths was small in each group, this estimate appeared to be of 
smaller magnitude than that observed among survivors diagnosed at ages 0-19 (SMR=10; 95% 
CI: 2.6-17.4), but similar to that reported in the U.S.-based Childhood Cancer Survivor Study for 
survivors diagnosed before age 21 (SMR=4.2; 95% CI: 3.2-5.4).[62] It is unclear how the SMR 
for infectious diseases for AYA cancer survivors in the U.S. would compare to estimates 
reported for U.S. childhood cancer survivors. To date, the only AYA-focused analysis of 
noncancer mortality using U.S. SEER data was restricted to survivors of bone and soft tissue 
sarcoma, and reported an SMR of 4.01 (95% CI: 2.57-5.96) for infectious disease death in this 




2.2.3. Renal outcomes 
A number of reports have documented renal effects in childhood cancer patients,[80-84] 
including an excess incidence of acute renal failure, chronic kidney disease, and other renal 
diseases.[82, 85] Studies investigating renal outcomes specifically among AYA cancer patients 
are less common, though patients ages 15-19 are often included in studies of late effects in 
childhood cancer. A study of renal and urinary outcomes in childhood cancer survivors in Nordic 
countries, which included patients with a maximum age at diagnosis of 19 years, found an 
elevated rate of first hospitalization for any glomerular diseases, renal tubule-interstitial diseases, 
acute renal failure, and chronic kidney disease in one-year survivors relative to a matched 
comparison group.[82] The magnitude of the rate ratio for any renal or urinary tract disease was 
the lowest, though still statistically significant, in the subgroup of patients aged 15 to 19 years at 
diagnosis (RR=2.1; 95% CI: 1.9-2.2). Cancer types associated with the greatest excess of 
hospitalizations for acute renal failure and/or chronic kidney disease included leukemia, 
lymphomas, malignant bone tumors, soft tissue sarcomas, and germ cell neoplasms, all cancers 
common in AYAs. Similarly, in a study using data from the Kaiser Permanente Southern 
California health plan, Chao et al. found a higher incidence of renal failure among childhood 
cancer survivors, with a maximum age at diagnosis of 18 years, than among age-matched 
controls (IRR=13.7; 95% CI: 3.3-57.6).[85] However, renal failure was a relatively rare outcome 
overall, with an incidence of only 1.3 per 1000 person-years in the cancer survivor group. The 
most common cancer types among patients included in this study were leukemia and 
lymphomas. 
Rates of hospitalization for any disease of the genitourinary system among AYA cancer 
survivors have been investigated in studies from Denmark[71] and Canada.[74] Rugbjerg et al. 
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reported a modestly elevated rate among five-year survivors in Denmark compared to matched 
controls (RR=1.28; 95% CI: 1.25-1.31), which was somewhat higher among men than among 
women. Among five-year AYA survivors diagnosed at ages 20-24 years in British Columbia, 
Zhang et al. also found an excess of hospitalization for genitourinary diseases relative to a 
matched comparison group (RR=1.34; 95% CI: 1.09-1.63).[74] The extent to which these 
estimates reflect hospitalization for kidney diseases, as opposed to other urinary tract conditions, 
is unclear, as is the extent to which estimates may have been influenced by bias due to increased 
surveillance among cancer survivors. However, taken together with reports from studies of 
childhood cancer survivors, these findings suggest that renal late effects severe enough to require 
hospitalization may be an important contributor to excess morbidity and mortality among AYA 
cancer survivors. 
2.2.4. Pulmonary outcomes 
In the study by Rugbjerg et al. from Denmark, rates of hospitalization for diseases of the 
respiratory system were significantly elevated among five-year AYA cancer survivors compared 
to a matched comparison group (RR=1.47; 95% CI: 1.43, 1.52).[71] The excess of 
hospitalizations for respiratory causes was most pronounced among survivors diagnosed with 
leukemia (RR=4.9; 95% CI: 4.0-6.0). Likewise, Zhang et al. reported a rate ratio of 1.71 (95% 
CI: 1.26, 2.31) for hospitalization for respiratory diseases for AYAs diagnosed at ages 20-24 in 
British Columbia relative to a matched noncancer cohort.[74] 
Few studies have evaluated respiratory mortality among AYA cancer survivors compared 
to individuals without a cancer history, though those that have are consistent with the findings 
for hospitalization noted above. In a study from Finland, a total of 15 deaths from respiratory 
causes were observed among 9,245 childhood and AYA cancer survivors over 147,446 person-
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years of follow-up, with 13 of these occurring among patients diagnosed at ages 20-34.[77] This 
corresponded to an SMR of 2.3 (95% CI: 1.3-3.8) overall, and 2.4 (95% CI: 1.3-4.1) in the 20-34 
year age group. The number of deaths was insufficient to produce stable estimates within strata 
defined by cancer type. A second report from Finland, with more recent years of follow-up, also 
found excess mortality from respiratory diseases among AYAs diagnosed at ages 20-34 
(SMR=1.7; 95% CI: 1.1-2.4).[78] Site-specific analyses were performed for central nervous 
system (CNS) tumors (SMR=5.5), Hodgkin lymphoma (SMR=6.6), and Non-Hodgkin 
lymphoma (SMR=5.0), though the numbers of observed deaths in each group were only 6, 10, 
and 4, respectively, and estimates were imprecise.  
Though limited by small sample sizes, these studies from Finland suggest that the excess 
of deaths from respiratory causes may be smaller in AYA cancer survivors than in childhood 
cancer survivors. In the U.S.-based Childhood Cancer Survivor Study, for example, Mertens et 
al. reported an SMR of 8.8 (95% CI: 6.8, 11.2) for deaths from pulmonary causes.[86] For those 
with diagnoses of Hodgkin or Non-Hodgkin lymphoma, SMRs were 10.8 and 9.1, respectively. 
To our knowledge, no study has evaluated SMRs for respiratory causes among AYA cancer 
survivors in the U.S., which may differ from Finland in background cause-specific mortality 
rates. Differences in respiratory mortality according to factors such as time since diagnosis have 
also not been examined. 
2.2.5. Gastrointestinal and liver outcomes 
 Studies of childhood cancer survivors, with patients as old as 19 or 20 years at diagnosis, 
have demonstrated an increased occurrence of gastrointestinal and liver conditions, or 
hospitalization for these conditions, among survivors compared to either siblings or the general 
population.[87, 88] In a report from the Childhood Cancer Survivor Study, Goldsby et al. 
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examined self-reported conditions of the liver and upper and lower gastrointestinal tract, and 
found that more than 40% of childhood cancer survivors had experienced one or more of these 
complications by 20 years after cancer treatment.[87] Though relatively uncommon overall, the 
rate of liver cirrhosis, beginning at 5 years post-diagnosis, was nearly 9 times as high in 
survivors as in cancer-free siblings (RR=8.9; 95% CI: 2.0-40.0). Rates of ulcers, esophageal 
disease, gallstones, intestinal polyps/diverticular disease, and colostomy/ileostomy were also 
significantly elevated among survivors. Abdominal radiation and surgery were associated with 
late-onset complications, as were high-dose alkylating agents and anthracyclines. Unexpectedly, 
older age at diagnosis (10+ years) was also a significant predictor of complications.  
Similarly, a registry-based study of childhood cancer survivors in Scandinavian countries, 
known as the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study, found an 
increased rate of hospitalization for any gastrointestinal or liver disease among one-year 
survivors of childhood and adolescent cancers compared to expected rates in the general 
population (RR=1.6; 95% CI: 1.6, 1.7).[88] The excess of hospitalizations was greatest in the 1 
to 4 years after cancer diagnosis, but remained significantly elevated at 20 years or more. 
Analyses of specific gastrointestinal and liver diseases suggested that hospitalizations for many 
of those with the greatest potential to affect mortality, including liver cirrhosis, viral hepatitis, 
intestinal obstruction, and ulcers, were all in excess among childhood and adolescent cancer 
survivors. However, neither ALiCCS or the U.S.-based Childhood Cancer Survivor Study have 
investigated whether mortality from gastrointestinal or liver conditions is also elevated among 
survivors compared to individuals without cancer, likely due to an insufficient number of deaths 
from these relatively rare causes. 
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Morbidity and mortality from gastrointestinal and liver diseases have not been well-
characterized among young adults with cancer. Rugbjerg et al. reported an increased rate of 
hospitalization for diseases of the digestive organs (RR=1.39; 95% CI: 1.35, 1.42) in five-year 
AYA cancer survivors compared to sex- and age-matched controls in Denmark.[71] Likewise, 
Zhang et al. found a modestly elevated rate of hospitalization for any digestive conditions among 
five-year AYAs survivors (diagnosed at ages 20-24) in British Columbia relative to a matched 
comparison group (RR=1.29; 95% CI: 1.07-1.56).[74] To date, mortality from gastrointestinal 
conditions such as liver disease and cirrhosis or ulcers has not been specifically examined in 
AYA cancer survivors compared to the general population. 
2.2.6. Mortality disparities among AYAs with cancer by race and socioeconomic status 
Studies of potential disparities among AYA cancer patients have generally restricted their 
analyses to cancer-specific and overall survival, with little investigation into deaths from specific 
noncancer causes. Notably, almost all prior AYA-specific studies of race- and socioeconomic 
status-related disparities have exclusively used data on patients diagnosed in California. In a 
report using data from the California Cancer Registry, DeRouen et al. examined overall survival 
among all AYAs diagnosed with a first invasive cancer from 2001-2011.[89] Independent of age, 
neighborhood socioeconomic status, and insurance status, Black AYAs with breast cancer, 
testicular cancer, Hodgkin lymphoma, leukemia, and cervical cancer experienced poorer overall 
survival than white AYAs with the same cancer type. Being in the lowest quintile of 
neighborhood socioeconomic status was also associated with shorter survival for AYAs with 
several cancer types, including breast cancer, lymphomas, and leukemia. The extent to which 
estimates were driven by deaths from cancer, relative to noncancer deaths, was not indicated. 
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Others have investigated survival disparities in studies focused on specific cancer types. 
Among AYAs diagnosed with Hodgkin lymphoma in California from 1988-2011, Keegan et al. 
reported significantly lower overall survival for Black patients compared to white patients 
(HR=1.40; 95% CI: 1.14-1.71), with slightly greater than half of all deaths in both groups due to 
Hodgkin lymphoma.[90] Likewise, AYAs in the lowest, compared to the highest, quintile of 
neighborhood socioeconomic status, had an HR or 1.88 (95% CI: 1.53-2.30) for death from all 
causes. These associations largely persisted in analyses stratified by disease stage. In a separate 
report, Keegan et al. examined disparities in survival among AYAs diagnosed with differentiated 
(papillary or follicular) thyroid cancer in California between 1988 and 2010.[91] While 
race/ethnicity was not strongly associated with overall survival, those in the two lowest quintiles 
of neighborhood socioeconomic status had significantly poorer survival than those in the highest 
three quintiles (HR=1.85; 95% CI: 1.48-2.31). Male gender was also strongly associated with 
poorer overall survival (HR=2.68; 95% CI: 2.14-3.34). The authors indicated that patterns were 
similar in analyses of noncancer-specific survival, though associations with specific causes of 
noncancer deaths were not reported. Elevated all-cause mortality among Black compared to 
White AYAs identified in the California Cancer Registry has also been reported in studies 
specific to testicular cancer patients (HR=1.41; 95% CI: 1.01-1.97)[92] and female breast cancer 
patients (HR=1.45; 95% CI: 1.31-1.61).[93] In contrast, Chao et al. did not find significant 
differences in all-cause mortality for Black versus White race among AYAs with Non-Hodgkin 
lymphoma diagnosed at Kaiser Permanente Southern California during 1990-2010, though 
results suggested an increase in mortality for Asians/Pacific Islanders and individuals with the 
lowest neighborhood incomes.[94]  
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 Despite the overall paucity of research addressing disparities in noncancer mortality 
among AYAs, there is some evidence to suggest that, among U.S. childhood and AYA cancer 
survivors, mortality from cardiovascular disease may differ significantly according to race. 
Berkman et al. identified cases diagnosed from 1973 to 2011 at ages 0-34 years in the SEER 
registries, and estimated hazard ratios (HR) for death from cardiovascular causes for blacks 
compared to whites.[95] For all cancers types combined, the HR for cardiovascular disease death 
was 2.13 (95% CI: 1.85, 2.46), though this varied somewhat by cancer type. In the subgroup of 
those aged 15-34 years at diagnosis, the magnitude of this association was smaller and non-
significant, though imprecise (HR=1.33; 95% CI: 0.60, 2.95). Individuals diagnosed at ages 35-
39 were not included, and estimates of race-specific incidence of cardiovascular disease 
mortality were not reported. 
2.3. Summary of literature review 
 Though numerous studies have examined noncancer health outcomes among long-term 
survivors of childhood cancers, little research has evaluated such outcomes among patients 
diagnosed as AYAs. To date, the few AYA-specific investigations of mortality from noncancer 
causes after cancer have been based almost exclusively in Northern European countries, with 
sample sizes too small to adequately examine mortality from noncancer causes other than 
cardiovascular disease, or to consider variability according to cancer type and other patients 
characteristics. Additionally, limited research has investigated potential disparities in noncancer 
outcomes after AYA cancer, an important consideration for the diverse patient population 
diagnosed and treated in the U.S. Thus for patients and physicians planning follow up care after 
initial treatment, and for AYAs across various phases of survivorship, there remains a need for 
AYA-specific research that examines long-term patterns of mortality from causes other than 
28 
 
cancer, especially from causes other than cardiovascular disease, and that investigates potential 





CHAPTER 3. AIMS 
 Each year, more than 70,000 adolescents and young adults (AYAs) ages 15-39 are 
diagnosed with cancer in the United States. Over the past three decades, 5-year relative survival 
among AYAs has steadily increased, and currently stands at over 80% for all sites combined.[2] 
These gains are largely attributable to advances in cancer treatments, which, while extending 
survival from the original cancer diagnosis, may also contribute to future morbidity and mortality 
from noncancer causes.  
 Previous population-based studies have documented higher mortality from infectious 
diseases, cardiovascular diseases, and suicide among individuals with a cancer diagnosis 
compared with the general population.[96, 97] However, most investigations of noncancer 
mortality have focused on individuals diagnosed as children or older adults. To date, little 
research has investigated long-term mortality, including noncancer causes of death, specifically 
in the AYA cancer population, despite increasingly widespread recognition of the unique 
characteristics and needs of AYAs with cancer.[22] AYA patients are known to differ from 
childhood and adult cancer patients with respect to cancer type distribution, underlying disease 
biology, treatment setting, treatment protocols and dose intensity, and personal characteristics 
such as psychosocial development, insurance status and healthcare access,[2, 5, 22] all factors 
which may contribute to subsequent risk of mortality from causes other than the original cancer 
diagnosis. Clinical practice guidelines from the National Comprehensive Cancer Network have 
specifically acknowledged a lack of evidence on long-term adverse effects following AYA 
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cancers, particularly for those typically diagnosed at the upper end of the AYA age range (e.g. 
breast cancer).[22]   
 This research investigated mortality from noncancer causes among AYA cancer patients 
diagnosed during 1973-2015 and included in the Surveillance, Epidemiology, and End Results 
(SEER) database. Noncancer causes of deaths in SEER were ascertained from death certificates 
and categorized into 25 groups, which included, among others, diseases of the heart, 
cerebrovascular disease, suicide and self-inflicted injury, pneumonia and influenza, and other 
infectious and parasitic diseases. The specific aims were:  
Aim 1: To examine mortality from noncancer causes among AYA cancer patients 
compared to the general population. We estimated SMRs for all noncancer causes combined 
and for cause-specific categories, both overall and in subgroups defined by cancer type, stage, 
age at diagnosis and time since diagnosis.  
We hypothesized that noncancer mortality would be significantly elevated among AYA patients, 
particularly for infectious disease mortality and cardiovascular disease mortality. 
Aim 2: To examine characteristics associated with noncancer mortality within the AYA 
cancer patient population. Using competing risk methods, we estimated the 5-, 10-, and 20- 
year cumulative incidence of all noncancer mortality, cardiovascular disease mortality, and 
infectious disease mortality, both overall and according to cancer type and other patient 
characteristics. We also estimated hazard ratios for all noncancer mortality, cardiovascular 
mortality, and infectious disease mortality among AYA cancer patients, with a focus on 
disparities related to race/ethnicity, county-level socioeconomic status indicators, rural-urban 
continuum, and geographic region.  
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We hypothesized that greater noncancer mortality would be associated with non-Hispanic Black 






CHAPTER 4. METHODS 
4.1. Data source 
The Surveillance, Epidemiology, and End Results (SEER) program, funded by the 
National Cancer Institute (NCI) since 1973, is a system of population-based cancer registries that 
collects and publishes data on cancer incidence and survival in the U.S. Since the 1970’s, the 
SEER program has expanded from its original 9 registries (SEER 9) to the 20 registries included 
today (SEER 18). These registries are located strategically across the country and cover 
approximately 35% of the total U.S. population. SEER areas are demographically representative 
of the entire U.S., and include 32% of whites, 30% of African Americans, 44% of Hispanics, 
49% of American Indian/Alaska Natives, 57% of Asians, and 69% of Native Hawaiian/Pacific 
Islanders.[98]  
 Patient information collected by SEER registries includes patient demographic 
information, primary tumor site and morphology, stage at diagnosis, and first course of 
treatment. SEER also conducts follow-up for patient vital status, and reports survival and 
mortality data, including cause of death. Quality control activities are conducted on a continual 
basis by staff from NCI and each the SEER registries and by external contractors to standardize 
the coding of patient data, evaluate the accuracy and consistency of data coding, and other 




4.2. Aim 1  
4.2.1. Study population 
 
For Aim 1 analyses, we used SEER*Stat (version 8.3.5)[100] to identify all patients in 
the SEER 9 database with a first primary malignancy diagnosed at ages 15 to 39 years between 
January 1, 1973 and December 31, 2015. We selected only cases with a known patient age and a 
neoplasm with malignant behavior. Death certificate and autopsy only cases were excluded, as 
were those for whom the state death certificate was not available, or was available but did not 
have cause of death information. We also excluded patients with Kaposi sarcoma because high 
rates of infectious disease mortality associated with this cancer type were expected to inflate 
overall estimates of noncancer mortality among AYAs with cancer relative to the general 
population. Because general population mortality rates are not produced for individuals of 
unknown race, AYA cancer patients with unknown race (~1% of all patients[101]) were 
excluded for analyses in Aim 1.  
4.2.2. Key variables 
 SEER defines variables for the major cancer site groups using the International 
Classification of Diseases for Oncology 3rd Edition (ICD-O-3) primary site and histology codes 
submitted by the registries. A variable adapted specifically for cancers in AYAs is also available 
in the SEER database, with cancer sites recoded based on a classification scheme from Barr et al. 
(AYA Site Recode/WHO 2008; Appendix 1).[102] We utilized this classification scheme to 
define all cancer types, with the exception of those that do not have their own AYA-specific 
recode (e.g. testicular cancer), which were defined according to the regular site recode ICD-O-
3/WHO 2008.  
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 Cause of death information in SEER is ascertained from death certificates. Using ICD 
versions 8-10 (depending on the year of death), SEER defines noncancer causes of death using 
25 categories (Table 4.1; Appendix 2).[103] These categories have been consistently defined 
over time and include, ‘Diseases of the Heart,’ ‘Septicemia,’ ‘Pneumonia and Influenza,’ and 
‘Suicide and Self-Inflicted Injury,’ and other noncancer causes listed among the leading causes 
of death in the U.S.[104] SEER also defines deaths from in situ, benign, or unknown behavior 
neoplasms as a separate category of noncancer deaths.[103] However, for our analyses in Aims 1 
and 2, we did not include these deaths in our definition of ‘all noncancer deaths.’ 
Table 4.1 Noncancer causes of death in SEER 
Category Causes of Death ICD-10 codes 
Infectious diseases 
Tuberculosis, syphilis, HIV, septicemia, 
pneumonia and influenza, other 
infectious and parasitic diseases 
A15-A19, A50-A53, B20-B24, 
A40-A41, J09-J18, A00-A08, 
A20-A33, A35-A39, A42-A49, 
A54-B19, B25-B99 
Cardiovascular diseases 
Diseases of heart, hypertension without 
heart disease, cerebrovascular disease, 
atherosclerosis, aortic aneurysm and 
dissection, other diseases of arteries, 
arterioles, capillaries 
I00-I09, I11, I13, I20-I51, I10, 
I12, I60-I69, I70, I71, I72-I78 
Respiratory Chronic obstructive pulmonary disease and allied conditions J40-J47 
Gastrointestinal and liver Stomach and duodenal ulcers, chronic liver disease and cirrhosis K25-K28, K70, K73-K74 
Renal Nephritis, nephrotic syndrome, and nephrosis N00-N07, N17-N19, N25-N27 
External causes 
Accidents and adverse effects, suicide 
and self-inflicted injury, homicide and 
legal intervention 
V01-X59, Y85-Y86, U03, 
X60-X84, Y87.0, U01-U02, 
X85-Y09, Y35, Y87.1, Y89.0 
Other  All other noncancer causes of death   -- 
*In situ, benign or unknown behavior neoplasm 
D00-D48 
*Was not included in our definition of noncancer mortality 
Table adapted from ref [103] 
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4.2.3. Statistical analysis 
 
 All analyses in Aim 1 were conducted using SEER*Stat.[100] For noncancer causes of 
death available in SEER, we estimated standardized mortality ratios (SMR) comparing the 
number of observed deaths among AYAs with cancer to that expected in the general population 
with the same distribution of age, sex, and race over the same time period. General population 
mortality rates available in SEER were obtained from the Centers for Disease Control and 
Prevention’s National Center for Health Statistics. Within SEER*Stat, the number of expected 
deaths was calculated as the product of the general population mortality rate for each cause of 
death and the person-time at risk in the AYA cancer patient sample. For all calculations, we 
allowed a 2-month latency exclusion period. This was the default setting in SEER*Stat and 
represented the number of months after cancer diagnosis during which person-time at-risk and 
potential events of interest were ignored. Thus person-time was accrued from two months after 
the date of cancer diagnosis until death, the date of last contact, or December 2015, whichever 
occurred first. The 95% confidence intervals for SMRs were estimated using exact methods. We 
also reported absolute excess risks (AER), calculated as the difference between the observed and 
expected deaths, divided by the total person-years of observation. These were multiplied by 
10,000 to yield the number of excess deaths per 10,000 person-years. SMRs and AERs were 
estimated for all noncancer causes of death combined, for each of the 25 individual noncancer 
causes of death, and for cause-specific categories defined as infectious, cardiovascular, 
respiratory, gastrointestinal and liver, renal, external, and other causes, as shown in abbreviated 
form in Table 4.1, and in full in Appendix 2.  
 In subgroup analyses, we estimated SMRs and AERs according to cancer site, age at 
diagnosis (15-19, 20-24, 25-29, 30-34, 35-39) and time since diagnosis (< 1 year, 1- <5 years, 5- 
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<10 years, 10-<20 years, 20+ years). For the 12 most common cancer types (Table 4.2), we also 
conducted site-specific analyses, according to age at diagnosis, cancer stage, and time since 
diagnosis. Stage was categorized using Ann Arbor staging (I, II, III, IV; diagnosis years 1983+) 
for lymphomas and SEER Historic Stage A (localized, regional, distant) for most other 
malignancies. Analyses according to stage could not be performed for leukemias and central 
nervous system tumors due to lack of a consistently defined stage variable over the entirety of 
the study period. 
 In sensitivity analyses, we considered latency exclusion periods of 0 months (i.e. person-
time begins at diagnosis) or 6 months, to assess the sensitivity of results to varying the start of 
follow-up for noncancer deaths. We also 
conducted sensitivity analyses to assess the 
potential influence of varying degrees of 
cause of death misclassification on SMR 
estimates. For example, for all noncancer 
deaths combined, we re-estimated SMRs 
assuming that 10% (or 20% or 30%) of 
observed deaths were actually attributable to 
cancer, but were misclassified as noncancer 
deaths.  
4.3. Aim 2 
4.3.1. Study population 
In Aim 2, we used SEER*Stat to identify all patients in the SEER 18 registries with a 
first primary cancer at ages 15-39 years during 1985-2015, selecting only those with a known 
Table 4.2 Cancers examined in site-specific analyses, 




Central nervous system tumors 
Soft tissue sarcomas* 
Melanoma 
Thyroid carcinoma 





*Excludes Kaposi sarcoma 
**Defined using Site recode ICD-O-3/WHO 2008 
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patient age and a neoplasm with malignant behavior. Patients diagnosed prior to 1985 were 
excluded to facilitate analyses of county-level socioeconomic characteristics, which were only 
reported for selected years (see section 4.3.2). As in Aim 1, we excluded patients with Kaposi 
sarcoma, unknown race, death certificate and autopsy only cases, and those for whom the state 
death certificate was not available, or was available but did not have cause of death information. 
4.3.2. Key variables 
 Person-time of follow-up for each patient was calculated from the date of diagnosis to 
either the date of last contact or the date of death in the SEER database. This variable is recorded 
in SEER in months, rather than days, due to confidentiality issues regarding the reporting of days 
in some U.S. registries. 
 SEER registries do not collect individual-level information on education, income, or 
other socioeconomic characteristics. However, county-level information, based on data from the 
U.S. Census Bureau,[105, 106] is linked to patient data by state-county Federal Information 
Processing Standards (FIPS) codes and is available in the SEER database. For our analyses, we 
focused on two county attributes: percent of persons below poverty and percent of persons with 
less than a high school education. In SEER, these variables are currently defined from the 
decennial census for the years 1990 and 2000,[106] and from the American Community Survey 
(ACS) for the years 2007-2015.[107] The ACS is conducted each year by U.S. Census Bureau, 
and five-year estimates for demographic and social characteristics for U.S. counties are 
published and accessible through SEER.[107] Within SEER*Stat, we accessed census data on 
percent of persons below poverty and percent of persons with less than a high school education 
for all U.S. counties for 1990 (decennial census), 2000 (decennial census), and 2008-2012 (ACS) 
to create quartile cut points. We then assigned quartile values for each county attribute variable 
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using 1990 cut points for patients diagnosed during 1985-1994, using 2000 cut points for patients 
diagnosed during 1995-2004, and using 2008-2012 cut points for patients diagnosed during 
2005-2015.     
 We also performed analyses according to the county’s rural-urban continuum code, a 
classification scheme which was developed by the U.S. Department of Agriculture[108] and is 
also linked to 
patient data within 
the SEER database. 
These variables 
have been defined 
for each county for 
the years 1974, 
1983, 1993, 2003, 
and 2013.  For our 
analyses, we used rural-urban designations for the years 2003 and 2013. Although coding 
schemes are available for earlier years, as listed above, they are not fully comparable with those 
of 2003 and 2013, due to changes in the definitions of metro vs nonmetro areas,[108] and cannot 
be used together in the same analysis. Therefore analyses according to rural-urban continuum 
were restricted to patients diagnosed in 1998 and later, so that a maximum of 5 years was 
allowed between cancer diagnosis and the year for which the rural-urban continuum code was 
defined. We used the rural-urban continuum variable from 2003 for patients diagnosed during 
1998-2007, and from 2013 for patients diagnosed during 2008-2015. The 2003 and 2013 coding 
schemes assign counties to one of nine categories, which range from metro counties with a 




1 Counties in metro areas of 1 million or more 
Metro 2 Counties in metro areas of 250,000 to 1 million 
3 Counties in metro areas of fewer than 250,000 
4 Urban population of 20,000 or more, adjacent to metro area 
Urban 5 Urban population of 20,000 or more, not adjacent to metro area 
6 Urban population of 2,500 to 19,999, adjacent to metro area 
7 Urban population of 2,500 to 19,999, not adjacent to metro area 
Rural 8 
Completely rural or less than 2,500 urban population, adjacent 
to metro area 
9 Completely rural or less than 2,500 urban population, not adjacent to metro area 
88,99 Unknown   
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population of one million or more, to nonmetro counties that are not adjacent to a metro area and 
have a population of less than 2,500.[108] We redefined categories as metro, urban, and rural, a 
recategorization scheme which has been used in previous SEER analyses (Table 4.3).[109]  
 Disparities were also evaluated according to geographic region. We categorized SEER 
registries into West, South, Northeast, and Midwest, as shown in Table 4.4.[110] Due to small 
numbers of patients in the Alaska Native and Hawaii registries, we excluded these registries 
from analyses according to region. 
 
4.3.3. Statistical analysis 
 All analyses in Aim 2 were stratified by sex to accommodate adjustment for cancer type, 
including male-only and female-only cancers as separate categories, in statistical models. Cause-
specific hazard ratios for all noncancer deaths, cardiovascular disease deaths, and infectious 
disease deaths (see Appendix 2) according to race, county-level socioeconomic characteristics, 
rural-urban continuum, and geographic region were estimated using Cox proportional hazards 
regression models. For individuals with 0 months of survival, we assigned a survival time of 0.5 
months for consistency with previous literature.[111] The proportional hazards assumption was 
assessed through visual inspection of plots of the survival function versus time, and the log(-
log(survival)) versus log(time). Multivariable models accounted for age at diagnosis, cancer 
type, year of diagnosis, and race, covariates that were determined a priori and are available 
Table 4.4. Geographic regions defined using SEER registries 
Region  SEER registries 
West San-Francisco-Oakland; San-Jose Monterey; Los Angeles; Greater California; 
New Mexico; Seattle/Puget Sound; Utah 
South Atlanta; Rural Georgia; Greater Georgia; Kentucky; Louisiana 
Northeast Connecticut; New Jersey 
Midwest Detroit; Iowa 
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through SEER. We also estimated the cumulative incidence of deaths from all noncancer causes, 
cardiovascular diseases, and infectious diseases at 5, 10, and 20 years using nonparametric 
methods to account for death from other causes as a competing risk,[112] among all AYA 
patients and according to cancer type, race, and other patient characteristics. Analyses were 






CHAPTER 5. NONCANCER MORTALITY AMONG ADOLESCENTS AND YOUNG 
ADULTS WITH CANCER 
5.1 Background 
 Each year, more than 70,000 adolescents and young adults (AYAs, ages 15-39 years) are 
diagnosed with cancer in the U.S.[113] Though a heterogeneous group, AYAs with cancer have 
been increasingly recognized as a distinct patient subpopulation, differing from childhood and 
older adult cancer patients in cancer type distribution, underlying disease biology, and treatment 
protocols.[5] Despite the unique characteristics associated with cancers in this age group, few 
studies have examined long-term health outcomes among patients diagnosed as AYAs. 
 Five-year relative survival among AYAs with cancer has steadily increased over the past 
few decades, and currently stands at >80% for all invasive cancers combined.[8] Among patients 
diagnosed at young ages, improvements in survival are largely attributable to recent advances in 
cancer treatments, which, while preventing death from the primary cancer, may increase risk of 
future morbidity and mortality from noncancer causes. The cardiotoxic and/or 
immunosuppressive effects of many chemotherapeutic agents are perhaps most well-known, and 
may predispose patients to treatment-related complications from heart disease or infection. 
However, documented adverse effects of anti-cancer therapies are even more wide-ranging, with 
the potential to impact short- and/or long-term function of nearly all organ systems.[4] Recent 
evidence suggests that AYAs with cancer continue to have a small, but statistically significant 
excess of all-cause mortality relative to the general population even after surviving 20 years 
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beyond diagnosis,[114] but the extent to which deaths from causes other than cancer may 
contribute has rarely been examined.[76-78] 
 The objective of this study was to compare rates of mortality from noncancer causes 
among AYA cancer patients with those in the general U.S. population using nationally 
representative cancer registry data.  
5.2 Methods 
5.2.1 Data source 
 We identified AYA patients using data from the Surveillance, Epidemiology, and End 
Results (SEER) program,[98]  a system of population-based cancer registries that collects and 
reports data on cancer incidence and survival in the U.S. Patient information collected by SEER 
includes demographic information, primary tumor site and morphology, stage, and first course of 
treatment. SEER also conducts active follow-up for patient vital status and reports the number of 
months survived since cancer diagnosis and the cause of death as ascertained from death 
certificates. U.S. general population mortality rates from the National Center for Health Statistics 
are accessible through the SEER program.  
5.2.2 Study population 
 For this study, we used data from the original SEER 9 registries,[115] and included 
patients with a first malignant primary diagnosed at ages 15 to 39 years between 1973 and 2015 
(N=249,021). Because general population mortality rates for comparison are not available for 
individuals without a known race, we excluded patients with unknown race (N=3,053). Death 
certificate and autopsy only cases were excluded (N=3), as were patients for whom the death 
certificate was either not available or was available without cause of death information 
(N=2,693). We further excluded patients with Kaposi sarcoma (N=7,631) due to its strong 
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association with HIV infection,[116] and the likelihood of high infectious disease mortality rates 
within this group. We categorized cancer type using an AYA-specific recode of International 
Classification of Diseases for Oncology 3rd Edition (ICD-O-3) primary site and histology 
codes.[117] 
5.2.3 Noncancer causes of death 
 SEER recodes ICD 8-10 codes from death certificates and categorizes deaths from 
noncancer causes in 26 major groups.[103] These groups have been defined consistently over 
time and include many of the leading causes of death in the U.S., such as ‘Diseases of the Heart,’ 
‘Pneumonia and Influenza,’ and ‘Suicide and Self-Inflicted Injury.” We further consolidated 
these groups into 7 broad categories of infectious diseases, cardiovascular diseases (CVD), 
respiratory diseases, gastrointestinal and liver diseases, renal diseases, external causes, and other 
causes, as shown in Appendix 2. Although SEER also includes deaths from ‘In situ, benign or 
unknown behavior neoplasm’ among its 26 groups of noncancer deaths,[103] we did not 
consider these deaths as noncancer deaths for our analyses. 
5.2.4 Statistical analysis 
 We estimated standardized mortality ratios (SMRs) as the number of observed deaths 
from noncancer causes among AYAs with cancer divided by the number expected in the general 
population with the same distribution of age, sex, race, and calendar year. The number of 
expected deaths was calculated as the product of the general population mortality rate for each 
cause of noncancer death and the person-time at risk in the AYA cancer patient cohort. For all 
SMR calculations, we allowed a 2-month latency exclusion period, during which person-time at 
risk and deaths were ignored. Thus person-time among AYAs with cancer was accrued from two 
months after the date of cancer diagnosis until death, date of last contact, or December 2015, 
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whichever occurred first. Exact methods were used to calculate 95% confidence intervals (CI) 
for all SMRs. We also estimated absolute excess risks (AER), calculated as the difference 
between observed and expected noncancer deaths, divided by the total person-years of 
observation, and reported as the number of excess deaths per 10,000 person-years. 
 In subgroup analyses, SMRs were estimated according to cancer type, age at diagnosis, 
and time since diagnosis. For selected cancers, we also performed cancer type-specific analyses, 
and estimated SMRs according to age at diagnosis, time since diagnosis and disease stage. Ann 
Arbor staging was used for lymphomas (diagnosed in 1983 and later), and SEER Historic Stage 
A, a summary staging measure, was used for most other cancer types.[118] We did not conduct 
analyses according to stage for central nervous system (CNS) tumors or leukemias, due to lack of 
a consistently defined stage variable across the study period in SEER. We also re-estimated 
SMRs excluding patients with non-Hodgkin lymphoma (NHL), to further reduce the influence of 
HIV-related deaths on estimates among all AYAs with cancer combined. All analyses were 
performed using SEER*Stat, version 8.3.5.[119]  
 In sensitivity analyses, we considered latency exclusion periods of 0 and 6 months, rather 
than 2 months, for estimation of SMRs among AYAs of all cancer types combined. We also 
conducted a sensitivity analysis to assess the potential influence of cause of death 
misclassification on SMR estimates. This was done by re-estimating SMRs under the assumption 
that a specified proportion (10%, 20%, or 30%) of observed noncancer deaths from a particular 
cause had been misattributed. 
5.3 Results 
 
 Among 235,641 AYAs with cancer included in these analyses, a total of 12,948 deaths 
from noncancer causes were observed over approximately 3.1 million total person-years of 
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follow-up (Table 5.1). The majority of included AYAs were female (60%), diagnosed at ages 30-
39 years (65%), and diagnosed between 1993 and 2015 (60%). Overall, noncancer mortality 
among AYA cancer survivors was 1.84 (95% CI: 1.80-1.87) times that in the general U.S. 
population, reflecting an excess of approximately 19 noncancer deaths per 10,000 person-years 
among survivors (Table 5.2). SMRs were particularly elevated for the cause-specific categories 
of infectious diseases (SMR=5.13; 95% CI: 4.95-5.32), cardiovascular diseases (SMR=1.55; 
95% CI: 1.50-1.60), renal diseases (SMR=2.40; 95% CI: 2.12-2.71), and other causes 
(SMR=2.06; 95% CI: 2.00-2.13), but were also weakly elevated for respiratory diseases (SMR= 
1.16; 95% CI: 1.05-1.28) and external causes (SMR= 1.08; 95% CI: 1.03-1.13). When AYAs 
with NHL (N=14,209 patients, N=2,212 noncancer deaths) were excluded, SMRs for all 
noncancer deaths (SMR=1.60) and infectious disease deaths (SMR=2.74) were attenuated but 
still elevated among AYA cancer survivors. SMRs for other broad cause of death categories 
were not substantially changed when NHL patients were excluded (data not shown). 
5.3.1 All noncancer mortality  
 For all noncancer causes combined, mortality was significantly increased relative to the 
general population for AYAs with every cancer type we evaluated, other than thyroid cancer and 
melanoma, with the highest SMRs among those with NHL (SMR=6.33), leukemias (SMR=5.26), 
CNS tumors (SMR=3.38), and Hodgkin lymphoma (HL) (SMR=3.12) (Table 5.3). AYAs with 
thyroid cancer (SMR=0.81) and melanoma (SMR=0.65) had significantly lower noncancer 
mortality than the general population. Among AYAs of all cancer types combined, SMRs for all 
noncancer mortality decreased with increasing age at diagnosis, from 2.63 among those aged 15-
19 to 1.67 among those aged 35-39, and with increasing time since diagnosis, from 10.30 within 
the first year to 1.34 at 20+ years post-diagnosis. SMRs for all noncancer mortality also tended to 
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be higher among AYAs with a more advanced disease stage, but were significantly elevated even 
for those with localized disease for soft tissue sarcomas, head and neck cancers, cervical/uterine 
cancers, and colon and rectal cancers, and for those with stage I HL or NHL (Table 5.5).  
5.3.2 Cardiovascular disease mortality 
 The highest SMRs for cardiovascular disease mortality were observed for AYAs with HL 
(SMR=4.44), CNS tumors (SMR=3.32), and leukemias (SMR=3.06), followed by those with 
NHL (SMR=2.05), cervical/uterine cancers (SMR=1.83), and head and neck cancers 
(SMR=1.80). SMRs were also significantly elevated for those with breast cancer (SMR=1.38) 
and colon and rectal cancers (SMR=1.35) (Table 5.3). There was a clear trend of decreasing 
SMRs with increasing age at diagnosis overall (Table 5.3), and among AYAs with NHL, HL, 
and breast cancer (Table 5.9). SMRs for cardiovascular diseases also decreased with increasing 
time since diagnosis for most cancer types, although an increase at 10+ years post-diagnosis was 
apparent for AYAs with HL and CNS tumors (Table 5.7).  
5.3.3 Infectious disease mortality 
 Mortality from infectious diseases was significantly elevated among AYAs with all 
cancer types examined other than melanoma and thyroid cancer (Table 5.3). SMRs were highest 
among those with NHL (SMR=47.71) and leukemias (SMR=16.06). There was little evidence of 
a trend in SMRs according to age at diagnosis, except for a suggested decrease with increasing 
age among patients with leukemias (Table 5.9). Overall, SMRs declined sharply with time since 
diagnosis, from 67.49 within the first year of diagnosis, to 1.61 at 20+ years post-diagnosis 
(Table 5.3), but remained significantly elevated at 20+ years overall and for patients with 
leukemias, NHL, HL, CNS tumors, and cervical/uterine cancers (Table 5.7).  
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5.3.4 Mortality from other noncancer causes 
 Though the number of observed deaths was small, AYAs with leukemias had the highest 
SMRs among all cancer types examined for respiratory diseases (SMR=4.69), gastrointestinal 
and liver diseases (SMR=4.06), renal diseases (SMR=10.25), and other causes of death 
(SMR=9.89) (Tables 5.3, 5.4). SMRs for respiratory diseases were also substantially elevated for 
those with HL (SMR=2.08), head and neck cancers (SMR=3.32), and cervical/uterine cancers 
(SMR=1.83), while those for gastrointestinal and liver diseases only appeared elevated for AYAs 
with head and neck cancers (SMR=1.65), cervical/uterine cancers (SMR=1.57), and colon and 
rectal cancers (SMR=1.52) (Table 5.3). For renal diseases, SMRs ranged from ~3 to 5 for AYAs 
with head and neck cancers, cervical/uterine cancers, colon/rectal cancers, HL, NHL, and CNS 
tumors, and were also significantly elevated for AYAs with testicular cancer (SMR=1.78) (Table 
5.4). Patterns for respiratory diseases, gastrointestinal and liver diseases, and renal diseases, 
suggested a decrease in SMRs with increases in age at diagnosis and time since diagnosis 
(Tables 5.7-5.10). In cancer type-specific analyses, SMRs were elevated at 20 or more years 
post-diagnosis for renal disease among AYAs with leukemias, HL, and cervical/uterine cancers, 
for respiratory disease among those with HL, head and neck cancers, and cervical/uterine 
cancers, for gastrointestinal and liver diseases among those with leukemias, and for external 
causes among those with CNS tumors, soft tissue sarcomas, head and neck cancers, and 
cervical/uterine cancers (Tables 5.7-5.8). 
5.3.5 Sensitivity analyses 
 Using a latency exclusion period of 0 months, rather than 2 months, a total of 13,792 
deaths from all noncancer causes were observed among AYAs of all cancer types combined, 
with corresponding SMR of 1.94 (95% CI: 1.91, 1.98) (Table 5.11). SMRs for cause-specific 
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categories also tended to be slightly elevated compared to those estimated in primary analyses 
using a 2-month latency exclusion period. In contrast, when a 6-month latency exclusion period 
was used, the SMR for all noncancer mortality among AYAs of all cancer types combined was 
1.70 (95% CI: 1.67, 1.73), reflecting a total of 11,854 observed deaths. SMRs for cause-specific 
categories tended to be slightly attenuated compared to the primary analysis, but remained 
significantly elevated for infectious diseases, cardiovascular diseases, respiratory diseases, renal 
diseases, external causes, and other causes.  
 In sensitivity analyses examining the potential influence of cause of death 
misclassification, the SMR for all noncancer mortality among AYAs of all cancer types 
combined remained significantly elevated even when 30% of observed noncancer deaths were 
assumed to have been misclassified (SMR=1.29; 95% CI: 1.26, 1.31) (Table 5.12). SMRs for 
infectious diseases, cardiovascular diseases, renal diseases, and other causes also remained 
significantly elevated under the assumption of 30% misclassification.  
5.4 Discussion 
 This study represents one of the largest to date, and one of the first among U.S. patients, 
to examine noncancer mortality rates among AYAs with cancer. In our analyses, mortality from 
all noncancer causes among AYA cancer survivors was approximately 1.8 times that of the 
general population, with the highest SMRs among those with hematologic malignancies and 
CNS tumors, cancers more predominant among the patients diagnosed as adolescents. SMRs 
tended to be lower for AYAs diagnosed with breast cancer, colorectal cancer, and other cancers 
more commonly diagnosed in older adults. For all cancers types combined, SMRs were generally 
greatest within the first year of cancer diagnosis, but remained significantly elevated at 20+ years 
post-diagnosis for all noncancer mortality, and specifically for infectious diseases, cardiovascular 
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diseases, and renal diseases, underscoring the importance of comprehensive long-term follow-up 
care for patients with a history of AYA cancer. 
 Many modern cancer therapies, including anthracycline-based chemotherapies, alkylating 
chemotherapies, and chest radiation, have been associated with acute and/or chronic 
cardiotoxicities,[41] potentially contributing to increases in mortality from heart disease among 
cancer patients and survivors. In contrast to the extensive literature on long-term cardiovascular 
outcomes among childhood cancer survivors,[86, 120, 121] there exists relatively little research 
to date specific to young adults with cancer, particularly for those with cancer types other than 
HL.[122-124] The SMR for heart diseases in our overall analyses (1.58) is similar to that in a 
recent study of five-year AYA cancer survivors in England and Wales (SMR=1.4),[76] but 
considerably smaller than that among five-year survivors of childhood cancers in the U.S.-based 
Childhood Cancer Survivor Study (SMR=7.0).[86] The lower SMRs for heart disease among 
AYA patients compared to childhood cancer patients may be a reflection of both higher rates of 
mortality from heart disease in the general population with increasing age, and differences in 
cancer type distribution between children and AYAs. Lymphomas, leukemias, and CNS tumors, 
all cancers which span both the childhood and AYA age range, were among the cancer types 
with the highest SMRs for CVD in the current study. However, though SMRs were of smaller 
magnitude, our findings also suggest that some cancer types diagnosed almost exclusively 
among older AYAs, and therefore not included in most childhood cancer studies, such as breast, 
cervical/uterine, colon/rectal, and head and neck cancers, are also associated with an increased 
risk of CVD mortality compared to the general population. Notably, SMRs remained 
significantly elevated at more than 20 years post-diagnosis for AYAs with breast, 
cervical/uterine, and head and neck cancers, highlighting priority groups for long-term 
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cardiovascular surveillance and disease management additional to those identified in previous 
childhood cancer studies.  
 Infections are a significant cause of morbidity and treatment-related complications among 
cancer patients, and may develop as a consequence of neutropenia from aggressive 
chemotherapeutic regimens, exposure to invasive procedures or medical devices, hematopoietic 
stem cell transplantation (HSCT), malnutrition, and/or effects of the malignancy itself on 
immune function.[50, 51] The exceptionally high SMR for infectious disease mortality 
associated with NHL in our analyses is undoubtedly a reflection of its relationship with HIV 
infection, particularly given the time period spanned by our study. However, even when NHL 
patients were excluded, SMRs remained significantly elevated among all other AYAs with 
cancer combined. Other cancer types with noticeably high SMRs for infectious diseases included 
leukemia and HL, consistent with the potential for hematologic malignancies to directly 
compromise bone marrow, and with a greater likelihood of exposure to immunosuppressive 
chemotherapies and HSCT in these patients than in those with non-hematologic cancers.[55, 61] 
However, with the exception of melanoma and thyroid cancer, SMRs for infectious diseases 
were also significantly elevated for AYAs with all other cancer types we examined, likely 
reflecting a combination of treatment- and host-related risk factors. For some cancer types, 
including hematologic malignancies, CNS tumors, and cervical/uterine cancers, the increase 
persisted at more than 20 years post-diagnosis, and further research may be needed to investigate 
cancer treatment-related and other contributors to the long-term excess risk in these groups. 
 Though rare relative to deaths from cardiovascular and infectious diseases, deaths from 
renal diseases, defined in our analysis as nephritis, nephrotic syndrome, and nephrosis, were also 
increased among AYAs with cancer. Across cancer types that we evaluated, only soft tissue 
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sarcomas, thyroid cancer, melanoma, and breast cancer were not associated with an excess of 
renal disease mortality. Alkylating chemotherapies, such as ifosfamide and cisplatin, have been 
linked to nephrotoxicity in prior clinical studies, and are thought to be among the more common 
causes of kidney damage following cancer treatment.[64] However, other cancer therapies, 
including nitrosoureas, methotrexate, HSCT, anti-infective drugs, immunosuppressive drugs, and 
radiation to the kidneys (including from total body irradiation) may also be associated with acute 
and/or chronic nephrotoxicities,[64, 125] and may be at least partially responsible for the 
observed increases in deaths from renal diseases among AYAs with hematologic malignancies 
and other cancer types.  
 Our results suggest that mortality from suicide is significantly increased among AYA 
cancer survivors relative to the age-matched general population, potentially reflecting the 
psychological distress and reduced quality of life that may be associated with a cancer diagnosis 
and treatment. However, the SMR observed in the current study (1.23) is smaller than SMRs 
reported by most previous studies of suicide among predominately older adult cancer 
patients.[126-128] Though based on a small number of deaths, mortality from pregnancy-related 
complications was also elevated among AYA cancer survivors. This is consistent with a prior 
study reporting an increased risk of serious pregnancy complications, such as pre-eclampsia and 
post-partum hemorrhage, among women with an AYA cancer history.[129]  
 In our analyses, AYAs with melanoma and thyroid cancer had significantly lower 
noncancer mortality than the general population. Relative to many of the other cancer types that 
we examined, particularly those such as hematologic malignancies and CNS tumors, melanoma 
and thyroid cancer are more often treated with lower intensity regimens that would be less likely 
to increase risk of mortality from noncancer causes. Other factors specific to these cancer types 
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may also contribute to reduced mortality. Given the relationship between skin malignancies and 
sun exposure, patients with melanoma may be more physically active, on average, than the 
general population, potentially contributing to lower mortality from CVD and many other 
noncancer conditions. Higher socioeconomic status and greater access to healthcare may explain 
much of the reduction in noncancer mortality among AYAs with thyroid cancer, as these factors 
have been associated with a higher thyroid cancer incidence in the U.S.,[130] a relationship 
thought to be largely attributable to overdiagnosis.  
  Strengths of this study include the large population-based cohort and the more 3 million 
person-years of follow-up, which allowed us to examine noncancer mortality according to 
characteristics such as cancer type and time since diagnosis. A limitation of our analyses is the 
potential for cause of death misclassification due to inaccurate coding of death certificates. 
However, for several noncancer causes of death, including suicide[131] and coronary heart 
disease,[132] prior studies have suggested reasonable validity (sensitivity and specificity >70%) 
for cause of death codes abstracted from death certificates compared to the gold standard 
measure of cause of death determination by a physician review panel.[132, 133] In our 
sensitivity analyses, we found that the SMR for all noncancer mortality among AYAs of all 
cancer types combined remained significantly elevated even under the assumption that 30% of 
observed noncancer deaths had been misclassified. SMRs for cause-specific categories (e.g. 
“Diseases of the Heart”) represent weighted averages of the component conditions, potentially 
obscuring variation across finer subcategorizations. It will important to investigate more 
precisely defined outcomes in future etiological studies designed to better understand the 
pathophysiology of these conditions and pinpoint prevention efforts. Due to concerns over 
patient confidentiality, HIV deaths and deaths due to ‘other infectious and parasitic diseases’ are 
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combined into a single code in SEER data.[103] Therefore we could not directly evaluate the 
contribution of HIV-related deaths to elevated SMRs among AYAs with cancer. Also, we were 
unable to consider the impact of cancer relapse on our findings, as this information is not 
captured in SEER data. Lastly, elevated SMRs for cardiovascular disease and other noncancer 
causes may be largely attributable to acute complications or late effects of specific therapies 
received by AYAs with cancer. However, detailed cancer treatment information is not available 
in SEER, precluding analyses of noncancer mortality according to receipt of specific 
chemotherapeutic agents or chemo- or radiotherapy doses in this study.  
 Results of the current study suggest that AYAs with cancer face an elevated burden 
 of mortality from noncancer causes relative to the general population that persists many years 
after cancer diagnosis, suggesting the importance of comprehensive, coordinated follow-up care 
throughout survivorship. Examining long-term patterns of noncancer health outcomes according 
to receipt of specific cancer therapies is an area for future research among AYA cancer 
survivors, particularly those diagnosed at ages 21-39 years who are not represented in studies of 







Table 5.1. Characteristics of AYAs diagnosed with cancer, SEER 9, 1973-2015 
 N Persons % Persons  N Person-years % Person-years 
Total 235,641 100%  3,124,255.19 100% 
      
Cancer type      
Leukemias 9,624 4%  70,566.31 2% 
Non-Hodgkin lymphoma 14,209 6%  146,911.65 5% 
Hodgkin lymphoma 15,974 7%  252,654.37 8% 
CNS tumors 10,561 4%  98,698.03 3% 
Soft tissue sarcomas a 8,345 4%  114,612.32 4% 
Melanoma 27,923 12%  441,883.48 14% 
Thyroid 26,406 11%  398,556.76 13% 
Head and neck 5,923 3%  82,284.00 3% 
Breast 36,225 15%  463,375.21 15% 
Cervix/uterus 16,814 7%  275,709.66 9% 
Colon and rectum 10,582 4%  104,123.26 3% 
Testicular 18,957 8%  307,808.68 10% 
Other 34,098 14%  367,071.46 12% 
      
Sex      
Male 93,090 40%  1,169,179.46 37% 
Female 142,551 60%  1,955,075.73 63% 
      
Race      
White 192,774 82%  2,675,111.67 86% 
Black 23,413 10%  242,498.40 8% 
Other 19,454 8%  206,645.12 7% 
      
Age at diagnosis      
15-19 15,357 7%  214,346.07 7% 
20-24 25,518 11%  366,981.39 12% 
25-29 41,679 18%  595,550.00 19% 
30-34 62,308 26%  829,385.36 27% 
35-39 90,779 39%  1,117,992.37 36% 
      
Diagnosis year      
1973-1982 39,397 17%  876,954.72 28% 
1983-1992 54,393 23%  1,012,284.10 32% 
1993-2002 59,519 25%  797,044.47 26% 
2003-2015 82,332 35%  437,971.91 14% 
      
Abbreviations: AYAs, adolescents and young adults; CNS, central nervous system  
a Excludes Kaposi sarcoma      
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Table 5.2. Rates of mortality from noncancer causes among AYAs with cancer compared to the general 
population 





All noncancer 12948 7053.34 1.84 (1.80-1.87) 18.87 414.43 
      
Infectious 3068 597.58 5.13 (4.95-5.32) 7.91 98.20 
Tuberculosis 9 5.11 1.76 (0.81-3.35) 0.01 0.29 
Syphilis 0 0.22 0 (0-16.58) 0.00 0.00 
Septicemia 319 121.14 2.63 (2.35-2.94) 0.63 10.21 
Other Infectious and  
Parasitic Diseases including  
HIV 2,292 338.27 6.78 (6.50-7.06) 6.25 73.36 
Pneumonia and Influenza 448 132.83 3.37 (3.07-3.70) 1.01 14.34 
      
Cardiovascular 3,573 2311.77 1.55 (1.50-1.60) 4.04 114.36 
Diseases of Heart 2,906 1841.72 1.58 (1.52-1.64) 3.41 93.01 
Hypertension without Heart  
Disease 75 56.89 1.32 (1.04-1.65) 0.06 2.40 
Cerebrovascular Diseases 489 340.24 1.44 (1.31-1.57) 0.48 15.65 
Atherosclerosis 20 10.26 1.95 (1.19-3.01) 0.03 0.64 
Aortic Aneurysm and  
Dissection 37 36.72 1.01 (0.71-1.39) 0.00 1.18 
Other Diseases of Arteries,  
Arterioles, Capillaries 46 25.93 1.77 (1.30-2.37) 0.06 1.47 
      
Respiratory      
Chronic Obstructive  
Pulmonary Disease and  
Allied Conditions 408 351.95 1.16 (1.05-1.28) 0.18 13.06 
      
Gastrointestinal and liver 370 336.63 1.10 (0.99-1.22) 0.11 11.84 
Stomach and Duodenal  
Ulcers 33 13.68 2.41 (1.66-3.39) 0.06 1.06 
Chronic Liver Disease and  
Cirrhosis 337 322.95 1.04 (0.94-1.16) 0.04 10.79 
      
Renal      
Nephritis, Nephrotic  
Syndrome and Nephrosis 270 112.39 2.40 (2.12-2.71) 0.50 8.64 
      
External 1,802 1668.25 1.08 (1.03-1.13) 0.43 57.68 
Accidents and Adverse  
Effects 1,120 1042.17 1.07 (1.01-1.14) 0.25 35.85 
Suicide and Self-Inflicted  
Injury 540 437.42 1.23 (1.13-1.34) 0.33 17.28 
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Homicide and Legal  
Intervention 142 188.67 0.75 (0.63-0.89) -0.15 4.55 
      
Other 3457 1674.78 2.06 (2.00-2.13) 5.70 110.65 
Diabetes Mellitus 373 304.65 1.22 (1.10-1.36) 0.22 11.94 
Alzheimers disease (ICD-9  
and 10 only) 28 28.93 0.97 (0.64-1.40) 0.00 0.90 
Complications of Pregnancy,  
Childbirth, Puerperium 66 8.73 7.56 (5.84-9.61) 0.18 2.11 
Congenital Anomalies 95 42.61 2.23 (1.80-2.73) 0.17 3.04 
Certain Conditions  
Originating in Perinatal  
Period 4 0.33 12.04 (3.28-30.83) 0.01 0.13 
Symptoms, Signs and Ill- 
Defined Conditions 258 142.55 1.81 (1.60-2.04) 0.37 8.26 
Other Causes of Death 2,633 1146.98 2.30 (2.21-2.38) 4.76 84.28 
      
Abbreviations: AYAs, adolescents and young adults; PY, person-years; SMR, standardized mortality ratio; HIV, 
human immunodeficiency virus 






Table 5.3. SMRs for mortality from all noncancer causes, infectious diseases, cardiovascular diseases, and respiratory diseases among AYAs with cancer 
according to patient characteristics 
 All noncancer Infectious Cardiovascular Respiratory 
  N deaths SMR (95% CI) N deaths SMR (95% CI) N deaths SMR (95% CI) N deaths SMR (95% CI) 
Cancer type        
Leukemias 703 5.26 (4.87-5.66) 187 16.06 (13.84-18.53) 111 3.06 (2.52-3.69) 18 4.69 (2.78-7.42) 
Non-Hodgkin lymphoma 2212 6.33 (6.07-6.60) 1521 47.71 (45.35-50.17) 224 2.05 (1.79-2.34) 20 1.55 (0.95-2.40) 
Hodgkin lymphoma 1551 3.12 (2.96-3.28) 308 6.80 (6.07-7.61) 625 4.44 (4.10-4.81) 33 2.08 (1.43-2.93) 
CNS tumors 593 3.37 (3.11-3.66) 91 5.71 (4.59-7.01) 150 3.32 (2.81-3.90) 8 1.70 (0.73-3.35) 
Soft tissue sarcomas a 391 1.38 (1.25-1.52) 51 1.93 (1.43-2.53) 108 1.16 (0.95-1.40) 14 1.13 (0.62-1.90) 
Melanoma 662 0.65 (0.60-0.70) 82 1.03 (0.82-1.27) 185 0.54 (0.47-0.63) 18 0.33 (0.19-0.51) 
Thyroid 606 0.81 (0.75-0.88) 42 0.70 (0.51-0.95) 204 0.84 (0.73-0.96) 24 0.58 (0.37-0.86) 
Other head and neck 489 2.09 (1.91-2.29) 64 3.15 (2.42-4.02) 151 1.80 (1.53-2.11) 36 3.32 (2.33-4.60) 
Breast 1197 1.25 (1.18-1.32) 116 1.47 (1.22-1.77) 457 1.38 (1.25-1.51) 49 0.72 (0.53-0.95) 
Cervix/uterus 1145 2.03 (1.91-2.15) 112 2.45 (2.02-2.95) 361 1.83 (1.65-2.03) 75 1.83 (1.44-2.29) 
Colon and rectum 513 1.76 (1.61-1.91) 109 4.20 (3.45-5.06) 140 1.35 (1.14-1.59) 12 0.84 (0.43-1.47) 
Testicular 998 1.10 (1.03-1.17) 133 1.70 (1.42-2.01) 295 1.03 (0.91-1.15) 19 0.66 (0.40-1.04) 
         
Sex         
Male 7108 1.94 (1.90-1.99) 2293 7.08 (6.79-7.37) 1787 1.49 (1.42-1.56) 136 1.12 (0.94-1.32) 
Female 5840 1.72 (1.68-1.77) 775 2.83 (2.64-3.04) 1786 1.61 (1.54-1.69) 272 1.18 (1.05-1.33) 
         
Age at diagnosis       
15-19 666 2.63 (2.44-2.84) 108 5.77 (4.73-6.97) 164 4.04 (3.45-4.71) 11 3.00 (1.50-5.37) 
20-24 1235 2.28 (2.15-2.41) 216 4.52 (3.94-5.17) 328 2.77 (2.48-3.09) 23 1.91 (1.21-2.87) 
25-29 2075 1.94 (1.86-2.03) 525 5.34 (4.89-5.82) 542 1.83 (1.68-1.99) 55 1.50 (1.13-1.96) 
30-34 3449 1.83 (1.77-1.89) 960 5.78 (5.42-6.16) 884 1.42 (1.33-1.52) 102 1.11 (0.91-1.35) 
35-39 5523 1.67 (1.63-1.72) 1259 4.72 (4.46-4.99) 1655 1.34 (1.28-1.41) 217 1.07 (0.91-1.19) 
         
Time since diagnosis (years)       
2 mo - <1  2017 10.30 (9.85-10.76) 1274 67.49 (63.84-71.30) 157 5.47 (4.65-6.40) 4 2.44 (0.66-6.24) 





5-<10 1625 1.65 (1.57-1.73) 314 3.15 (2.81-3.52) 381 1.61 (1.45-1.78) 18 1.19 (0.70-1.88) 
10-<20  2857 1.41 (1.36-1.46) 351 1.92 (1.72-2.13) 972 1.44 (1.36-1.54) 83 1.24 (0.99-1.54) 
20+ 4033 1.34 (1.29-1.38) 344 1.61 (1.44-1.79) 1690 1.38 (1.31-1.45) 283 1.09 (0.97-1.22) 
Abbreviations: SMR-standardized mortality ratio; AYAs-adolescents and young adults; CNS-central nervous system 





Table 5.4. SMRs for mortality from gastrointestinal (GI) and liver diseases, renal diseases, external causes, and other causes among AYAs with cancer 
according to patient characteristics 
 GI and liver Renal External Other 
  N deaths SMR (95% CI) N deaths SMR (95% CI) N deaths SMR (95% CI) N deaths SMR (95% CI) 
Cancer type         
Leukemias 25 4.06 (2.63-5.99) 16 10.25 (5.86-16.65) 71 1.53 (1.19-1.92) 275 9.89 (8.76-11.13) 
Non-Hodgkin lymphoma 18 1.07 (0.63-1.68) 23 4.81 (3.05-7.22) 125 1.27 (1.06-1.51) 281 3.73 (3.31-4.19) 
Hodgkin lymphoma 25 1.07 (0.69-1.58) 24 3.97 (2.55-5.91) 189 1.18 (1.02-1.36) 347 3.28 (2.94-3.64) 
CNS tumors 9 1.11 (0.51-2.11) 10 5.25 (2.52-9.65) 114 1.80 (1.48-2.16) 211 5.77 (5.02-6.61) 
Soft tissue sarcomas a 12 0.93 (0.48-1.63) 4 0.86 (0.24-2.21) 84 1.21 (0.96-1.50) 118 1.83 (1.52-2.19) 
Melanoma 20 0.38 (0.23-0.59) 5 0.34 (0.11-0.79) 156 0.65 (0.55-0.76) 196 0.81 (0.70-0.93) 
Thyroid 21 0.58 (0.36-0.89) 19 1.51 (0.91-2.36) 112 0.67 (0.55-0.80) 184 0.97 (0.83-1.12) 
Other head and neck 19 1.65 (0.99-2.58) 11 2.98 (1.49-5.33) 93 1.81 (1.46-2.22) 115 2.22 (1.83-2.66) 
Breast 40 0.96 (0.69-1.31) 21 1.02 (0.63-1.55) 136 0.94 (0.79-1.11) 378 1.40 (1.26-1.55) 
Cervix/uterus 38 1.57 (1.11-2.16) 42 3.40 (2.45-4.60) 135 1.58 (1.33-1.87) 382 2.40 (2.16-2.65) 
Colon and rectum 21 1.52 (0.94-2.33) 18 3.58 (2.12-5.66) 74 1.19 (0.94-1.50) 139 2.06 (1.73-2.43) 
Testicular 49 1.01 (0.75-1.34) 18 1.78 (1.06-2.82) 249 0.90 (0.79-1.02) 235 1.32 (1.16-1.50) 
         
Sex         
Male 199 1.06 (0.92-1.22) 126 2.85 (2.37-3.39) 1084 1.02 (0.96-1.09) 1483 2.06 (1.96-2.17) 
Female 171 1.15 (0.98-1.33) 144 2.11 (1.78-2.49) 718 1.18 (1.10-1.27) 1974 2.06 (1.97-2.16) 
         
Age at diagnosis         
15-19 15 1.95 (1.09-3.22) 13 6.77 (3.60-11.57) 144 1.08 (0.91-1.28) 211 4.44 (3.86-5.08) 
20-24 31 1.38 (0.93-1.95) 27 4.99 (3.29-7.25) 261 1.17 (1.03-1.32) 349 3.10 (2.79-3.45) 
25-29 52 1.01 (0.75-1.32) 40 2.91 (2.08-3.96) 337 1.02 (0.92-1.14) 524 2.16 (1.98-2.36) 
30-34 105 1.11 (0.91-1.34) 59 1.96 (1.49-2.53) 445 1.04 (0.94-1.14) 894 1.98 (1.85-2.11) 
35-39 167 1.04 (0.89-1.21) 131 2.14 (1.79-2.54) 615 1.11 (1.03-1.20) 1479 1.80 (1.71-1.90) 
         
Time since diagnosis (years)         
2 mo - <1  25 3.99 (2.58-5.89) 27 19.47 (12.83-28.33) 133 1.32 (1.10-1.56) 397 10.42 (9.42-11.49) 





5-<10 61 1.25 (0.96-1.61) 20 2.19 (1.34-3.38) 381 1.05 (0.94-1.16) 450 2.14 (1.94-2.34) 
10-<20  110 0.94 (0.77-1.13) 59 2.24 (1.70-2.89) 516 1.05 (0.96-1.14) 766 1.64 (1.53-1.76) 
20+ 125 0.94 (0.79-1.13) 123 1.78 (1.48-2.12) 345 1.05 (0.95-1.17) 1123 1.42 (1.34-1.50) 
Abbreviations: SMR-standardized mortality ratio; AYAs-adolescents and young adults; GI-gastrointestinal; CNS-central nervous system 





Table 5.5. SMRs for mortality from all noncancer causes, infectious diseases, cardiovascular diseases and respiratory diseases among AYAs with cancer 
according to stage, stratified by cancer type 
  All noncancer Infectious Cardiovascular Respiratory 
  
N 
deaths SMR (95% CI) 
N 
deaths SMR (95% CI) 
N 
deaths SMR (95% CI) 
N 
deaths SMR (95% CI) 
Non-Hodgkin lymphoma a           
I 650 8.03 (7.43-8.68) 503 66.47 (60.79, 72.54) 51 2.25 (1.70, 2.99) 3 1.39 (0.29, 4.07) 
II 193 4.88 (4.21-5.61) 120 33.93 (28.13, 40.57) 19 1.75 (1.06, 2.74) 0 0 (0, 3.35) 
III 221 9.88 (8.62-11.27) 143 54.52 (45.95, 64.22) 26 3.61 (2.36, 5.29) 3 4.48 (0.92, 13.09) 
IV 758 12.36 (11.49-13.27) 592 
98.13 (90.38, 
106.40) 38 2.27 (1.61, 3.12) 6 3.75 (1.37, 8.15) 
Hodgkin lymphoma a         
I  157 2.02 (1.71-2.36) 19 2.58 (1.56, 4.04) 65 3.17 (2.45, 4.04) 1 0.49 (0.01, 2.70) 
II 300 2.56 (2.28-2.86) 60 5.86 (4.47, 7.55) 117 4.18 (3.46, 5.01) 3 1.04 (0.21, 3.03) 
III 183 3.11 (2.67-3.59) 48 8.68 (6.40, 11.51) 52 3.61 (2.69, 4.73) 3 2.25 (0.46, 6.58) 
IV 168 4.27 (3.65-4.97) 70 18.01 (14.04, 22.76) 34 3.29 (2.28, 4.59) 3 3.09 (0.64, 9.02) 
Soft tissue sarcomas b         
Localized 234 1.24 (1.09-1.41) 24 1.39 (0.89, 2.07) 72 1.14 (0.89, 1.43) 8 0.92 (0.40, 1.81) 
Regional  82 1.44 (1.14-1.78) 8 1.44 (0.62, 2.83) 22 1.22 (0.76, 1.84) 3 1.41 (0.29, 4.11) 
Distant 28 5.71 (379-8.25) 7 15.48 (6.22, 31.89) 6 5.22 (1.91, 11.35) 0 0 (0, 37.69) 
Melanoma         
Localized 545 0.60 (0.55-0.66) 63 0.90 (0.69, 1.15) 156 0.52 (0.44, 0.61) 16 0.33 (0.19, 0.53) 
Regional  49 0.96 (0.71-1.27) 7 1.74 (0.70, 3.59) 10 0.63 (0.30, 1.15) 1 0.44 (0.01, 2.44) 
Distant 15 2.47 (1.38-4.07) 5 9.81 (3.19, 22.90) 4 2.53 (0.82, 5.90) 0 0 (0, 14.59) 
Thyroid         
Localized 334 0.77 (0.69-0.85) 24 0.70 (0.45, 1.04) 120 0.84 (0.70, 1.00) 13 0.51 (0.27, 0.88) 
Regional  226 0.85 (0.74-0.97) 18 0.85 (0.50, 1.34) 65 0.77 (0.60, 0.98) 8 0.58 (0.25, 1.15) 
Distant 27 1.14 (0.75-1.65) 0 0 (0, 1.87) 10 1.33 (0.64, 2.45) 2 1.74 (0.21, 6.30) 
Other head and neck         
Localized 231 1.65 (1.44-1.88) 25 2.11 (1.36, 3.11) 74 1.44 (1.13, 1.81) 16 2.30 (1.31, 3.73) 
Regional  139 2.26 (1.90-2.66) 26 4.53 (2.96, 6.63) 56 2.65 (2.00, 3.44) 12 2.36 (2.62, 8.87) 





Breast         
Localized 588 0.99 (0.91-1.08) 46 0.96 (0.70, 1.28) 207 0.99 (0.86, 1.13) 32 0.73 (0.50, 1.03) 
Regional  519 1.58 (1.44-1.72) 56 2.02 (1.53, 2.62) 212 1.90 (1.66, 2.18) 18 0.81 (0.48, 1.29) 
Distant 47 4.00 (2.94-5.32) 10 9.33 (4.48, 17.16) 21 6.30 (3.90, 9.63) 0 0 (0, 6.98) 
Cervix/uterus         
Localized 854 1.81 (1.70-1.94) 76 2.02 (1.59, 2.52) 277 1.68 (1.49, 1.89) 60 1.73 (1.32, 2.23) 
Regional  174 2.95 (2.53-3.42) 25 5.07 (3.28, 7.49) 43 2.16 (1.56, 2.90) 10 2.53 (1.21, 4.65) 
Distant 28 4.84 (3.22-7.00) 4 8.37 (2.28, 21.43) 11 5.72 (2.86, 10.24) 1 2.78 (0.07, 15.50) 
Colon and rectum         
Localized 204 1.38 (1.19-1.58) 39 3.01 (2.14, 4.11) 68 1.27 (0.99, 1.61) 6 0.79 (0.29, 1.73) 
Regional  213 1.84 (1.60-2.10) 42 4.08 (2.94, 5.51) 51 1.24 (0.92, 1.62) 5 0.90 (0.29, 2.10) 
Distant 59 4.44 (3.38-5.73) 15 12.04 (6.74, 19.85) 12 3.11 (1.61, 5.43) 0 0 (0, 7.84) 
Testicular         
Localized 570 0.91 (0.84-0.99) 66 1.24 (0.96, 1.57) 171 0.86 (0.73, 1.00) 10 0.50 (0.24, 0.92) 
Regional  243 1.30 (1.14-1.47) 34 2.06 (1.43, 2.88) 74 1.26 (0.99, 1.58) 4 0.69 (0.19, 1.78) 
Distant 162 2.19 (1.86-2.55) 30 4.58 (3.09, 6.54) 40 1.82 (1.30, 2.47) 3 1.49 (0.31, 4.34) 
                  
Abbreviations: SMR, standardized mortality ratio; AYAs, adolescents and young adults; GI, gastrointestinal 
a Ann Arbor staging classification, includes patients diagnosed in 1983 and later only 
b Excludes Kaposi sarcoma 





Table 5.6. SMRs for mortality from gastrointestinal (GI) and liver diseases, renal diseases, external causes, and other causes among AYAs with cancer 
according to stage, stratified by cancer type 
 GI and liver Renal External Other 
 
N 
deaths SMR (95% CI) 
N 
deaths SMR (95% CI) 
N 
deaths SMR (95% CI) 
N 
deaths SMR (95% CI) 
Non-Hodgkin lymphoma a          
I 1 0.25 (0.01, 1.38) 7 7.04 (2.83, 14.49) 26 0.98 (0.64, 1.44) 59 3.43 (2.61, 4.42) 
II 1 0.51 (0.01, 2.85) 4 8.45 (2.30, 21.64) 15 1.14 (0.64, 1.88) 34 4.01 (2.77, 5.60) 
III 3 2.31 (0.48, 6.74) 0 0 (0, 11.74) 18 2.10 (1.25, 3.32) 28 5.06 (3.36, 7.32) 
IV 5 1.67 (0.54, 3.90) 9 12.39 (5.67, 23.52) 30 1.47 (0.99, 2.10) 78 6.07 (4.80, 7.58) 
Hodgkin lymphoma a         
I  6 1.64 (0.60, 3.56) 0 0 (0, 4.05) 26 0.97 (0.63, 1.42) 40 2.42 (1.73, 3.29) 
II 5 0.95 (0.31, 2.23) 1 0.77 (0.02, 4.31) 50 1.13 (0.84, 1.49) 64 2.51 (1.93, 3.20) 
III 3 1.12 (0.23, 3.28) 5 7.95 (2.58, 18.56) 33 1.49 (1.02, 2.09) 39 3.21 (2.29, 4.39) 
IV 1 0.57 (0.01, 3.15) 4 8.58 (2.34, 21.96) 16 1.16 (0.66, 1.89) 40 4.90 (3.50, 6.67) 
Soft tissue sarcomas b         
Localized 7 0.82 (0.33, 1.69) 3 0.96 (0.33, 1.69) 54 1.22 (0.92, 1.59) 66 1.53 (1.18, 1.95) 
Regional  3 1.15 (0.24, 3.35) 0 0 (0, 4.03) 18 1.20 (0.71, 1.90) 28 2.18 (1.45, 3.15) 
Distant 0 0 (0, 19.78) 0 0 (0, 67.37) 4 2.02 (0.55, 5.17) 11 11.16 (5.57, 19.97) 
Melanoma         
Localized 15 0.33 (0.18, 0.54) 3 0.23 (0.05, 0.67) 130 0.62 (0.52, 0.73) 162 0.76 (0.64, 0.88) 
Regional  2 0.78 (0.09, 2.82) 0 0 (0, 5.60) 15 1.07 (0.60, 1.76) 14 1.23 (0.67, 2.06) 
Distant 0 0 (0, 11.87) 0 0 (0, 47.41) 1 0.61 (0.02, 3.39) 5 3.84 (1.25, 8.96) 
Thyroid         
Localized 8 0.39 (0.17, 0.76) 9 1.19 (0.54, 2.25) 58 0.63 (0.47, 0.81) 102 0.91 (0.74, 1.10) 
Regional  12 0.93 (0.48, 1.62) 9 2.14 (0.98, 4.06) 44 0.69 (0.50, 0.92) 70 1.06 (0.83, 1.34) 
Distant 1 0.87 (0.02, 4.82) 1 2.73 (0.07, 15.19) 5 0.85 (0.28, 1.98) 8 1.40 (0.61, 2.77) 
Other head and neck         
Localized 10 1.46 (0.70, 2.68) 6 2.68 (0.98, 5.83) 49 1.67 (1.24, 2.21) 51 1.62 (1.21, 2.13) 
Regional  5 1.58 (0.51, 3.69) 2 2.13 (0.26, 7.69) 29 1.94 (1.30, 2.79) 41 3.06 (2.20, 4.15) 
Distant 2 5.00 (0.61, 18.05) 2 15.71 (1.90, 56.74) 6 2.82 (1.03, 6.13) 10 5.64 (2.71, 10.38) 





Breast         
Localized 21 0.82 (0.51, 1.26) 9 0.69 (0.31, 1.30) 83 0.97 (0.78, 1.21) 190 1.13 (0.98, 1.31) 
Regional  16 1.09 (0.62, 1.77) 8 1.17 (0.50, 2.30) 41 0.76 (0.51, 1.03) 168 1.81 (1.55, 2.11) 
Distant 1 1.85 (0.05, 10.33) 2 9.93 (1.20, 35.88) 3 1.07 (0.22, 3.14) 10 3.04 (1.46, 5.60) 
Cervix/uterus         
Localized 29 1.45 (0.97, 2.08) 34 3.29 (2.28, 4.60) 102 1.46 (1.19, 1.77) 276 2.08 (1.84, 2.34) 
Regional  4 1.53 (0.42, 3.91) 4 3.26 (0.89, 8.36) 20 2.06 (1.26, 3.18) 68 4.10 (3.18, 5.20) 
Distant 0 0 (0, 14.49) 2 16.91 (2.05, 61.07) 2 1.93 (0.23, 6.96) 8 4.97 (2.15, 9.79) 
Colon and rectum         
Localized 6 0.86 (0.32, 1.88) 5 1.91 (0.62, 4.45) 23 0.76 (0.48, 1.15) 57 1.65 (1.25, 2.14) 
Regional  13 2.36 (1.25, 4.03) 7 3.54 (1.42, 7.29) 41 1.66 (1.19, 2.25) 54 2.03 (1.53, 2.65) 
Distant 0 0 (0, 5.96) 6 33.20 (12.18, 72.26) 5 1.26 (0.41, 2.94) 21 7.12 (4.41, 10.89) 
Testicular         
Localized 34 1.02 (0.71, 1.42) 7 0.99 (0.40, 2.05) 158 0.84 (0.72, 0.98) 124 1.01 (0.84, 1.20) 
Regional  6 0.60 (0.22, 1.31) 7 3.46 (1.39, 7.13) 56 0.96 (0.73, 1.25) 62 1.70 (1.30, 2.18) 
Distant 7 1.85 (0.74, 3.81) 4 5.19 (1.41, 13.29) 32 1.29 (0.88, 1.82) 46 3.26 (2.39, 4.35) 
                  
Abbreviations: SMR, standardized mortality ratio; AYAs, adolescents and young adults; GI, gastrointestinal 
a Ann Arbor staging classification, includes patients diagnosed in 1983 and later only 





Table 5.7 SMRs for mortality from all noncancer causes, infectious diseases, cardiovascular diseases, and respiratory diseases among AYAs with cancer 
according to time since diagnosis, stratified by cancer type 
  All noncancer Infectious Cardiovascular Respiratory 
  N deaths SMR (95% CI) N deaths SMR (95% CI) N deaths SMR (95% CI) 
N 
deaths SMR (95% CI) 
Leukemias         
2 mo- <1 year 165 19.75 (16.85, 23.00) 53 70.96 (53.13, 92.82) 17 16.40 (9.55, 26.26) 0 0 (0, 66.41) 
1 - <5 years 281 10.57 (9.37, 11.88) 85 33.78 (26.98, 41.77) 29 6.98 (4.68, 10.03) 4 19.07 (5.20, 48.82) 
5- <10 years 92 3.71 (2.99, 4.54) 18 7.50 (4.45, 11.86) 20 3.68 (2.25, 5.68) 6 20.45 (7.51, 44.52) 
10-<20 years 95 2.37 (1.92, 2.90) 20 5.64 (3.45, 8.71 22 1.77 (1.11, 2.68) 3 2.94 (0.61, 8.59) 
20+ years 70 2.06 (1.61, 2.61) 11 4.51 (2.25, 8.07) 23 1.75 (1.11, 2.62) 5 2.22 (0.72, 5.18) 
Non-Hodgkin lymphoma        
2 mo- <1 year 1125 81.40 (76.71, 86.30) 1007 624.07 (586.13, 663.83) 31 
16.03 (10.89, 
22.76) 0 0 (0, 37.57) 
1 - <5 years 505 9.50 (8.69, 10.37) 339 57.50 (51.54, 63.96) 36 3.85 (2.69, 5.32) 3 6.55 (1.35, 19.15) 
5- <10 years 186 3.12 (2.69, 3.60) 90 14.13 (11.37, 17.37) 27 1.89 (1.24, 2.74) 0 0 (0, 4.83) 
10-<20 years 218 2.03 (1.77, 2.31) 63 6.36 (4.88, 8.13) 54 1.50 (1.13, 1.96) 9 3.05 (1.40, 5.79) 
20+ years 178 1.55 (1.33, 1.79) 22 2.72 (1.71, 4.12) 76 1.59 (1.25, 1.99) 8 0.93 (0.40, 1.83) 
Hodgkin lymphoma        
2 mo- <1 year 85 6.03 (4.81, 57.85) 50 43.88 (32.57, 57.85) 6 4.12 (1.51, 8.96) 0 0 (0, 42.82) 
1 - <5 years 235 3.68 (3.22, 4.18) 90 15.31 (12.31, 15.21) 42 5.06 (3.64, 6.84) 0 0 (0, 8.12) 
5- <10 years 204 2.68 (2.32, 3.07) 51 6.24 (4.64, 8.20) 49 3.42 (2.53, 4.52) 0 0 (0, 4.77) 
10-<20 years 393 2.58 (2.33, 2.85) 54 3.41 (2.56, 4.45) 184 4.24 (3.65, 4.89) 4 1.23 (0.34, 3.16) 
20+ years 634 3.32 (3.07, 3.59) 63 4.42 (3.40, 5.66) 344 4.71 (4.22, 5.23) 29 2.57 (1.72, 3.69) 
CNS tumors         
2 mo- <1 year 62 6.60 (5.06, 8.46) 22 26.47 (16.59, 40.07) 12 10.47 (5.41, 18.29) 0 0 (0, 62.03) 
1 - <5 years 140 4.06 (3.41, 4.79) 27 8.25 (5.44, 12.00) 22 4.35 (2.73, 6.59) 1 3.86 (0.10, 21.52) 
5- <10 years 78 2.37 (1.88, 2.96) 10 2.99 (1.43, 5.50) 12 1.82 (0.94, 3.19) 0 0 (0, 10.04) 
10-<20 years 145 2.80 (2.37, 3.30) 17 3.43 (2.00, 5.49) 38 2.56 (1.81, 3.51) 1 0.82 (0.02, 4.56) 
20+ years 168 3.56 (3.04, 4.14) 15 4.23 (2.37, 6.98) 66 3.77 (2.91, 4.79) 6 2.15 (0.79, 4.67) 





Soft tissue sarcomas a 
2 mo- <1 year 34 4.37 (3.03, 6.11) 9 11.54 (5.28, 21.91) 2 1.94 (0.24, 7.02) 0 0 (63.01) 
1 - <5 years 64 1.99 (1.53, 2.54) 17 4.86 (2.83, 7.78) 9 1.68 (0.77, 3.20) 0 0 (0, 12.87) 
5- <10 years 59 1.55 (1.18, 2.00) 8 1.81 (0.78, 3.56) 14 1.59 (0.87, 2.68) 1 2.03 (0.05, 11.33) 
10-<20 years 89 1.11 (0.89, 1.36) 5 0.59 (0.19, 1.39) 35 1.32 (0.92, 1.83) 2 0.91 (0.11, 3.30) 
20+ years 145 1.16 (0.98, 1.36) 12 1.28 (0.66, 2.24) 48 0.93 (0.69, 1.23) 11 1.18 (0.59, 2.10) 
Melanoma         
2 mo- <1 year 27 1.20 (0.79, 1.74) 6 3.01 (1.11, 6.56) 6 1.88 (0.69, 4.09) 0 0 (0, 22.21) 
1 - <5 years 90 0.84 (0.68, 1.04) 19 1.92 (1.16, 3.00) 12 0.64 (0.33, 1.11) 3 3.04 (0.63, 8.87) 
5- <10 years 101 0.74 (0.60, 0.90) 14 1.10 (0.60, 1.85) 24 0.73 (0.47, 1.09) 0 0 (0, 1.82) 
10-<20 years 176 0.59 (0.51, 0.68) 18 0.74 (0.44, 1.17) 54 0.54 (0.41, 0.71) 2 0.20 (0.02, 0.71) 
20+ years 268 0.58 (0.51, 0.65) 25 0.81 (0.52, 1.19) 89 0.48 (0.38, 0.58) 13 0.31 (0.17, 0.53) 
Thyroid         
2 mo- <1 year 17 1.02 (0.59, 1.63) 1 0.75 (0.02, 4.17) 2 0.84 (0.10, 3.03) 0 0 (0, 22.99) 
1 - <5 years 67 0.85 (0.66, 1.08) 4 0.60 (0.16, 1.52) 15 1.09 (0.61, 1.80) 0 0 (0, 4.03) 
5- <10 years 79 0.80 (0.64, 1.00) 7 0.79 (0.32, 1.63) 20 0.88 (0.54, 1.36) 0 0 (0, 2.18) 
10-<20 years 163 0.80 (0.68, 0.93) 10 0.57 (0.27, 1.04) 55 0.85 (0.64, 1.11) 6 0.84 (0.31, 1.83) 
20+ years 280 0.80 (0.70, 0.89) 20 0.80 (0.49, 1.23) 112 0.81 (0.66, 0.97) 18 0.57 (0.34, 0.90) 
Other head and neck        
2 mo- <1 year 26 4.06 (2.65, 5.95) 6 8.63 (3.17, 18.78) 3 2.87 (0.59, 8.39) 0 0 (0, 78.54) 
1 - <5 years 87 3.27 (2.62, 4.03) 22 7.55 (4.73, 11.44) 16 3.00 (1.72, 4.87) 2 8.52 (1.03, 30.77) 
5- <10 years 75 2.32 (1.83, 2.91) 4 1.14 (0.31, 2.92) 23 2.64 (1.67, 3.95) 2 4.65 (0.56, 16.81) 
10-<20 years 132 1.98 (1.66, 2.35) 22 3.54 (2.22, 5.36) 39 1.59 (1.13, 2.18) 9 4.63 (2.12, 8.78) 
20+ years 169 1.67 (1.42, 1.94) 10 1.43 (0.68, 2.63) 70 1.58 (1.23, 2.00) 23 2.82 (1.78, 4.22) 
Breast         
2 mo- <1 year 54 2.29 (1.72, 2.98) 11 4.51 (2.25, 8.07) 11 2.34 (1.17, 4.18) 0 0 (0, 10.63) 
1 - <5 years 206 1.93 (1.68, 2.22) 31 2.89 (1.97, 4.10) 56 2.27 (1.72, 2.95) 1 0.53 (0.01, 2.93) 
5- <10 years 160 1.26 (1.07, 1.47) 17 1.42 (0.83, 2.28) 48 1.33 (0.98, 1.76) 2 0.59 (0.07, 2.14) 
10-<20 years 303 1.13 (1.00, 1.26) 20 0.89 (0.54, 1.38) 112 1.18 (0.97, 1.42) 11 0.77 (0.38, 1.38) 





Cervix/uterus         
2 mo- <1 year 47 4.82 (3.54, 6.41) 10 11.05 (5.30, 20.32) 10 5.65 (2.71, 10.38) 0 0 (0, 28.47) 
1 - <5 years 109 2.45 (2.01, 2.95) 20 4.81 (2.94, 7.42) 20 2.12 (1.30, 3.28) 1 1.40 (0.04, 7.82) 
5- <10 years 126 2.10 (1.75, 2.50) 14 2.52 (1.38, 4.23) 33 2.07 (1.43, 2.91) 2 1.43 (0.17, 5.16) 
10-<20 years 304 2.06 (1.83, 2.30) 24 1.89 (1.21, 2.82) 102 2.03 (1.66, 2.47) 12 1.74 (0.90, 3.05) 
20+ years 559 1.84 (1.69, 2.00) 44 1.97 (1.43, 2.64) 196 1.64 (1.42, 1.88) 60 1.88 (1.44, 2.42) 
Colon and rectum        
2 mo- <1 year 60 5.55 (4.23, 7.14) 23 18.64 (11.82, 27.97) 7 3.82 (1.53, 7.86) 0 0 (0, 40.62) 
1 - <5 years 116 2.92 (2.42, 3.51) 44 9.64 (7.01, 12.94) 21 2.53 (1.57, 3.87) 1 2.46 (0.06, 13.73) 
5- <10 years 89 2.10 (1.68, 2.58) 21 4.56 (2.82, 6.96) 18 1.52 (0.90, 2.40) 1 1.52 (0.04, 8.47) 
10-<20 years 109 1.32 (1.08, 1.59) 14 1.87 (1.02, 3.13) 37 1.19 (0.84, 1.65) 2 0.73 (0.09, 2.64) 
20+ years 139 1.19 (1.00, 1.41) 7 0.87 (0.35, 1.79) 57 1.13 (0.85, 1.46) 8 0.77 (0.33, 1.52) 
Testicular         
2 mo- <1 year 51 2.22 (1.65, 2.92) 12 5.96 (3.08, 10.40) 4 1.64 (0.45, 4.20) 0 0 (0, 37.31) 
1 - <5 years 135 1.28 (1.07, 1.51) 26 2.46 (1.60, 3.60) 12 0.82 (0.42, 1.43) 0 0 (0, 6.76) 
5- <10 years 126 0.95 (0.79, 1.13) 19 1.30 (0.78, 2.03) 24 0.87 (0.56, 1.29) 0 0 (0, 3.49) 
10-<20 years 276 0.99 (0.87, 1.11) 41 1.55 (1.11, 2.11) 82 0.92 (0.73, 1.14) 3 0.56 (0.12, 1.65) 
20+ years 410 1.12 (1.01, 1.23) 35 1.42 (0.99, 1.97) 173 1.13 (0.96, 1.31) 16 0.74 (0.42, 1.20) 
Abbreviations: SMR, standardized mortality ratio; AYAs, adolescents and young adults; GI, gastrointestinal 





Table 5.8 SMRs for mortality from gastrointestinal (GI) and liver diseases, renal diseases, external causes, and other causes among AYAs with cancer 
according to time since diagnosis, stratified by cancer type 
  GI and liver Renal External Other 
  
N 
deaths SMR (95% CI) 
N 
deaths SMR (95% CI) 
N 
deaths SMR (95% CI) 
N 
deaths SMR (95% CI) 
Leukemias          
2 mo- <1 year 0 0 (0, 17.05) 2 41.18 (4.99, 148.74) 18 3.72 (2.20, 5.88) 75 53.15 (41.81, 66.62) 
1 - <5 years 7 8.24 (3.31, 16.99) 5 28.50 (9.25, 66.50) 24 1.72 (1.10, 2.56) 127 26.87 (22.40, 31.98) 
5- <10 years 5 4.67 (1.52, 10.91) 1 4.80 (0.12, 26.76) 13 1.23 (0.65, 2.10) 29 6.03 (4.04, 8.66) 
10-<20 years 6 2.66 (0.98, 5.79) 3 6.28 (1.29, 18.34) 14 1.19 (0.65, 2.00) 27 3.15 (2.08, 4.59) 
20+ years 7 3.96 (1.59, 8.15) 5 7.69 (2.50, 17.94) 2 0.37 (0.05, 1.34) 17 2.05 (1.19, 3.28) 
Non-Hodgkin 
lymphoma         
2 mo- <1 year 4 10.18 (2.77, 26.07) 6 68.24 (25.04, 148.53) 14 1.92 (1.05, 3.21) 63 26.38 (20.27, 33.75) 
1 - <5 years 3 1.58 (0.33, 4.62) 5 12.89 (4.19, 30.08) 30 1.18 (0.80, 1.69) 89 9.12 (7.33, 11.23) 
5- <10 years 0 0 (0, 1.31) 3 5.54 (1.14, 16.20) 29 1.26 (0.84, 1.81) 37 3.14 (2.21, 4.33) 
10-<20 years 3 0.48 (0.10, 1.39) 6 4.44 (1.63, 9.65) 39 1.39 (0.98, 1.89) 44 1.91 (1.39, 2.56) 
20+ years 8 1.45 (0.63, 2.86) 3 1.25 (0.26, 3.64) 13 0.90 (0.48, 1.54) 48 1.69 (1.25, 2.24) 
Hodgkin 
lymphoma         
2 mo- <1 year 0 0 (0, 13.47) 0 0 (0, 50.87) 9 1.03 (0.47, 1.95) 20 8.69 (5.31, 13.42) 
1 - <5 years 4 2.47 (0.67, 6.33) 3 8.09 (1.67, 23.63) 41 1.13 (0.81, 1.53) 55 4.99 (3.76, 6.50) 
5- <10 years 2 0.71 (0.09, 2.56) 1 1.79 (0.05, 9.97) 45 1.28 (0.94, 1.72) 56 3.88 (2.93, 5.03) 
10-<20 years 8 1.00 (0.43, 1.96) 4 2.48 (0.68, 6.36) 53 1.10 (0.83, 1.44) 86 2.67 (2.14, 3.30) 
20+ years 11 1.04 (0.52, 1.86) 16 4.67 (2.67, 7.59) 41 1.27 (0.91, 1.72) 130 2.83 (2.36, 3.36) 
CNS tumors         
2 mo- <1 year 0 0 (0, 15.22) 1 20.03 (0.51, 111.58) 8 1.46 (0.63, 2.88) 19 12.01 (7.23, 18.75) 
1 - <5 years 3 2.82 (0.58, 8.25) 4 19.65 (5.35, 50.31) 35 1.89 (1.31, 2.62) 48 7.88 (5.81, 10.44) 
5- <10 years 1 0.74 (0.02, 4.11) 0 0 (0, 15.15) 24 1.64 (1.05, 2.44) 31 4.90 (3.33, 6.96) 
10-<20 years 4 1.43 (0.39, 3.65) 3 5.32 (1.10, 15.54) 29 1.78 (1.19, 2.56) 53 4.80 (3.59, 6.28) 






sarcomas a         
2 mo- <1 year 0 0 (0, 17.27) 0 0 (0, 71.47) 8 1.88 (0.81, 3.70) 15 10.80 (6.04, 17.81) 
1 - <5 years 0 0 (0, 3.36) 0 0 (0, 15.38) 16 1.02 (0.58, 1.66) 22 3.65 (2.28, 5.52) 
5- <10 years 2 1.19 (0.14, 4.31) 0 0 (0, 10.51) 16 1.09 (0.62, 1.77) 18 2.35 (1.39, 3.71) 
10-<20 years 5 1.16 (0.38, 2.71) 0 0 (0, 3.43) 19 0.94 (0.57, 1.47) 23 1.31 (0.83, 1.96) 
20+ years 5 0.90 (0.29, 2.10) 4 1.37 (0.37, 3.51) 25 1.70 (1.10, 2.51) 40 1.26 (0.90, 1.72) 
Melanoma         
2 mo- <1 year 0 0 (0, 5.21) 0 0 (0, 28.47) 6 0.50 (0.18, 1.08) 9 2.10 (0.96, 3.99) 
1 - <5 years 3 0.71 (0.15, 2.07) 0 0 (0, 5.43) 30 0.59 (0.40, 0.84) 23 1.09 (0.69, 1.64) 
5- <10 years 4 0.56 (0.15, 1.42) 0 0 (0, 3.47) 32 0.65 (0.42, 0.87) 27 0.94 (0.62, 1.36) 
10-<20 years 4 0.21 (0.06, 0.55) 3 0.89 (0.18, 2.61) 54 0.73 (0.55, 0.95) 41 0.60 (0.43, 0.82) 
20+ years 9 0.42 (0.19, 0.80) 2 0.21 (0.03, 0.76) 34 0.67 (0.47, 0.94) 96 0.80 (0.65, 0.98) 
Thyroid         
2 mo- <1 year 0 0 (0, 7.02) 0 0 (0, 28.48) 9 1.06 (0.48, 2.01) 5 1.36 (0.44, 3.16) 
1 - <5 years 3 0.97 (0.20, 2.84) 1 1.49 (0.04, 8.31) 20 0.55 (0.34, 0.86) 24 1.34 (0.86, 2.00) 
5- <10 years 4 0.80 (0.22, 2.05) 1 1.02 (0.03, 5.71) 25 0.69 (0.45, 1.03) 22 0.95 (0.60, 1.45) 
10-<20 years 8 0.67 (0.29, 1.31) 5 1.87 (0.61, 4.36) 31 0.62 (0.42, 0.88) 48 0.97 (0.71, 1.28) 
20+ years 6 0.39 (0.14, 0.86) 12 1.48 (0.76, 2.59) 27 0.73 (0.48, 1.06) 85 0.89 (0.71, 1.10) 
Other head and 
neck         
2 mo- <1 year 1 4.01 (0.10, 22.36) 3 66.77 (13.77, 195.13) 3 0.95 (0.20, 2.78) 10 8.60 (4.12, 15.81) 
1 - <5 years 1 0.83 (0.02, 4.63) 2 9.98 (1.21, 36.04) 22 1.87 (1.17, 2.83) 22 4.40 (2.76, 6.66) 
5- <10 years 2 2.26 (0.62, 5.80) 0 0 (0, 12.78) 26 2.32 (1.52, 3.40) 16 2.51 (1.44, 4.08) 
10-<20 years 9 2.23 (1.02, 4.23) 4 4.84 (1.32, 12.38) 18 1.19 (0.71, 1.88) 31 2.20 (1.50, 3.13) 
20+ years 4 0.94 (0.26, 2.40) 2 0.86 (0.10, 3.10) 24 2.36 (1.51, 3.51) 36 1.43 (1.00, 1.98) 
Breast         
2 mo- <1 year 2 1.86 (0.23, 6.73) 2 7.38 (0.89, 26.65) 10 1.18 (0.57, 2.17) 18 2.85 (1.69, 4.51) 
1 - <5 years 5 0.92 (0.30, 2.15) 4 3.13 (0.85, 8.01) 31 0.91 (0.62, 1.29) 78 2.74 (2.17, 3.42) 
5- <10 years 10 1.39 (0.67, 2.55) 1 0.58 (0.01, 3.24) 29 0.89 (0.60, 1.28) 53 1.55 (1.16, 2.03) 
10-<20 years 15 1.04 (0.58, 1.71) 3 0.61 (0.13, 1.79) 44 1.01 (0.73, 1.35) 98 1.32 (1.07, 1.61) 





Cervix/uterus         
2 mo- <1 year 4 9.47 (2.58, 24.26) 2 19.10 (2.31, 69.01) 7 1.82 (0.73, 3.76) 14 5.44 (2.98, 9.13) 
1 - <5 years 4 1.83 (0.50, 4.68) 3 6.01 (1.24, 17.58) 22 1.40 (0.88, 2.12) 39 3.31 (2.35, 4.53) 
5- <10 years 4 1.20 (0.33, 3.08) 2 2.68 (0.32, 9.68) 27 1.59 (1.05, 2.31) 44 2.75 (2.00, 3.70) 
10-<20 years 10 1.24 (0.60, 2.29) 6 2.47 (0.91, 5.37) 47 1.73 (1.27, 2.30) 103 2.56 (2.09, 3.10) 
20+ years 16 1.57 (0.90, 2.55) 29 3.39 (2.27, 4.87) 32 1.48 (1.01, 2.09) 182 2.05 (1.76, 2.37) 
Colon and rectum         
2 mo- <1 year 1 2.50 (0.06, 13.95) 4 47.01 (12.81, 120.36) 3 0.59 (0.12, 1.72) 22 10.59 (6.64, 16.04) 
1 - <5 years 2 1.14 (0.14, 4.13) 4 11.53 (3.14, 29.51) 27 1.65 (1.09, 2.39) 17 2.15 (1.25, 3.44) 
5- <10 years 5 2.17 (0.70, 5.06) 2 4.47 (0.54, 16.13) 17 1.25 (0.73, 1.99) 25 2.82 (1.82, 4.16) 
10-<20 years 5 1.03 (0.33, 2.40) 3 2.46 (0.51, 7.19) 20 1.19 (0.72, 1.83) 28 1.53 (1.01, 2.20) 
20+ years 8 1.79 (0.77, 3.53) 5 1.71 (0.55, 3.98) 7 0.70 (0.28, 1.45) 47 1.55 (1.14, 2.07) 
Testicular         
2 mo- <1 year 0 0 (0, 7.17) 2 22.24 (2.69, 80.34) 17 1.17 (0.68, 1.88) 16 4.83 (2.76, 7.84) 
1 - <5 years 2 0.63 (0.08, 2.26) 1 2.08 (0.05, 11.61) 57 0.95 (0.72, 1.23) 37 2.28 (1.60, 3.14) 
5- <10 years 6 1.01 (0.37, 2.19) 1 1.26 (0.03, 7.02) 50 0.83 (0.61, 1.09) 26 1.15 (0.75, 1.68) 
10-<20 years 20 1.15 (0.70, 1.77) 4 1.57 (0.43, 4.01) 71 0.83 (0.65, 1.05) 55 1.03 (0.77, 1.34) 
20+ years 21 0.99 (0.61, 1.51) 10 1.62 (0.78, 2.98) 54 0.96 (0.72, 1.25) 101 1.23 (1.00, 1.49) 
Abbreviations: SMR, standardized mortality ratio; AYAs, adolescents and young adults; GI, gastrointestinal 





Table 5.9. SMRs for mortality from all noncancer causes, infectious diseases, cardiovascular diseases, and respiratory diseases among AYAs with cancer 
according to age at diagnosis, stratified by cancer type 
 All noncancer Infectious Cardiovascular Respiratory 
  N deaths SMR (95% CI) 
N 
deaths SMR (95% CI) 
N 
deaths SMR (95% CI) N deaths SMR (95% CI) 
Leukemias          
15-19 103 6.39 (5.22-7.75) 24 24.51 (15.71-36.47) 11 5.23 (2.61-9.36) 2 11.94 (1.45-43.13) 
20-24 109 8.02 (6.59-9.68) 23 22.28 (14.13-33.44) 8 3.62 (1.56-7.14) 4 22.29 (6.07-57.06) 
25-29 122 6.28 (5.22-7.50) 37 19.51 (13.74-26.90) 26 5.87 (3.84-8.60) 3 7.87 (1.62-23.00) 
30-34 150 4.88 (4.13-5.72) 39 13.51 (9.61-18.47) 25 2.84 (1.84-4.20) 2 2.25 (0.27-8.15) 
35-39 219 4.06 (3.54-4.64) 64 13.19 (10.16-16.85) 41 2.19 (1.58-2.98) 7 3.15 (1.27-6.50) 
Non-Hodgkin lymphoma       
15-19 67 3.88 (3.01-4.93 15 13.20 (7.39-21.77) 16 6.64 (3.80-10.79) 0 0 (0-19.96) 
20-24 157 5.70 (4.84-6.67) 73 29.62 (23.21-37.24) 25 4.58 (2.97-6.77) 0 0 (0-7.81) 
25-29 349 7.05 (6.33-7.83) 238 48.45 (42.49-55.01) 36 2.86 (2.01-3.96) 3 2.38 (0.49-6.96) 
30-34 708 7.66 (7.10-8.24) 543 60.82 (55.81-66.16) 60 2.05 (1.56-2.63) 8 2.40 (1.03-4.72) 
35-39 931 5.72 (5.36-6.10) 652 45.17 (41.77-48.77) 87 1.46 (1.17-1.80) 9 1.18 (0.54-2.24) 
Hodgkin lymphoma        
15-19 206 3.67 (3.19-4.21) 32 7.29 (4.99-10.29) 79 8.71 (6.90-10.86) 5 6.28 (2.04-14.65) 
20-24 337 3.57 (3.20-3.98) 58 6.76 (5.13-8.73) 138 7.01 (5.89-8.28) 6 3.25 (1.19-7.07) 
25-29 354 2.99 (2.69-3.32) 75 6.50 (5.11-8.14) 141 4.45 (3.75-5.25) 6 1.79 (0.66-3.89) 
30-34 343 2.95 (2.65-3.28) 79 7.23 (5.73-9.02) 132 3.50 (2.93-4.15) 7 1.56 (0.63-3.22) 
35-39 311 2.76 (2.47-3.09) 64 6.51 (5.02-8.32) 135 3.17 (2.66-3.76) 9 1.68 (0.77-3.19) 
CNS tumors        
15-19 52 2.23 (1.67-2.92) 5 2.93 (0.95-6.83) 12 3.35 (1.73-5.85) 0 0 (0-12.21) 
20-24 108 4.32 (3.54-5.22) 16 7.72 (4.41-12.53) 15 3.24 (1.81-5.34) 1 2.54 (0.06-14.18) 
25-29 119 3.83 (3.17-4.58) 28 9.17 (6.10-13.26) 28 3.96 (2.63-5.73) 3 4.25 (0.88-12.41) 
30-34 157 3.77 (3.20-4.41) 26 6.22 (4.07-9.12) 41 3.55 (2.55-4.81) 2 1.75 (0.21-6.32) 
35-39 157 2.87 (2.44-3.36) 16 3.24 (1.85-5.26) 54 2.95 (2.21-3.85) 2 0.93 (0.11-3.35) 
Soft tissue sarcomas a       





20-24 44 1.53 (1.11-2.05) 3 1.06 (0.22-3.09) 8 1.21 (0.52-2.37) 0 0 (0-5.88) 
25-29 60 1.23 (0.94-1.58) 9 1.79 (0.82-3.40) 14 1.01 (0.55-1.69) 3 1.96 (0.40-5.72) 
30-34 109 1.57 (1.29-1.89) 15 2.18 (1.22-3.60) 28 1.18 (0.79-1.71) 4 1.34 (0.36-3.43) 
35-39 147 1.26 (1.06-1.48) 20 1.98 (1.21-3.06) 53 1.16 (0.87-1.52) 7 1.01 (0.41-2.08) 
Melanoma         
15-19 14 0.74 (0.41-1.25) 1 0.83 (0.02-4.60) 1 0.33 (0.01-1.84) 0 0 (0-11.62) 
20-24 42 0.68 (0.49-0.92) 4 0.83 (0.23-2.12) 11 0.82 (0.41-1.48) 1 0.64 (0.02-3.55) 
25-29 110 0.70 (0.58-0.84) 14 1.07 (0.59-1.80) 28 0.64 (0.43-0.93) 4 0.66 (0.18-1.69) 
30-34 183 0.62 (0.53-0.71) 19 0.79 (0.47-1.23) 45 0.46 (0.34-0.62) 5 0.33 (0.11-0.76) 
35-39 313 0.64 (0.57-0.71) 44 1.20 (0.87-1.61) 100 0.54 (0.44-0.66) 8 0.25 (0.11-0.49) 
Thyroid         
15-19 24 1.10 (0.71-1.64) 1 0.61 (0.02-3.38) 7 1.78 (0.72-3.67) 0 0 (0-7.89) 
20-24 56 0.85 (0.64-1.11) 4 0.73 (0.20-1.86) 16 1.05 (0.60-1.70) 0 0 (0-1.81) 
25-29 120 0.90 (0.75-1.08) 10 0.91 (0.44-1.68) 36 0.97 (0.68-1.34) 6 1.02 (0.38-2.23) 
30-34 164 0.73 (0.62-0.85) 13 0.71 (0.38-1.22) 56 0.75 (0.57-0.97) 7 0.54 (0.22-1.12) 
35-39 242 0.79 (0.70-0.90) 14 0.60 (0.33-1.01) 89 0.80 (0.64-0.98) 11 0.54 (0.27-0.96) 
Other head and neck        
15-19 14 2.49 (1.36-4.18) 2 4.43 (0.54-16.01) 6 6.59 (2.42-14.34) 0 0 (0-41.74) 
20-24 23 1.72 (1.09-2.57) 3 2.24 (0.46-6.55) 6 1.91 (0.70-4.15) 1 3.36 (0.08-18.70) 
25-29 60 2.18 (1.66-2.81) 12 4.56 (2.36-7.97) 18 2.25 (1.33-3.55) 3 3.25 (0.67-9.49) 
30-34 92 1.64 (1.32-2.01) 15 2.87 (1.61-4.73) 24 1.24 (0.79-1.85) 8 3.27 (1.41-6.45) 
35-39 300 2.29 (2.04-2.57) 32 2.99 (2.05-4.23) 97 1.85 (1.50-2.26) 24 3.39 (2.17-5.05) 
Breast b         
15-24 12 2.08 (1.07-3.63) 0 0 (0-6.43) 7 5.01 (2.01-10.32) 0 0 (0-20.01) 
25-29 84 1.71 (1.36-2.12) 5 1.07 (0.35-2.50) 26 1.87 (1.22-2.74) 6 2.61 (0.96-5.68) 
30-34 316 1.44 (1.29-1.61) 36 1.87 (1.31-2.58) 114 1.61 (1.33-1.93) 12 0.90 (0.46-1.56) 
35-39 792 1.16 (1.08-1.24) 76 1.40 (1.10-1.75) 312 1.26 (1.13-1.41) 32 0.61 (0.42-0.86) 
Cervix/uterus b        
15-24 44 2.19 (1.59-2.94) 4 2.01 (0.55-5.14) 8 1.50 (0.65-2.96) 4 5.10 (1.39-13.06) 
25-29 164 2.02 (1.72-2.36) 17 2.35 (1.37-3.76) 44 1.81 (1.31-2.43) 9 2.08 (0.95-3.95) 





35-39 604 2.11 (1.95-2.29) 57 2.61 (1.98-3.38) 207 1.94 (1.68-2.22) 42 1.79 (1.29-2.42) 
Colon and rectum b        
15-24 26 2.64 (1.73-3.87) 3 3.84 (0.79-11.21) 8 4.06 (1.75-7.99) 0 0 (0-17.12) 
25-29 60 2.33 (1.78-3.00) 10 3.82 (1.83-7.03) 13 1.85 (0.98-3.16) 1 1.32 (0.03-7.38) 
30-34 137 1.92 (1.61-2.27) 40 5.94 (4.24-8.08) 28 1.20 (0.80-1.74) 3 0.96 (0.20-2.82) 
35-39 290 1.56 (1.39-1.76) 56 3.54 (2.67-4.59) 91 1.27 (1.03-1.56) 8 0.78 (0.34-1.54) 
Testicular         
15-19 45 1.44 (1.05-1.93) 9 4.19 (1.91-7.95) 10 2.06 (0.99-3.79) 0 0 (0-12.05) 
20-24 137 1.16 (0.97-1.37) 11 1.06 (0.53-1.90) 33 1.27 (0.88-1.79) 3 1.59 (0.33-4.64) 
25-29 247 1.13 (0.99-1.28) 39 1.92 (1.37-2.63) 68 1.12 (0.87-1.41) 3 0.58 (0.12-1.70) 
30-34 308 1.14 (1.02-1.28) 42 1.75 (1.26-2.37) 101 1.11 (0.91-1.35) 6 0.66 (0.24-1.44) 
35-39 261 0.97 (0.85-1.09) 32 1.48 (1.01-2.09) 83 0.79 (0.63-0.98) 7 0.57 (0.23-1.18) 
                  
Abbreviations: SMR, standardized mortality ratio; AYAs, adolescents and young adults; GI, gastrointestinal 
a Excludes Kaposi sarcoma 





Table 5.10. SMRs for mortality from gastrointestinal (GI) and liver diseases, renal diseases, external causes, and other causes among AYAs with cancer 
according to age at diagnosis, stratified by cancer type 
 GI and liver Renal External Other 
  N deaths SMR (95% CI) N deaths SMR (95% CI) N deaths SMR (95% CI) N deaths SMR (95% CI) 
Leukemias         
15-19 2 5.26 (0.64-18.99) 3 30.82 (6.36-90.07) 14 1.45 (0.79-2.43) 47 17.19 (12.63-22.85) 
20-24 5 12.20 (3.96-28.48) 1 9.36 (0.24-52.14) 18 2.54 (1.50-4.01) 50 19.58 (14.53-25.81) 
25-29 2 2.44 (0.30-8.82) 3 14.78 (3.05-43.20) 10 1.29 (0.62-2.38) 41 10.46 (7.50-14.18) 
30-34 4 2.55 (0.70-6.54) 4 10.59 (2.89-27.12) 15 1.56 (0.87-2.57) 61 9.24 (7.07-11.87) 
35-39 12 4.02 (2.08-7.02) 5 6.44 (2.09-15.04) 14 1.13 (0.62-1.90) 76 6.34 (4.99-7.93) 
Non-Hodgkin lymphoma         
15-19 1 2.27 (0.06-12.66) 2 18.27 (2.21-66.01) 12 1.20 (0.62-2.09) 21 7.15 (4.43-10.93) 
20-24 3 3.05 (0.63-8.92) 3 11.90 (2.45-34.77) 22 1.74 (1.09-2.64) 31 5.85 (3.98-8.30) 
25-29 3 1.36 (0.28-3.97) 5 8.68 (2.82-20.26) 22 1.25 (0.79-1.90) 42 4.04 (2.91-5.46) 
30-34 4 0.85 (0.23-2.17) 3 2.39 (0.49-7.00) 25 1.01 (0.65-1.49) 65 3.24 (2.50-4.13) 
35-39 7 0.82 (0.33-1.69) 10 3.86 (1.85-7.11) 44 1.32 (0.96-1.77) 122 3.33 (2.76-3.97) 
Hodgkin lymphoma         
15-19 3 1.72 (0.36-5.04) 5 11.89 (3.86-27.74) 33 1.13 (0.78-1.59) 49 4.65 (3.44-6.15) 
20-24 6 1.57 (0.57-3.41) 5 5.78 (1.88-13.48) 56 1.38 (1.04-1.80) 68 3.58 (2.78-4.54) 
25-29 6 1.05 (0.38-2.28) 5 3.67 (1.19-8.57) 41 1.04 (0.75-1.41) 80 3.15 (2.50-3.92) 
30-34 9 1.48 (0.68-2.82) 4 2.48 (0.68-6.35) 30 1.01 (0.68-1.45) 82 3.17 (2.52-3.94) 
35-39 1 1.68 (0.77-3.19) 5 2.81 (0.91-6.56) 29 1.33 (0.89-1.90) 68 2.70 (2.10-3.43) 
CNS tumors         
15-19 1 1.53 (0.04-8.50) 1 6.03 (0.15-33.58) 15 1.18 (0.66-1.94) 18 4.32 (2.56-6.83) 
20-24 1 1.10 (0.03-6.13) 2 10.15 (1.23-36.66) 25 2.08 (1.34-3.07) 48 10.09 (7.44-13.38) 
25-29 2 1.54 (0.19-5.56) 4 12.60 (3.43-32.26) 18 1.48 (0.87-2.33) 36 5.57 (3.90-7.72) 
30-34 2 0.93 (0.11-3.36) 0 0 (0-7.70) 26 1.97 (1.29-2.88) 60 6.72 (5.13-8.65) 
35-39 3 0.98 (0.20-2.86) 3 4.02 (0.83-11.74) 30 2.27 (1.53-3.25) 49 4.01 (2.97-5.30) 
Soft tissue sarcomas a         
15-19 1 1.77 (0.04-9.84) 1 6.74 (0.17-37.55) 7 0.78 (0.31-1.61) 13 3.83 (2.04-6.55) 
20-24 0 0 (0-3.23) 0 0 (0-11.28) 18 1.59 (0.94-2.52) 15 2.53 (1.42-4.18) 





30-34 5 1.48 (0.48-3.46) 1 0.84 (0.02-4.70) 19 1.24 (0.75-1.94) 37 2.30 (1.62-3.17) 
35-39 5 0.92 (0.30-2.14) 2 0.88 (0.11-3.17) 23 1.24 (0.79-1.87) 37 1.33 (0.93-1.83) 
Melanoma         
15-19 0 0 (0-5.84) 0 0 (0-27.02) 10 1.02 (0.49-1.88 2 0.53 (0.06-1.92) 
20-24 0 0 (0-1.36) 1 1.70 (0.04-9.46) 14 0.55 (0.30-0.93) 11 0.81 (0.41-1.45) 
25-29 4 0.51 (0.14-1.30) 0 0 (1.95) 27 0.56 (0.37-0.82) 33 0.91 (0.62-1.27) 
30-34 9 0.57 (0.26-1.09) 4 0.95 (0.26-2.43) 44 0.63 (0.46-0.85) 57 0.81 (0.61-1.05) 
35-39 7 0.28 (0.11-0.57) 0 0 (0-0.46) 61 0.70 (0.54-0.91) 93 0.79 (0.64-0.96) 
Thyroid         
15-19 1 1.26 (0.03-7.02) 0 0 (0-17.86) 6 0.61 (0.22-1.33) 9 1.82 (0.83-3.46) 
20-24 2 0.68 (0.08-2.45) 4 5.01 (1.36-12.82) 17 0.73 (0.43-1.17) 13 0.82 (0.43-1.39) 
25-29 3 0.46 (0.10-1.36) 5 2.57 (0.84-6.01) 26 0.71 (0.46-1.03) 34 1.01 (0.70-1.42) 
30-34 6 0.54 (0.20-1.19) 3 0.77 (0.16-2.25) 31 0.67 (0.45-0.95) 15 0.26 (0.15-0.43) 
35-39 9 0.61 (0.28-1.16) 7 1.22 (0.49-2.52) 32 0.63 (0.43-0.89) 80 1.02 (0.81-1.27) 
Other head and neck         
15-19 0 0 (0-24.62) 0 0 (0-73.04) 3 1.04 (0.22-3.05) 3 2.73 (0.56-7.99) 
20-24 0 0 (0-6.64) 1 6.49 (0.16-36.16) 7 1.36 (0.55-2.79) 5 1.81 (0.59-4.23) 
25-29 1 0.74 (0.02-4.10) 0 0 (0-10.10) 11 1.34 (0.67-2.40) 15 2.48 (1.39-4.10) 
30-34 4 1.38 (0.37-3.52) 0 0 (0-4.39) 18 1.41 (0.83-2.22) 23 1.85 (1.17-2.78) 
35-39 14 2.14 (1.17-3.59) 10 4.38 (2.10-8.05) 54 2.42 (1.81-3.15) 69 2.34 (1.82-2.96) 
Breast b         
15-24 1 4.73 (0.12-26.36) 0 0 (0-39.07) 3 1.73 (0.36-5.06) 1 0.63 (0.02-3.52) 
25-29 1 0.47 (0.01-2.62) 3 3.38 (0.70-9.87) 17 1.47 (0.86-2.36) 26 1.89 (1.24-2.77) 
30-34 10 1.03 (0.49-1.88) 5 1.11 (0.36-2.59) 43 1.09 (0.79-1.47) 96 1.56 (1.26-1.90) 
35-39 28 0.94 (0.63-1.37) 14 0.92 (0.50-1.54) 73 0.78 (0.62-0.99) 257 1.33 (1.17-1.50) 
Cervix/uterus b         
15-24 2 2.38 (0.29-8.61) 1 2.89 (0.07-16.13) 7 1.33 (0.53-2.73) 18 3.26 (1.93-5.14) 
25-29 7 1.90 (0.76-3.91) 4 2.61 (0.71-6.68) 27 1.57 (1.03-2.28) 56 2.46 (1.86-3.19) 
30-34 13 1.67 (0.89-2.85) 12 3.12 (1.61-5.45) 43 1.53 (1.10-2.05) 109 2.17 (1.78-2.62) 
35-39 16 1.35 (0.77-2.20) 25 3.78 (2.45-5.58) 58 1.67 (1.27-2.16) 199 2.46 (2.13-2.83) 
Colon and rectum b         





25-29 2 1.73 (0.21-6.24) 4 11.60 (3.16-29.70) 12 1.46 (0.75-2.55) 18 3.19 (1.89-5.05) 
30-34 3 0.86 (0.18-2.52) 5 4.47 (1.45-10.44) 17 0.99 (0.58-1.59) 41 2.49 (1.79-3.38) 
35-39 14 1.59 (0.87-2.67) 9 2.59 (1.18-4.92) 42 1.31 (0.94-1.76) 70 1.61 (1.26-2.04) 
Testicular         
15-19 1 1.02 (0.03-5.69) 0 0 (0-20.98) 16 0.90 (0.51-1.46) 9 1.82 (0.83-3.46) 
20-24 5 0.96 (0.31-2.24) 5 5.47 (1.78-12.76) 44 0.83 (0.60-1.11) 36 1.72 (1.21-2.38) 
25-29 10 0.87 (0.42-1.60) 2 0.95 (0.11-3.42) 64 0.84 (0.64-1.07) 61 1.46 (1.12-1.88) 
30-34 18 1.17 (0.70-1.85) 5 1.59 (0.52-3.72) 71 0.96 (0.75-1.22) 65 1.20 (0.92-1.53) 
35-39 15 0.98 (0.55-1.62) 6 1.60 (0.59-3.49) 54 0.97 (0.73-1.26) 64 1.14 (0.88-1.45) 
                  
Abbreviations: SMR, standardized mortality ratio; AYAs, adolescents and young adults; GI, gastrointestinal 
a Excludes Kaposi sarcoma 




Table 5.11. Sensitivity analysis varying the latency exclusion period 
 
0 month latency exclusion 
 
6 month latency exclusion 
  Observed SMR (95% CI)  Observed SMR (95% CI) 
All noncancer 13792 1.94 (1.91, 1.98)  11854 1.70 (1.67, 1.73) 
      
Infectious 3590 5.97 (5.77, 6.17)  2311 3.92 (3.76, 4.08) 
Tuberculosis 10 1.94 (0.93, 3.56)  9 1.80 (0.82, 3.41) 
Syphilis 0 0 (0, 16.42)  0 0 (0, 16.88) 
Septicemia 330 2.72 (2.43, 3.03)  298 2.47 (2.20, 2.77) 
Other Infectious and 
Parasitic Diseases 
including HIV 
2785 8.16 (7.86, 8.47) 
 
1584 4.76 (4.53, 5.01) 
Pneumonia and 
Influenza 465 3.48 (3.17, 3.82)  
420 3.19 (2.89, 3.51) 
      
Cardiovascular 3667 1.58 (1.53, 1.63)  3500 1.52 (1.47, 1.57) 
Diseases of Heart 2977 1.61 (1.56, 1.67)  2847 1.55 (1.50, 1.61) 
Hypertension without 
Heart Disease 77 1.35 (1.07, 1.69)  
75 1.32 (1.04, 1.66) 
Cerebrovascular 
Diseases 509 1.49 (1.36, 1.63)  
478 1.41 (1.29, 1.55) 
Atherosclerosis 21 2.04 (1.26, 3.12)  20 1.95 (1.19, 3.02) 
Aortic Aneurysm and 
Dissection 37 1.00 (0.71, 1.38)  
36 0.99 (0.69, 1.37) 
Other Diseases of 
Arteries, Arterioles, 
Capillaries 
46 1.77 (1.29, 2.36) 
 
44 1.71 (1.24, 2.29) 
      





411 1.17 (1.06, 1.29) 
 
405 1.15 (1.04, 1.27) 
      
Gastrointestinal and 
liver 385 1.14 (1.03, 1.26)  
355 1.06 (0.95, 1.18) 
Stomach and 
Duodenal Ulcers 35 2.55 (1.78, 3.54)  
30 2.21 (1.49, 3.15) 
Chronic Liver 
Disease and Cirrhosis 350 1.08 (0.97, 1.20)  
325 1.01 (0.91, 1.13) 
      




286 2.54 (2.25, 2.85) 
 
260 2.33 (2.05, 2.63) 




External 1834 1.09 (1.04, 1.14)  1746 1.07 (1.02, 1.13) 
Accidents and 
Adverse Effects 1143 1.08 (1.02, 1.15)  
1087 1.07 (1.01, 1.13) 
Suicide and Self-
Inflicted Injury 546 1.23 (1.13, 1.34)  
524 1.23 (1.12, 1.33) 
Homicide and Legal 
Intervention 145 0.75 (0.64, 0.89)  
135 0.74 (0.62, 0.88) 
      
Other 3619 2.15 (2.08, 2.22)  3277 1.98 (1.91, 2.04) 
Diabetes Mellitus 378 1.24 (1.12, 1.37)  372 1.23 (1.11, 1.36) 
Alzheimers (ICD-9 
and 10 only) 28 0.97 (0.64, 1.40)  





76 8.51 (6.71, 10.66) 
 
56 6.70 (5.06, 8.70) 
Congenital 
Anomalies 105 2.44 (2.00, 2.95)  




4 11.85 (3.23, 30.33) 
 
4 12.44 (3.39, 31.84) 
Symptoms, Signs and 
Ill-Defined 
Conditions 
260 1.81 (1.59, 2.04) 
 
249 1.78 (1.56, 2.01) 
Other Cause of Death 2768 2.40 (2.31, 2.49)  2477 2.18 (2.09, 2.27) 
            





Table 5.12. Sensitivity analysis of cause of death misclassification, varying the extent to which observed deaths from noncancer causes among AYAs with 
cancer are overestimated   
      10% overestimated 20% overestimated 30% overestimated 
 Expected 
 Observed SMR (95% CI) Observed SMR (95% CI) Observed SMR (95% CI) 
All noncancer 7053.34  11653 1.65 (1.62, 1.68) 10358 1.47 (1.44, 1.50) 9064 1.29 (1.26, 1.31) 
         
Infectious 597.58  2761 4.62 (4.45, 4.80) 2454 4.11 (3.95, 4.27) 2148 3.59 (3.44, 3.75) 
Tuberculosis 5.11  8 1.59 (0.81, 3.09) 7 1.41 (0.68, 2.82) 6 1.23 (0.55, 2.56) 
Syphilis 0.22  0 0 0 0 0 0 
Septicemia 121.14  287 2.37 (2.11, 2.66) 255 2.11 (1.86, 2.38) 223 1.84 (1.62, 2.10) 
Other Infectious and 
Parasitic Diseases 
including HIV 
338.27  2063 6.10 (5.84, 6.36) 1834 5.42 (5.18, 5.67) 1604 4.74 (4.52, 4.98) 
Pneumonia and Influenza 132.83  403 3.04 (2.75, 3.35) 358 2.70 (2.43, 2.99) 314 2.36 (2.11, 2.63) 
         
Cardiovascular 2311.77  3216 1.39 (1.34, 1.44) 2858 1.24 (1.19, 1.28) 2501 1.08 (1.04, 1.13) 
Diseases of Heart 1841.72  2615 1.42 (1.37, 1.48) 2325 1.26 (1.21, 1.31) 2034 1.11 (1.06, 1.15) 
Hypertension without 
Heart Disease 56.89 
 68 1.19 (0.93, 1.50) 60 1.06 (0.80, 1.36) 53 0.92 (0.70, 1.20) 
Cerebrovascular Diseases 340.24  440 1.29 (1.18, 1.42) 391 1.15 (1.04, 1.27) 342 1.01 (0.90, 1.12) 
Atherosclerosis 10.26  18 1.75 (1.04, 2.77) 16 1.56 (0.89, 2.53) 14 1.36 (0.75, 2.29) 
Aortic Aneurysm and 
Dissection 36.72 
 33 0.91 (0.64, 1.26) 30 0.81 (0.55, 1.13) 26 0.71 (0.46, 1.01) 
Other Diseases of Arteries, 
Arterioles, Capillaries 25.93 
 41 1.60 (1.17, 2.15) 37 1.42 (1.01, 1.92) 32 1.24 (0.88, 1.74) 
         
Respiratory         
Chronic Obstructive 
Pulmonary Disease and 
Allied Conditions 
351.95  367 1.04 (0.94, 1.16) 326 0.93 (0.83, 1.03) 286 0.81 (0.72, 0.91) 
         
Gastrointestinal and 
liver 336.63 
 333 0.99 (0.89, 1.10) 296 0.88 (0.78, 0.99) 259 0.77 (0.68, 0.87) 
Stomach and Duodenal 
Ulcers 13.68 
 30  2.17 (1.48, 3.04)  





Chronic Liver Disease and 
Cirrhosis 322.95 
 303 0.94 (0.84, 1.05) 270 0.83 (0.74, 0.94) 236 0.73 (0.64, 0.83) 
         
Renal         
Nephritis, Nephrotic 
Syndrome and Nephrosis 112.39 
 243 2.16 (1.90, 2.45) 216 1.92 (1.67, 2.20) 189 1.68 (1.45, 1.94) 
         
External 1668.25  1622 0.97 (0.93, 1.02) 1442 0.86 (0.82, 0.91) 1261 0.76 (0.72, 0.80) 
Accidents and Adverse 
Effects 1042.17 
 1008 0.97 (0.91, 1.03) 896 0.86 (0.80, 0.92) 784 0.75 (0.70, 0.81) 
Suicide and Self-Inflicted 
Injury 437.42 
 486 1.11 (1.01, 1.21) 432 0.99 (0.90, 1.09) 378 0.86 (0.78, 0.96) 
Homicide and Legal 
Intervention 188.67 
 128 0.68 (0.57, 0.90) 114 0.60 (0.50, 0.72) 99 0.53 (0.43, 0.64) 
         
Other 1674.78  3111 1.86 (1.79, 1.92) 2766 1.65 (1.59, 1.71) 2420 1.45 (1.39, 1.50) 
Diabetes Mellitus 304.65  336 1.10 (0.99, 1.22) 298 0.98 (0.87, 1.10) 261 0.86 (0.76, 0.97) 
Alzheimers (ICD-9 and 10 
only) 28.93 




8.73  59 6.80 (5.24, 8.71) 53 6.05 (4.55, 7.81) 46 5.29 (3.95, 7.03) 
Congenital Anomalies 42.61  86 2.01 (1.62, 2.47) 76 1.78 (1.41, 2.23) 67 1.56 (1.22, 1.97) 
Certain Conditions 
Originating in Perinatal 
Period 
0.33  4 10.84 (3.28, 26.39) 3 9.63 (3.28, 26.39) 3 8.43 (1.86, 21.75) 
Symptoms, Signs and Ill-
Defined Conditions 142.55 
 232 1.63 (1.43, 1.85) 206 1.45 (1.26, 1.66) 181 1.27 (1.09, 1.46) 
Other Cause of Death 1146.98  2370 2.07 (1.98, 2.15) 2106 1.84 (1.76, 1.92) 1843 1.61 (1.54, 1.68) 
                  






CHAPTER 6. DISPARITIES IN MORTALITY FROM NONCANCER CAUSES AMONG 
ADOLESCENTS AND YOUNG ADULTS WITH CANCER 
6.1 Background 
 As a consequence of exposure to intensive treatment regimens, many cancer patients 
have increased risks of noncancer health conditions which may persist long after initial cancer 
treatment is complete. For patients diagnosed at younger ages, who have many potential years of 
life remaining after cancer, the implications of excess morbidity and mortality from noncancer 
conditions are especially profound. Several reports from the Childhood Cancer Survivor Study 
and other cohorts have described patterns of mortality from noncancer causes among long-term 
survivors of childhood cancers.[86, 134-138] However, for patients diagnosed as adolescents and 
young adults (AYAs, age 15-39 years), who represent approximately seven times more incident 
cancer diagnoses each year than in children under age 15,[4] little research has examined long-
term patterns of mortality from causes other than cancer. Identifying subgroups of AYA patients 
at highest risk of adverse outcomes may facilitate planning for long-term survivorship care in 
this population. 
 In addition to cancer type and other cancer-related factors, sociodemographic 
characteristics may also be important predictors of noncancer health outcomes among AYAs 
with cancer in the U.S. Reports from California have demonstrated disparities in all-cause and 
cancer-specific mortality among AYA cancer survivors according to race/ethnicity and area-level 
socioeconomic status (SES).[89-92, 94] However, whether the risk of mortality from noncancer 




race/ethnicity, SES, and other factors has not been well-studied in the AYA cancer survivor 
population. 
 Using population-based data from the Surveillance, Epidemiology, and End Results 
(SEER) program, we investigated factors associated with noncancer mortality among AYAs with 
cancer, with a focus on disparities related to race/ethnicity, county-level SES indicators, 
geographic region, and the rural-urban continuum. Outcomes of interest included mortality from 
all noncancer causes combined and from the cause-specific categories of cardiovascular diseases 
and infectious diseases. 
6.2 Methods 
6.2.1 Study population 
 We identified AYA patients using data from the SEER 18 registries.[139] The SEER 
program is a system of population-based cancer registries that collects and reports data on cancer 
incidence and survival. SEER registries are located strategically across the U.S., currently cover 
approximately 35% of the total U.S. population, and are demographically representative.[98] 
Demographic information, primary tumor site and morphology, disease stage, and first course of 
treatment are collected by SEER, as are the number of months survived since cancer diagnosis 
and the cause of death ascertained from state death certificates. For our analyses, we included all 
patients with a first malignant primary cancer diagnosed at ages 15-39 years between 1985 and 
2015. Death certificate and autopsy only cases were excluded, as were those for whom the death 
certificate was unavailable, or was available but lacked information on the specific cause of 
death. We also excluded patients with Kaposi sarcoma, due to its strong association with HIV 
infection,[116] and those with unknown race. We classified cancer type using an AYA recode of 




histology codes.[117] Testicular cancer, which is not classified separately within the AYA 
recode, was defined using the SEER ICD-O-3/WHO 2008 recode.[140] 
6.2.2 Patient characteristics 
 Race/ethnicity was categorized for our analyses as non-Hispanic White, non-Hispanic 
Black, Hispanic (all races), and other non-Hispanic. SEER registry was used to determine 
geographic region, with categories of West (San-Francisco-Oakland, San-Jose Monterey, Los 
Angeles, Greater California, New Mexico, Seattle/Puget Sound, Utah), South (Atlanta, Rural 
Georgia, Greater Georgia, Kentucky, Louisiana), Northeast (Connecticut, New Jersey), and 
Midwest (Detroit, Iowa). Patients in the Alaska native and Hawaii registries were excluded from 
analyses according to geographic region, as sample sizes from these registries were too small to 
define them as separate regions. 
 To assess disparities according to socioeconomic characteristics, we used county-level 
information on the percent of persons below poverty and percent of persons with less than a high 
school education. These variables are based on data from the U.S. Census Bureau that are linked 
to patient data in SEER.[105] We used information from the 1990 U.S. Census for patients 
diagnosed in 1985-1994, from the 2000 U.S. Census for patients diagnosed in 1995-2004, and 
from the 2008-2012 American Community Survey for patients diagnosed in 2005-2015. 
Quartiles were created using the distribution of these variables for all U.S. counties for the 
specified years.  
 We also categorized AYA patients based on their county’s rural-urban continuum code, a 
classification scheme which was developed by the U.S. Department of Agriculture and is also 
linked to patient data within the SEER database.[108] Counties are assigned to one of nine 




counties classified based on degree of urbanization and adjacency to metropolitan area(s). We 
used the rural-urban designation from the year 2003 for patients diagnosed in 1998-2007, and 
from the year 2013 for patients diagnosed in 2008-2015, allowing a maximum of 5 years 
between cancer diagnosis and the year for which the rural-urban continuum was defined. Patients 
diagnosed before 1998 were therefore excluded from analyses according to rural-urban code. For 
our analyses, we used rural-urban continuum code values to define the categories of metro (1-3), 
urban (4-6), and rural (7-9), as used previously.[109] 
6.2.3 Noncancer deaths 
 SEER recodes cause of death information from state death certificates and reports deaths 
from noncancer causes in 26 major categories.[103] These categories have been defined 
consistently over time and include many of the leading causes of death in the U.S. population, 
such as ‘Pneumonia and Influenza,’ and ‘Diseases of the Heart.’ Although SEER includes deaths 
from ‘In situ, benign or unknown behavior neoplasm’ among its 26 categories of noncancer 
causes of death, we did not consider deaths from this cause as noncancer deaths. Outcomes in 
our analyses included deaths from all noncancer causes combined and deaths from CVD 
(diseases of the heart; hypertension without heart disease; cerebrovascular disease; 
atherosclerosis; aortic aneurysm and dissection; other diseases of arteries, arterioles, capillaries) 
or ID (tuberculosis; syphilis; septicemia; pneumonia and influenza; other infectious and parasitic 
diseases including HIV), the two cause-specific categories with the largest number of total 
deaths. 
6.2.4 Statistical analysis 
 We estimated the cumulative incidence of death from all noncancer causes, CVD, and ID 




other causes, including cancer, as a competing risk.[112] Person-time of follow-up was accrued 
from cancer diagnosis until death or end of December, 2015, whichever occurred first. Patients 
recorded in SEER as having 0 completed months of survival were assigned a survival time of 0.5 
months for analysis.[111] To evaluate disparities according to race/ethnicity, county-level 
economic characteristics, rural-urban continuum, and geographic region, we estimated cause-
specific hazard ratios using Cox proportional hazards regression models. Multivariable 
regression models included age at diagnosis, cancer type, calendar year of diagnosis, and 
race/ethnicity. All analyses were performed separately for men and women. The proportional 
hazards assumption was assessed through visual inspection of plots of the survival function 
versus time and the log(-log(survival)) versus log(time). Because cancer type and age at 
diagnosis appeared to violate this assumption, these variables were included as stratification 
variables in multivariable models. In sensitivity analyses, we excluded AYAs with Non-Hodgkin 
lymphoma (NHL) to minimize the potential influence of the HIV/AIDs epidemic on estimated 
associations with race/ethnicity, geographic region, county-level economic characteristics, and 
rural-urban continuum. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, 
NC). 
6.3 Results 
 A total of 242,940 AYA women and 158,347 AYA men with cancer were included in 
these analyses. The most common cancer types among women were breast cancer (24%), thyroid 
cancer (17%), and melanoma (11%); those among men were testicular cancer (21%), melanoma 
(10%), and NHL (10%) (Table 6.1). The median follow-up was 7.1 years (IQR=2.5-13.5) among 




 Among AYA women with cancer, 5,418 deaths from noncancer causes occurred during 
the follow-up period, with 1,216 deaths from CVD and 1,017 from ID. Overall, the cumulative 
incidence of all noncancer deaths among women was 1.24%, 1.94%, and 3.77% at 5, 10, and 20 
years post-diagnosis, respectively (Table 6.2). When women with NHL were excluded, these 
values were 1.07%, 1.76% and 3.55% (data not shown). At 10 years, the cumulative incidence of 
all noncancer deaths was highest among women diagnosed with NHL (6.59%), leukemia 
(5.20%), and central nervous system tumors (2.54%). NHL and leukemia also had the highest 
10-year incidence of deaths from CVD and ID (Tables 6.3-6.4). Across the study period, the 
cumulative incidence of all noncancer deaths, CVD deaths and ID deaths was consistently lowest 
among women with melanoma and thyroid cancer.  
 Among AYA men with cancer, there were a total of 8,452 deaths from noncancer causes, 
of which 1,268 and 3,789 were from CVD and ID, respectively. Overall, the cumulative 
incidence of all noncancer deaths was 3.83%, 4.99%, and 7.78% at 5, 10, and 20 years post-
diagnosis, respectively (Table 6.5). When men with NHL were excluded, these values were 
2.11%, 3.21%, and 5.96% (data not shown). At 10 years, the incidence of all noncancer deaths 
was highest among AYA men with NHL (20.31%) and leukemia (5.33%), followed by Hodgkin 
lymphoma (4.71%), head and neck cancers (4.29%), and colorectal cancers (4.23%). For CVD 
deaths, the 10-year incidence was highest among those with leukemia (0.85%) and NHL 
(0.74%), while that for ID deaths was highest among those with NHL (16.99%) and Hodgkin 
lymphoma (2.70%) (Tables 6.6-6.7).  
 The cumulative incidence of all noncancer mortality, cardiovascular mortality, and 
infectious disease mortality according to race/ethnicity is shown in Figures 6.1-6.6. In models 




more than double the risk of all noncancer mortality (HR=2.31; 95% CI: 2.16-2.47), CVD 
mortality (HR=2.77; 95% CI: 2.41-3.18), and ID mortality (HR=5.24; 95% CI: 4.55-6.03) than 
non-Hispanic White women (Tables 6.8-6.10). ID mortality was also elevated among Hispanic 
women (HR=1.48; 95% CI: 1.22-1.80) relative to non-Hispanic White women. Further 
adjustment for county-level poverty resulted in little change in HRs according to race/ethnicity 
(data not shown). Compared to women in the Northeast region, those in the South had higher 
mortality from all noncancer causes (HR=1.18; 95% CI: 1.07-1.29) and from CVD (HR=1.40; 
95% CI: 1.15-1.71). In contrast, ID mortality was higher among women in the Northeast than in 
any other geographic region. Both all noncancer mortality and CVD mortality were higher 
among women in urban and rural areas than in metro areas, and appeared to increase with 
increasing county-level poverty. Compared to women in the lowest quartile of county-level 
poverty, the HR for CVD mortality for women in the highest quartile was 1.41 (95% CI: 1.17-
1.70). County-level poverty, education, and rural-urban continuum were not clearly associated 
with ID mortality among women.  
 Relative to non-Hispanic White men, non-Hispanic Black men had higher mortality from 
all noncancer causes (HR=2.17; 95% CI: 2.05-2.30), CVD (HR=2.44; 95% CI: 2.09-2.84), and 
ID (HR=2.39; 95% CI: 2.20-2.58) (Table 6.11-6.13). Hispanic men also had higher mortality 
from all noncancer causes (HR=1.43; 95% CI: 1.34-1.52) and ID (HR=1.74; 95% CI: 1.59-1.90) 
than non-Hispanic White men. In contrast, all noncancer mortality (HR=0.75; 95% CI: 0.67-
0.83) and ID mortality (HR=0.59; 95% CI: 0.49-0.71) were significantly lower among men of 
other non-Hispanic race/ethnicities than among non-Hispanic White men. Additional adjustment 
for quartile of county-level poverty did not appreciably alter HRs according to race/ethnicity 




had higher mortality from all noncancer causes, CVD, and ID, while those in the West had 
higher mortality from all noncancer causes and from ID. No clear trends were observed for 
associations with county-level poverty or education. Men in rural areas had higher all noncancer 
mortality (HR=1.57; 95% CI: 1.33-1.86) and CVD mortality (HR=2.13; 95% CI: 1.47-3.09) than 
men in metro areas; CVD mortality was also elevated among men in urban areas (HR=1.55; 95% 
CI: 1.15-2.07).  
 Patterns were generally similar in sensitivity analyses excluding women with NHL 
(Tables 6.14-6.16), although the HR for ID mortality among non-Hispanic Black women was 
somewhat attenuated (HR=4.20; 95% CI: 3.52-5.01). When men with NHL were excluded 
(Tables 6.17-6.19), the HR for ID mortality for non-Hispanic Black compared to non-Hispanic 
White was of greater magnitude (HR=3.97), while that for Hispanic men was slightly attenuated 
(HR=1.57). An increase in ID mortality among men in rural counties (vs metro) was also 
apparent (HR=1.61), while the HR for ID mortality among those in the West region (vs 
Northeast) was attenuated in analyses were restricted to non-NHL patients. 
6.4 Discussion 
 AYAs with cancer continue to represent an understudied patient population in the U.S. In 
this population-based study, we investigated long-term patterns of mortality from noncancer 
causes after an AYA cancer diagnosis, and examined disparities according to race/ethnicity and 
other patient characteristics. Among AYAs of all cancer types, we found a cumulative incidence 
of deaths from noncancer causes of approximately 2% and 5% among women and men, 
respectively, at 10 years post-diagnosis. Accounting for cancer type, patient characteristics 
associated with higher risk of mortality from all noncancer causes combined included non-




race/ethnicity was also a consistent predictor of mortality from both CVD and ID. Our analyses 
highlight disparities in noncancer mortality among AYAs with cancer, and identify subgroups of 
survivors that may be targeted for increased medical surveillance.     
 A number of reports have demonstrated that cancer survivors, including those diagnosed 
as AYAs, have elevated mortality from noncancer causes relative to the general population,[76-
78, 86, 97, 134-136] likely resulting from both the direct effects of cancer therapies on the risk 
and severity of noncancer health conditions, and the indirect effects of cancer and its treatment 
on overall health and well-being. Our results, like those reported among childhood cancer 
survivor cohorts,[86, 134-138] suggest that cancer type is an important predictor of noncancer 
mortality among survivors, with some of the highest risks among patients with hematologic 
malignancies and central nervous system tumors. In our analyses among AYAs, we also 
identified head and neck cancers and colorectal cancers, especially those among AYA men, as 
cancer types with relatively high mortality from noncancer causes throughout the survivorship 
period.  
 While previous studies have documented disparities in both all-cause and cancer-specific 
mortality according to race/ethnicity among AYAs with cancer in the U.S.,[89-92, 94] 
considerably less research has examined race-related disparities in noncancer health outcomes in 
this population. Racial differences in CVD mortality may be particularly critical to examine, as a 
cancer diagnosis and treatment could exacerbate disparities in cardiovascular outcomes reported 
in the general population.[141] In a study of 79,176 AYA cancer patients diagnosed in California 
during 1996-2012, the 10-year risk of incident CVD among African-Americans was 1.55 (95% 
CI: 1.33-1.81) times that among non-Hispanic whites with adjustment for cancer type.[75] 




found a non-significant increase in death from CVD among Black survivors compared to White 
(HR=1.33; 95% CI: 0.60, 2.95), though estimates were imprecise and models did not appear to 
account for cancer type.[95] Results of the current study also indicate a higher burden of CVD 
mortality among non-Hispanic Black AYAs with cancer, but suggest that the magnitude of this 
disparity may be considerably greater than previously reported. Differences between non-
Hispanic Black AYAs and other race/ethnicities persisted over time since cancer diagnosis, 
underscoring the importance of long-term follow-up care for cardiovascular health, particularly 
for non-Hispanic Black AYA cancer survivors.  
 Although our analyses indicate that deaths from ID are relatively rare among AYAs with 
cancer types other than NHL, characteristics that we identified as predictors of higher ID 
mortality may also be those associated with a higher incidence of life-threatening infections in 
this population. We found that non-Hispanic Black AYAs had a higher risk of ID mortality after 
cancer than non-Hispanic White AYAs, a relationship which remained apparent when NHL 
patients were excluded to minimize the influence of potential differences in HIV-related deaths 
according to race/ethnicity. Most ID deaths occurred within the first few years after cancer 
diagnosis, suggesting that many of these may be the result of acute complications of treatment 
for the primary cancer or relapse. Little large-scale research has examined infections among 
cancer patients and survivors, particularly those with solid tumors, and further investigation may 
be needed to identify cancer treatment-related and other contributors to disparities in ID 
incidence and mortality after AYA cancer. 
 To our knowledge, our study is the first to investigate variability in noncancer mortality 
among AYA cancer survivors according to U.S. geographic region and county-level 




data from the California Cancer Registry, reported that living in a lower SES neighborhood, 
defined based on a composite index of census tract-level poverty, education, and other 
characteristics, was associated with a higher risk of developing CVD after AYA cancer.[75] In 
our analyses, we observed few clear trends in noncancer mortality outcomes according to 
county-level poverty and education, aside from relatively weak increases in all noncancer 
mortality and CVD mortality with increasing county-level poverty among women. On the other 
hand, living in the South or in a rural county was associated with higher mortality from all 
noncancer causes and CVD among both men and women. AYA patients with cancer in the South 
and/or in rural areas may therefore be priority groups for efforts to improve health outcomes 
throughout survivorship. 
 Strengths of the current study include the large population-based sample of AYA cancer 
patients and the long follow-up, which allowed us to estimate the cumulative incidence of 
noncancer death up to 20+ years post-diagnosis and to investigate disparities according to 
race/ethnicity and other characteristics. Our study also has limitations. Cause of death, as 
recoded from state death certificates, is subject to misclassification, potentially leading to some 
misattribution of cancer deaths to noncancer causes. However, we do not expect that this 
misclassification would be strongly differential with respect to factors such as race and other 
patient characteristics that we examined. Additionally, SEER registries do not collect individual-
level SES characteristics, and our analyses thus relied on county-level characteristics to 
investigate disparities related to SES. Estimates therefore reflect the impact of living in a county 
with, for example, high poverty, rather than the impact of living in a household below the 
poverty level. We were also unable to consider the impact of health insurance status on 




Future investigations of noncancer outcomes in AYA cancer survivors may wish to consider 
joint associations between insurance status and race/ethnicity or other patient characteristics. 
Finally, the number of deaths among AYAs in our study was too small to conduct meaningful 
analyses of noncancer mortality from cause-specific categories other than CVD and ID, or to 
examine individual causes within the categories of CVD and ID. 
 In conclusion, results of the current study suggest that the risk of noncancer mortality 
after AYA cancer is highest among survivors who are non-Hispanic Black or live in the South or 
in rural counties. Identifying subgroups of AYA cancer survivors at increased risk of adverse 
noncancer health outcomes may inform the development of surveillance recommendations and 














6.5 Tables and figures  
 
Table 6.1. Characteristics of AYAs diagnosed with cancer, SEER 18, 1985-2015  
 Women  Men 
  N  %   N  % 
Total 242,940 100%  158,347 100%       
Cancer type      
Leukemia 7,691 3%  10,977 7% 
Non-Hodgkin lymphoma 9,387 4%  16,418 10% 
Hodgkin lymphoma 11,658 5%  12,310 8% 
Central nervous system tumors 7,674 3%  10,019 6% 
Soft tissue sarcomas 6,853 3%  6,886 4% 
Melanoma 25,645 11%  16,454 10% 
Thyroid carcinoma 41,414 17%  8,598 5% 
Other head and neck carcinomas 4,063 2%  5,499 3% 
Colorectal carcinomas 9,583 4%  10,474 7% 
Breast carcinoma a 59,472 24%  -- -- 
Testicular cancer  -- --  32,739 21% 
Cervical/uterine carcinomas 27,623 11%  -- -- 
Other 31,877 13%  27,973 18% 
      
Age at diagnosis      
15-19 12,168 5%  14,029 9% 
20-24 21,491 9%  20,642 13% 
25-29 38,522 16%  29,265 18% 
30-34 65,525 27%  39,473 25% 
35-39 105,234 43%  54,938 35%       
Calendar year      
1985-1994 38,449 16%  26,987 17% 
1995-2004 79,249 33%  52,322 33% 
2005-2015 125,242 52%  79,038 50%       
Race/ethnicity      
Non-Hispanic White 151,716 62%  104,370 66% 
Non-Hispanic Black 26,628 11%  13,925 9% 
Hispanic 41,443 17%  28,165 18% 
Other Non-Hispanic 23,153 10%  11,887 8%       
Geographic region b      
West 126,560 53%  86,611 56% 
South 45,811 19%  27,423 18% 
Northeast 35,105 15%  21,895 14% 
Midwest 29,686 13%  18,785 12%       
% of persons below poverty (quartiles, Q) c     
Q1 91,689 38%  59,806 38% 
Q2 58,791 24%  39,617 25% 
Q3 57,346 24%  36,496 23% 
Q4 35,031 14%  22,383 14% 
Missing 83   45        
% persons with <high school education (quartiles, Q)d     
Q1 87,705 36%  58,162 37% 
Q2 58,624 24%  38,051 24% 
Q3 45,208 19%  28,702 18% 
Q4 51,320 21%  33,387 21% 
Missing 83   45        




Metro 171,295 91%  109,340 91% 
Urban 11,794 6%  7,501 6% 
Rural 5,464 3%  3,489 3% 
Missing 715   430        
a Male breast carcinomas (N=146) are included in the 'Other' category 
b Alaska native and Hawaii registries are omitted 
c Quartile cutpoints were 11.15%, 15.15%, and 20.4% for AYAs diagnosed in 1985-1994; 9.54%, 12.95%, and 
17.52% for AYAs diagnosed in 1995-2004; and 11.68%, 15.58%, and 19.81% for AYAs diagnosed in 2005-2015.  
d Quartile cutpoints were 22.77%, 28.58%, and 38.07% for AYAs diagnosed in 1985-1994; 15.99%, 20.78%, and 
28.71% for AYAs diagnosed in 1995-2004; and 10.56%, 14.41%, and 20.35% for AYAs diagnosed in 2005-2015. 




Table 6.2. Cumulative incidence of all noncancer deaths among AYA women with cancer, SEER 18, 1985-2015 
  Cumulative incidence (%) 
  5-year (95% CI) 10-year (95% CI) 20-year (95% CI) 
Total  1.24 (1.19, 1.28) 1.94 (1.88, 2.01) 3.77 (3.64, 3.89) 
     
Cancer type     
Leukemia  4.26 (3.80, 4.76) 5.20 (4.66, 5.78) 7.48 (6.59, 8.43) 
Non-Hodgkin lymphoma  5.37 (4.91, 5.86) 6.59 (6.05, 7.15) 9.28 (8.43, 10.17) 
Hodgkin lymphoma  1.08 (0.90, 1.30) 1.93 (1.66, 2.23) 4.32 (3.76, 4.95) 
Central nervous system tumors  1.57 (1.30, 1.89) 2.54 (2.16, 2.98) 4.84 (4.09, 5.69) 
Soft tissue sarcomas  1.20 (0.95, 1.49) 1.94 (1.59, 2.34) 3.89 (3.21, 4.67) 
Melanoma  0.36 (0.29, 0.45) 0.66 (0.55, 0.78) 1.64 (1.40, 1.91) 
Thyroid carcinoma  0.32 (0.27, 0.39) 0.71 (0.61, 0.83) 1.81 (1.56, 2.09) 
Other head and neck carcinomas  1.16 (0.85, 1.56) 2.25 (1.76, 2.84) 4.88 (3.87, 6.06) 
Breast carcinoma  0.76 (0.69, 0.84) 1.38 (1.28, 1.50) 2.96 (2.75, 3.19) 
Cervical/uterine carcinomas  1.14 (1.01, 1.28) 2.02 (1.83, 2.22) 4.69 (4.30, 5.12) 
Colorectal carcinomas  1.31 (1.08, 1.57) 2.15 (1.83, 2.53) 4.10 (3.42, 4.87) 
     
Age at diagnosis     
15-19  1.35 (1.14, 1.58) 1.81 (1.56, 2.09) 2.57 (2.18, 3.02) 
20-24  1.19 (1.05, 1.36) 1.76 (1.57, 1.98) 3.27 (2.89, 3.68) 
25-29  1.28 (1.17, 1.41) 1.79 (1.65, 1.95) 3.27 (2.99, 3.56) 
30-34  1.16 (1.08, 1.26) 1.78 (1.67, 1.90) 3.53 (3.30, 3.77) 
35-39  1.26 (1.19, 1.33) 2.14 (2.04, 2.24) 4.31 (4.11, 4.51) 
     
Calendar year     
1985-1994  1.40 (1.29, 1.52) 2.06 (1.92, 2.21) 3.69 (3.50, 3.88) 
1995-2004  1.24 (1.17, 1.32) 1.96 (1.86, 2.06) 3.83 (3.61, 4.06) 
2005-2015  1.17 (1.11, 1.24) 1.91 (1.79, 2.04) -- 
     
Race/ethnicity     
Non-Hispanic White  0.99 (0.94, 1.03) 1.64 (1.57, 1.71) 3.37 (3.23, 3.51) 
Non-Hispanic Black  2.96 (2.75, 3.18) 4.14 (3.88, 4.42) 7.25 (6.75, 7.77) 
Hispanic  1.23 (1.11, 1.35) 1.84 (1.68, 2.00) 3.34 (3.01, 3.71) 




Table 6.3 Cumulative incidence of cardiovascular disease death among AYA women with cancer, SEER 18, 
1985-2015 
 Cumulative incidence (%) 
  5-year (95% CI) 10-year (95% CI) 20-year (95% CI) 
Total 0.21 (0.19, 0.23) 0.37 (0.34, 0.40) 0.92 (0.86, 0.99) 
    
Cancer type    
Leukemia 0.47 (0.33, 0.65) 0.62 (0.44, 0.85) 1.35 (0.93, 1.90) 
Non-Hodgkin lymphoma 0.41 (0.29, 0.57) 0.78 (0.59, 1.01) 1.46 (1.09, 1.92) 
Hodgkin lymphoma 0.19 (0.12, 0.29) 0.34 (0.23, 0.48) 1.39 (1.06, 1.80) 
Central nervous system tumors 0.38 (0.25, 0.55) 0.61 (0.43, 0.85) 1.20 (0.84, 1.67) 
Soft tissue sarcomas 0.15 (0.07, 0.27) 0.35 (0.22, 0.55) 1.28 (0.87, 1.83) 
Melanoma 0.10 (0.06, 0.15) 0.13 (0.09, 0.19) 0.32 (0.23, 0.45) 
Thyroid carcinoma 0.08 (0.06, 0.12) 0.17 (0.13, 0.23) 0.50 (0.37, 0.66) 
Other head and neck carcinomas 0.25 (0.13, 0.47) 0.54 (0.32, 0.86) 1.24 (0.76, 1.92) 
Breast carcinoma 0.17 (0.14, 0.21) 0.33 (0.28, 0.39) 0.91 (0.78, 1.05) 
Cervical/uterine carcinomas 0.20 (0.15, 0.26) 0.38 (0.30, 0.47) 1.17 (0.96, 1.40) 
Colorectal carcinomas 0.17 (0.10, 0.28) 0.35 (0.23, 0.53) 0.69 (0.44, 1.05) 
Other    
    
Age at diagnosis    
15-19 0.15 (0.09, 0.24) 0.18 (0.11, 0.28) 0.25 (0.15, 0.39) 
20-24 0.15 (0.11, 0.22) 0.26 (0.19, 0.35) 0.66 (0.49, 0.88) 
25-29 0.15 (0.11, 0.20) 0.25 (0.19, 0.31) 0.62 (0.50, 0.77) 
30-34 0.19 (0.15, 0.22) 0.31 (0.26, 0.36) 0.86 (0.74, 0.99) 
35-39 0.25 (0.22, 0.29) 0.49 (0.44, 0.54) 1.20 (1.09, 1.32) 
    
Calendar year    
1985-1994 0.25 (0.21, 0.31) 0.45 (0.38, 0.52) 0.96 (0.87, 1.06) 
1995-2004 0.21 (0.18, 0.24) 0.37 (0.33, 0.42) 0.93 (0.81, 1.07) 
2005-2015 0.18 (0.16, 0.21) 0.30 (0.26, 0.36) -- 
    
Race/ethnicity    
Non-Hispanic White 0.17 (0.15, 0.19) 0.31 (0.28, 0.35) 0.80 (0.72, 0.87) 
Non-Hispanic Black 0.52 (0.44, 0.62) 0.88 (0.75, 1.01) 2.22 (1.91, 2.55) 
Hispanic 0.16 (0.12, 0.21) 0.25 (0.19, 0.32) 0.63 (0.48, 0.82) 




Table 6.4 Cumulative incidence of infectious disease deaths among AYA women with cancer, SEER 18, 1985-
2015 
 Cumulative incidence (%) 
  5-year (95% CI) 10-year (95% CI) 20-year (95% CI) 
Total 0.33 (0.30, 0.35) 0.42 (0.39, 0.45) 0.60 (0.55, 0.64) 
    
Cancer type    
Leukemia 1.14 (0.91, 1.42) 1.28 (1.03, 1.58) 1.62 (1.27, 2.04) 
Non-Hodgkin lymphoma 3.65 (3.27, 4.05) 4.00 (3.60, 4.44) 4.54 (4.05, 5.06) 
Hodgkin lymphoma 0.31 (0.22, 0.43) 0.50 (0.37, 0.66) 0.79 (0.57, 1.06) 
Central nervous system tumors 0.30 (0.19, 0.45) 0.37 (0.25, 0.55) 0.41 (0.27, 0.61) 
Soft tissue sarcomas 0.21 (0.12, 0.36) 0.26 (0.15, 0.43) 0.36 (0.20, 0.60) 
Melanoma 0.01 (0.00, 0.04) 0.03 (0.01, 0.06) 0.11 (0.06, 0.20) 
Thyroid carcinoma 0.02 (0.01, 0.04) 0.04 (0.02, 0.07) 0.09 (0.04, 0.17) 
Other head and neck carcinomas 0.17 (0.07, 0.36) 0.29 (0.14, 0.55) 0.64 (0.33, 1.14) 
Breast carcinoma 0.12 (0.09, 0.15) 0.18 (0.15, 0.22) 0.33 (0.26, 0.41) 
Cervical/uterine carcinomas 0.27 (0.21, 0.34) 0.37 (0.30, 0.46) 0.63 (0.50, 0.78) 
Colorectal carcinomas 0.20 (0.12, 0.32) 0.25 (0.16, 0.39) 0.37 (0.23, 0.56) 
Other    
    
Age at diagnosis    
15-19 0.32 (0.23, 0.44) 0.39 (0.28, 0.53) 0.59 (0.40, 0.85) 
20-24 0.24 (0.18, 0.32) 0.30 (0.23, 0.39) 0.47 (0.34, 0.63) 
25-29 0.37 (0.31, 0.44) 0.46 (0.39, 0.54) 0.59 (0.49, 0.70) 
30-34 0.35 (0.30, 0.40) 0.43 (0.38, 0.49) 0.65 (0.57, 0.75) 
35-39 0.32 (0.28, 0.36) 0.42 (0.38, 0.47) 0.59 (0.53, 0.66) 
    
Calendar year    
1985-1994 0.49 (0.43, 0.57) 0.59 (0.52, 0.67) 0.76 (0.68, 0.85) 
1995-2004 0.38 (0.34, 0.42) 0.47 (0.43, 0.52) 0.63 (0.56, 0.71) 
2005-2015 0.24 (0.21, 0.27) 0.30 (0.26, 0.35) -- 
    
Race/ethnicity    
Non-Hispanic White 0.19 (0.17, 0.21) 0.24 (0.22, 0.27) 0.39 (0.35, 0.44) 
Non-Hispanic Black 1.28 (1.15, 1.43) 1.54 (1.39, 1.71) 1.98 (1.76, 2.21) 
Hispanic 0.29 (0.24, 0.35) 0.36 (0.33, 0.47) 0.52 (0.42, 0.65) 




Table 6.5. Cumulative incidence of all noncancer deaths among AYA men with cancer, SEER 18, 1985-2015 
  Cumulative incidence (%) 
  5-year (95% CI) 10-year (95% CI) 20-year (95% CI) 
Total  3.83 (3.73, 3.93) 4.99 (4.87, 5.11) 7.78 (7.58, 7.98) 
     
Cancer type     
Leukemia  4.08 (3.70, 4.49) 5.33 (4.86, 5.82) 8.20 (7.35, 9.10) 
Non-Hodgkin lymphoma  18.60 (17.99, 19.21) 20.31 (19.67, 20.97) 23.43 (22.62, 24.24) 
Hodgkin lymphoma  2.87 (2.57, 3.19) 4.71 (4.30, 5.15) 9.50 (8.71, 10.32) 
Central nervous system tumors 2.39 (2.08, 2.72) 3.35 (2.96, 3.76) 5.73 (5.06, 6.44) 
Soft tissue sarcomas  1.97 (1.64, 2.34) 2.74 (2.33, 3.19) 4.28 (3.64, 4.99) 
Melanoma  0.76 (0.63, 0.92) 1.53 (1.33, 1.76) 3.47 (3.05, 3.94) 
Thyroid carcinoma  0.98 (0.77, 1.23) 1.82 (1.49, 2.19) 4.57 (3.78, 5.45) 
Other head and neck carcinomas 2.71 (2.28, 3.19) 4.29 (3.70, 4.93) 8.41 (7.32, 9.59) 
Colorectal carcinomas  2.85 (2.52, 3.21) 4.23 (3.80, 4.70) 6.81 (6.05, 7.61) 
Testicular cancer  1.13 (1.01, 1.26) 2.05 (1.88, 2.24) 4.63 (4.26, 5.03) 
     
Age at diagnosis     
15-19  1.57 (1.36, 1.80) 2.24 (1.97, 2.54) 4.03 (3.51, 4.60) 
20-24  2.09 (1.89, 2.31) 3.00 (2.74, 3.28) 4.91 (4.45, 5.39) 
25-29  3.06 (2.85, 3.27) 3.99 (3.75, 4.25) 6.40 (5.99, 6.83) 
30-34  4.67 (4.46, 4.89) 5.79 (5.55, 6.05) 8.47 (8.08, 8.87) 
35-39  4.85 (4.67, 5.04) 6.36 (6.14, 6.59) 9.92 (9.55, 10.29) 
     
Calendar year     
1985-1994  7.62 (7.31, 7.94) 8.91 (8.57, 9.26) 11.48 (11.10, 11.87) 
1995-2004  3.88 (3.71, 4.04) 4.99 (4.80, 5.18) 7.48 (7.17, 7.80) 
2005-2015  2.35 (2.23, 2.47) 3.29 (3.11, 3.48) -- 
     
Race/ethnicity     
Non-Hispanic White  3.22 (3.11, 3.33) 4.30 (4.17, 4.44) 7.03 (6.80, 7.25) 
Non-Hispanic Black  9.00 (8.51, 9.50) 11.04 (10.48, 11.62) 15.34 (14.47, 16.23) 
Hispanic  4.22 (3.97, 4.48) 5.52 (5.21, 5.85) 8.27 (7.66, 8.90) 




Table 6.6 Cumulative incidence of cardiovascular disease deaths among AYA men with cancer, SEER 18, 1985-
2015 
 Cumulative incidence 
  5-year (95% CI) 10-year (95% CI) 20-year (95% CI) 
Total 0.34 (0.31, 0.37) 0.58 (0.53, 0.62) 1.42 (1.32, 1.52) 
    
Cancer type    
Leukemia 0.52 (0.39, 0.68) 0.85 (0.66, 1.07) 1.59 (1.21, 2.07) 
Non-Hodgkin lymphoma 0.48 (0.38, 0.60) 0.74 (0.60, 0.90) 1.31 (1.06, 1.60) 
Hodgkin lymphoma 0.28 (0.20, 0.40) 0.71 (0.55, 0.91) 2.75 (2.28, 3.28) 
Central nervous system tumors 0.53 (0.40, 0.70) 0.66 (0.50, 0.85) 1.36 (1.04, 1.75) 
Soft tissue sarcomas 0.33 (0.21, 0.50) 0.56 (0.38, 0.79) 0.82 (0.57, 1.15) 
Melanoma 0.12 (0.08, 0.19) 0.28 (0.20, 0.39) 0.95 (0.73, 1.23) 
Thyroid carcinoma 0.25 (0.15, 0.39) 0.45 (0.30, 0.66) 1.14 (0.77, 1.65) 
Other head and neck carcinomas 0.39 (0.24, 0.60) 0.80 (0.57, 1.12) 1.84 (1.36, 2.43) 
Colorectal carcinomas 0.38 (0.27, 0.53) 0.66 (0.50, 0.87) 1.30 (0.96, 1.72) 
Testicular cancer 0.09 (0.06, 0.14) 0.20 (0.15, 0.27) 0.89 (0.72, 1.10) 
Other    
    
Age at diagnosis    
15-19 0.18 (0.12, 0.27) 0.27 (0.18, 0.38) 0.73 (0.51, 1.02) 
20-24 0.22 (0.16, 0.30) 0.33 (0.25, 0.43) 0.81 (0.62, 1.06) 
25-29 0.23 (0.18, 0.30) 0.42 (0.34, 0.52) 1.08 (0.89, 1.30) 
30-34 0.33 (0.27, 0.39) 0.56 (0.48, 0.65) 1.35 (1.17, 1.56) 
35-39 0.49 (0.43, 0.55) 0.83 (0.75, 0.93) 2.00 (1.81, 2.20) 
    
Calendar year    
1985-1994 0.48 (0.40, 0.57) 0.69 (0.60, 0.80) 1.50 (1.35, 1.65) 
1995-2004 0.34 (0.29, 0.39) 0.57 (0.51, 0.64) 1.31 (1.15, 1.48) 
2005-2015 0.29 (0.25, 0.33) 0.50 (0.43, 0.58) -- 
    
Race/ethnicity    
Non-Hispanic White 0.28 (0.25, 0.31) 0.49 (0.44, 0.54) 1.34 (1.23, 1.46) 
Non-Hispanic Black 0.92 (0.76, 1.10) 1.42 (1.20, 1.66) 2.57 (2.15, 3.04) 
Hispanic 0.29 (0.23, 0.37) 0.58 (0.47, 0.71) 1.22 (0.96, 1.53) 




Table 6.7 Cumulative incidence of infectious disease deaths among AYA men with cancer, SEER 18, 1985-2015 
 Cumulative incidence 
  5-year (95% CI) 10-year (95% CI) 20-year (95% CI) 
Total 2.22 (2.15, 2.30) 2.48 (2.40, 2.56) 2.84 (2.74, 2.94) 
    
Cancer type    
Leukemia 1.25 (1.04, 1.48) 1.45 (1.21, 1.71) 2.02 (1.64, 2.47) 
Non-Hodgkin lymphoma 16.12 (15.55, 16.70) 16.99 (16.40, 17.59) 18.18 (17.51, 18.85) 
Hodgkin lymphoma 1.54 (1.33, 1.78) 2.10 (1.84, 2.40) 2.70 (2.35, 3.08) 
Central nervous system tumors 0.30 (0.21, 0.44) 0.38 (0.27, 0.54) 0.59 (0.41, 0.83) 
Soft tissue sarcomas 0.44 (0.30, 0.63) 0.57 (0.40, 0.79) 0.73 (0.50, 1.06) 
Melanoma 0.17 (0.11, 0.25) 0.26 (0.19, 0.37) 0.38 (0.27, 0.52) 
Thyroid carcinoma 0.07 (0.03, 0.16) 0.13 (0.06, 0.25) 0.37 (0.18, 0.71) 
Other head and neck carcinomas 0.71 (0.50, 0.98) 0.76 (0.55, 1.04) 1.28 (0.92, 1.75) 
Colorectal carcinomas 1.17 (0.97, 1.41) 1.59 (1.33, 1.88) 2.02 (1.66, 2.42) 
Testicular cancer 0.20 (0.16, 0.26) 0.32 (0.26, 0.40) 0.51 (0.41, 0.64) 
Other    
    
Age at diagnosis    
15-19 0.24 (0.16, 0.34) 0.31 (0.22, 0.43) 0.38 (0.27, 0.54) 
20-24 0.66 (0.55, 0.78) 0.75 (0.63, 0.88) 1.00 (0.84, 1.20) 
25-29 1.74 (1.59, 1.90) 1.96 (1.80, 2.14) 2.31 (2.11, 2.53) 
30-34 3.06 (2.89, 3.24) 3.37 (3.19, 3.56) 3.77 (3.55, 4.00) 
35-39 2.97 (2.83, 3.12) 3.30 (3.14, 3.46) 3.74 (3.55, 3.93) 
    
Calendar year    
1985-1994 5.70 (5.43, 5.98) 6.12 (5.84, 6.42) 6.47 (6.18, 6.77) 
1995-2004 2.38 (2.25, 2.52) 2.60 (2.46, 2.74) 2.92 (2.76, 3.08) 
2005-2015 0.79 (0.72, 0.86) 0.89 (0.82, 0.97)  
    
Race/ethnicity    
Non-Hispanic White 1.82 (1.73, 1.90) 2.03 (1.94, 2.12) 2.33 (2.22, 2.44) 
Non-Hispanic Black 5.77 (5.38, 6.18) 6.44 (6.01, 6.88) 7.42 (6.89, 7.98) 
Hispanic 2.56 (2.37, 2.76) 2.81 (2.60, 3.03) 3.23 (2.96, 3.52) 




Figure 6.1. Cumulative incidence of mortality from all noncancer causes according to race/ethnicity among AYA 







Figure 6.2. Cumulative incidence of mortality from cardiovascular diseases according to race/ethnicity among AYA 





Figure 6.3. Cumulative incidence of mortality from infectious diseases according to race/ethnicity among AYA 




Figure 6.4. Cumulative incidence of mortality from all noncancer causes according to race/ethnicity among AYA 






Figure 6.5. Cumulative incidence of mortality from cardiovascular diseases according to race/ethnicity among AYA 






Figure 6.6. Cumulative incidence of mortality from infectious diseases according to race/ethnicity among AYA men 








person-years    
Deaths Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) a 
Race/ethnicity      
Non-Hispanic White 1,492,030  3135 1 1 
Non-Hispanic Black 206,468  1203 2.75 (2.57, 2.94) 2.31 (2.16, 2.47) 
Hispanic 285,446  690 1.14 (1.05, 1.24) 1.04 (0.95, 1.13) 
Other non-Hispanic 188,076  390 0.98 (0.89, 1.09) 0.91 (0.82, 1.01) 
      
Geographic region      
West 1,121,237  2372 0.83 (0.76, 0.89) 0.88 (0.81, 0.95) 
South 341,555  1171 1.34 (1.22, 1.47) 1.18 (1.07, 1.29) 
Northeast 303,211  777 1 1 
Midwest 342,289  950 1.06 (0.97, 1.17) 1.03 (0.94, 1.13) 
      
% of persons below poverty (quartiles, Q)      
Q1 991,051  2164 1 1 
Q2 482,194  1155 1.12 (1.04, 1.20) 1.10 (1.03, 1.19) 
Q3 414,122  1263 1.40 (1.31, 1.50) 1.21 (1.12, 1.30) 
Q4 283,828  836 1.44 (1.32, 1.56) 1.27 (1.17, 1.38) 
      
% persons with <HS education (quartiles, Q)      
Q1 1,030,204  2351 1 1 
Q2 454,285  1083 1.10 (1.02, 1.18) 1.07 (0.99, 1.15) 
Q3 345,265  1129 1.45 (1.35, 1.56) 1.23 (1.14, 1.32) 
Q4 341,442  855 1.15 (1.06, 1.24) 1.09 (1.00, 1.19) 
      
Rural-urban continuum code b     
Metro 1,136,296  2655 1 1 
Urban 80,490  231 1.24 (1.08, 1.41) 1.27 (1.11, 1.45) 
Rural 35,891  137 1.63 (1.38, 1.94) 1.74 (1.47, 2.07) 
      
            
a Adjusted for race/ethnicity, calendar year; cancer type and age are stratification variables 




Table 6.9. Hazard ratios for cardiovascular disease deaths according to patient characteristics among AYA women 
with cancer, 1985-2015 
  
 Total person-
years   
Deaths Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) a 
Race/ethnicity       
Non-Hispanic White 1,492,030  720 1 1 
Non-Hispanic Black 206,468  299 3.16 (2.76, 3.62) 2.77 (2.41, 3.18) 
Hispanic 285,446  109 0.88 (0.71, 1.07) 0.85 (0.69, 1.04) 
Other non-Hispanic 188,076  88 1.02 (0.82, 1.27) 0.96 (0.77, 1.20) 
      
Geographic region      
West 1,121,237  496 0.85 (0.71, 1.02) 0.93 (0.77, 1.11) 
South 341,555  273 1.64 (1.34, 1.99) 1.40 (1.15, 1.71) 
Northeast 303,211  156 1 1 
Midwest 342,289  256 1.28 (1.05, 1.56) 1.20 (0.98, 1.47) 
      
% of persons below poverty (quartiles, Q)      
Q1 991,051  502 1 1 
Q2 482,194  251 1.16 (1.00, 1.35) 1.18 (1.01, 1.38) 
Q3 414,122  289 1.57 (1.36, 1.82) 1.37 (1.18, 1.60) 
Q4 283,828  174 1.51 (1.27, 1.80) 1.41 (1.17, 1.70) 
      
% persons with <HS education (quartiles, Q)      
Q1 1,030,204  552 1 1 
Q2 454,285  217 1.13 (0.96, 1.32) 1.15 (0.97, 1.36) 
Q3 345,265  280 1.77 (1.53, 2.04) 1.53 (1.32, 1.79) 
Q4 341,442  167 1.22 (1.02, 1.46) 1.29 (1.06, 1.57) 
      
Rural-urban continuum code b     
Metro 1,136,296  473 1 1 
Urban 80,490  50 1.50 (1.12, 2.00) 1.52 (1.14, 2.04) 
Rural 35,891  33 2.22 (1.56, 3.15) 2.37 (1.66, 3.39) 
      
            
a Adjusted for race/ethnicity, calendar year; cancer type and age are stratification variables 




Table 6.10. Hazard ratios for infectious disease deaths according to patient characteristics among AYA women 
with cancer, 1985-2015 
  
 Total person-
years   
Deaths Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) a 
Race/ethnicity       
Non-Hispanic White 1,492,030  408 1 1 
Non-Hispanic Black 206,468  400 6.48 (5.64, 7.44) 5.24 (4.55, 6.03) 
Hispanic 285,446  140 1.56 (1.29, 1.89) 1.48 (1.22, 1.80) 
Other non-Hispanic 188,076  69 1.25 (0.97, 1.61) 1.20 (0.93, 1.55) 
      
Geographic region      
West 1,121,237  387 0.53 (0.45, 0.63) 0.59 (0.49, 0.70) 
South 341,555  240 1.00 (0.83, 1.20) 0.79 (0.65, 0.96) 
Northeast 303,211  201 1 1 
Midwest 342,289  162 0.80 (0.65, 0.99) 0.72 (0.58, 0.88) 
      
% of persons below poverty (quartiles, Q)      
Q1 991,051  407 1 1 
Q2 482,194  186 0.84 (0.71, 1.00) 0.82 (0.68, 0.97) 
Q3 414,122  256 1.27 (1.08, 1.48) 0.98 (0.83, 1.15) 
Q4 283,828  168 1.30 (1.08, 1.55) 1.00 (0.82, 1.21) 
      
% persons with <HS education (quartiles, Q)      
Q1 1,030,204  409 1 1 
Q2 454,285  226 1.06 (0.90, 1.25) 1.06 (0.89, 1.26) 
Q3 345,265  247 1.51 (1.29, 1.77) 1.15 (0.97, 1.36) 
Q4 341,442  135 0.78 (0.64, 0.95) 0.78 (0.63, 0.96) 
      
Rural-urban continuum code b     
Metro 1,136,296  527 1 1 
Urban 80,490  33 0.90 (0.63, 1.27) 1.05 (0.74, 1.49) 
Rural 35,891  17 1.02 (0.63, 1.65) 1.41 (0.87, 2.29) 
      
            
a Adjusted for race/ethnicity, calendar year; cancer type and age are stratification variables 








person-years    
Deaths Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) a 
Race/ethnicity      
Non-Hispanic White 978,730  5163 1 1 
Non-Hispanic Black 86,152  1552 3.02 (2.85, 3.20) 2.17 (2.05, 2.30) 
Hispanic 165,373  1358 1.35 (1.27, 1.43) 1.43 (1.34, 1.52) 
Other non-Hispanic 81,894  379 0.80 (0.72, 0.89) 0.75 (0.67, 0.83) 
      
Geographic region      
West 704,855  4605 1.30 (1.21, 1.40) 1.31 (1.22, 1.40) 
South 186,783  1518 1.52 (1.40, 1.65) 1.42 (1.31, 1.55) 
Northeast 182,410  912 1 1 
Midwest 202,449  1208 1.28 (1.17, 1.40) 1.09 (1.00, 1.19) 
      
% of persons below poverty (quartiles, Q)      
Q1 605,693  3132 1 1 
Q2 300,442  2289 1.36 (1.29, 1.44) 1.42 (1.34, 1.50) 
Q3 240,034  1781 1.26 (1.18, 1.33) 1.29 (1.21, 1.37) 
Q4 165,527  1248 1.37 (1.28, 1.46) 1.37 (1.28, 1.47) 
      
% persons with <HS education (quartiles, Q)      
Q1 632,247  3855 1 1 
Q2 278,332  1590 0.84 (0.79, 0.89) 1.02 (0.96, 1.09) 
Q3 198,167  1625 1.17 (1.10, 1.24) 1.17 (1.10, 1.25) 
Q4 202,951  13380 0.93 (0.87, 0.99) 1.13 (1.06, 1.22) 
      
Rural-urban continuum code b     
Metro 680,340  3445 1 1 
Urban 47,994  243 1.01 (0.89, 1.15) 1.10 (0.97, 1.26) 
Rural 21,468  145 1.33 (1.13, 1.57) 1.57 (1.33, 1.86) 
      
            
a Adjusted for race/ethnicity, calendar year; cancer type and age are stratification variables 




Table 6.12. Hazard ratios for cardiovascular disease deaths according to patient characteristics among AYA men 
with cancer, 1985-2015 
  
 Total person-
years    
Deaths Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) a 
Race/ethnicity      
Non-Hispanic White 978,730  828 1 1 
Non-Hispanic Black 86,152  221 3.19 (2.74, 3.70) 2.44 (2.09, 2.84) 
Hispanic 165,373  146 1.15 (0.96, 1.37) 1.18 (0.99, 1.42) 
Other non-Hispanic 81,894  73 1.10 (0.87, 1.40) 0.98 (0.77, 1.25) 
      
Geographic region      
West 704,855  549 0.86 (0.73, 1.03) 0.91 (0.76, 1.09) 
South 186,783  247 1.56 (1.28, 1.90) 1.42 (1.16, 1.73) 
Northeast 182,410  164 1 1 
Midwest 202,449  265 1.32 (1.09, 1.61) 1.24 (1.01, 1.51) 
      
% of persons below poverty (quartiles, Q)      
Q1 605,693  550 1 1 
Q2 300,442  265 1.07 (0.93, 1.25) 1.11 (0.96, 1.29) 
Q3 240,034  285 1.46 (1.27, 1.69) 1.35 (1.16, 1.57) 
Q4 165,527  168 1.35 (1.13, 1.61) 1.31 (1.09, 1.58) 
      
% persons with <HS education (quartiles, Q)      
Q1 632,247  609 1 1 
Q2 278,332  225 1.03 (0.88, 1.20) 1.08 (0.92, 1.27) 
Q3 198,167  248 1.48 (1.27, 1.72) 1.32 (1.13, 1.54) 
Q4 202,951  186 1.21 (1.02, 1.43) 1.28 (1.06, 1.54) 
      
Rural-urban continuum code b     
Metro 680,340  483 1 1 
Urban 47,994  50 1.47 (1.10, 1.97) 1.55 (1.15, 2.07) 
Rural 21,468  30 1.97 (1.36, 2.84) 2.13 (1.47, 3.09) 
      
            
a Adjusted for race/ethnicity, calendar year; cancer type and age are stratification variables 








person-years    
Deaths Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) a 
Race/ethnicity      
Non-Hispanic White 978,730  2093 1 1 
Non-Hispanic Black 86,152  865 3.63 (3.35, 3.90) 2.39 (2.20, 2.58) 
Hispanic 165,373  709 1.47 (1.35, 1.60) 1.74 (1.59, 1.90) 
Other non-Hispanic 81,894  122 0.57 (0.48, 0.69) 0.59 (0.49, 0.71) 
      
Geographic region      
West 704,855  2322 1.80 (1.61, 2.02) 1.72 (1.53, 1.93) 
South 186,783  671 1.71 (1.50, 1.95) 1.59 (1.39, 1.82) 
Northeast 182,410  332 1 1 
Midwest 202,449  383 1.26 (1.09, 1.46) 0.92 (0.80, 1.07) 
      
% of persons below poverty (quartiles, Q)      
Q1 605,693  1225 1 1 
Q2 300,442  1250 1.67 (1.54, 1.81) 1.76 (1.63, 1.91) 
Q3 240,034  769 1.16 (1.06, 1.27) 1.33 (1.21, 1.47) 
Q4 165,527  545 1.30 (1.18, 1.44) 1.37 (1.23, 1.52) 
      
% persons with <HS education (quartiles, Q)      
Q1 632,247  1798 1 1 
Q2 278,332  647 0.60 (0.55, 0.66) 0.90 (0.81, 0.99) 
Q3 198,167  747 0.95 (0.87, 1.03) 1.08 (0.99, 1.18) 
Q4 202,951  597 0.67 (0.61, 0.73) 1.00 (0.90, 1.11) 
      
Rural-urban continuum code b     
Metro 680,340  1306 1 1 
Urban 47,994  58 0.64 (0.49, 0.83) 0.79 (0.60, 1.02) 
Rural 21,468  30 0.72 (0.50, 1.04) 1.07 (0.74, 1.54) 
      
            
a Adjusted for race/ethnicity, calendar year; cancer type and age are stratification variables 




Table 6.14 Hazard ratios for all noncancer deaths according to patient characteristics among AYA women with 
cancers other than Non-Hodgkin lymphoma, 1985-2015 
  
Total 
person-years    
Deaths Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) a 
Race/ethnicity      
Non-Hispanic White 1,441,573  2869 1 1 
Non-Hispanic Black 196,682  975 2.50 (2.33, 2.69) 2.11 (1.96, 2.27) 
Hispanic 274,657  588 1.09 (1.00, 1.19) 0.97 (0.89, 1.07) 
Other non-Hispanic 180,900  359 1.00 (0.90, 1.12) 0.92 (0.82, 1.03) 
      
Geographic region     
West 1,080,253  2131 0.89 (0.81, 0.97) 0.94 (0.86, 1.03) 
South 329,879  1019 1.41 (1.28, 1.56) 1.24 (1.12, 1.37) 
Northeast 290,801  643 1 1 
Midwest 330,698  859 1.13 (1.02, 1.25) 1.09 (0.99, 1.21) 
      
% of persons below poverty      
Q1 956,002  1922 1 1 
Q2 465,338  1030 1.14 (1.06, 1.23) 1.13 (1.04, 1.22) 
Q3 398,929  1120 1.44 (1.33, 1.55) 1.25 (1.16, 1.35) 
Q4 272,731  719 1.43 (1.31, 1.56) 1.28 (1.17, 1.41) 
      
% persons with <HS education      
Q1 995,397  2120 1 1 
Q2 436,400  931 1.08 (1.00, 1.17) 1.05 (0.97, 1.14) 
Q3 332,767  987 1.45 (1.34, 1.56) 1.23 (1.14, 1.34) 
Q4 328,435  753 1.17 (1.08, 1.28) 1.11 (1.01, 1.21) 
      
Rural-urban continuum code b     
Metro 1,091,102  2309 1 1 
Urban 77,613  207 1.27 (1.10, 1.46) 1.27 (1.10, 1.46) 
Rural 35,037  124 1.67 (1.40, 2.01) 1.68 (1.40, 2.02) 
      
            
a Adjusted for race/ethnicity, calendar year; cancer type and age are stratification variables 




Table 6.15 Hazard ratios for cardiovascular disease death according to patient characteristics among AYA women 
with cancers other than Non-Hodgkin lymphoma, 1985-2015 
  
Total person-
years    
Deaths Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) a 
Race/ethnicity     
Non-Hispanic White 1,441,573  672 1 1 
Non-Hispanic Black 196,682  282 3.24 (2.82, 3.73) 2.84 (2.46, 3.27) 
Hispanic 274,657  98 0.85 (0.69, 1.05) 0.82 (0.66, 1.02) 
Other non-Hispanic 180,900  86 1.07 (0.86, 1.34) 1.01 (0.80, 1.26) 
      
Geographic region     
West 1,080,253  461 0.84 (0.70, 1.02) 0.92 (0.76, 1.11) 
South 329,879  250 1.60 (1.31, 1.97) 1.35 (1.10, 1.67) 
Northeast 290,801  145 1 1 
Midwest 330,698  247 1.31 (1.07, 1.61) 1.23 (1.00, 1.52) 
      
% of persons below poverty      
Q1 956,002  475 1 1 
Q2 465,338  236 1.16 (0.99, 1.35) 1.17 (1.00, 1.38) 
Q3 398,929  269 1.56 (1.34, 1.81) 1.35 (1.15, 1.58) 
Q4 272,731  158 1.47 (1.22, 1.76) 1.37 (1.13, 1.66) 
      
% persons with <HS education      
Q1 995,397  523 1 1 
Q2 436,400  199 1.11 (0.93, 1.31) 1.13 (0.95, 1.34) 
Q3 332,767  265 1.78 (1.53, 2.07) 1.53 (1.31, 1.79) 
Q4 328,435  151 1.18 (0.98, 1.43) 1.24 (1.02, 1.52) 
      
Rural-urban continuum code b     
Metro 1,091,102  438 1 1 
Urban 77,613  45 1.45 (1.07, 1.97) 1.46 (1.07, 1.99) 
Rural 35,037  29 2.07 (1.42, 3.01) 2.17 (1.48, 3.17) 
      
            
a Adjusted for race/ethnicity, calendar year; cancer type and age are stratification variables 




Table 6.16 Hazard ratios for infectious disease death according to patient characteristics among AYA women with 
cancers other than Non-Hodgkin lymphoma, 1985-2015 
  
Total 
person-years    
Deaths Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) a 
Race/ethnicity      
Non-Hispanic White 1,441,573  306 1 1 
Non-Hispanic Black 196,682  221 5.03 (4.23, 5.99) 4.20 (3.52, 5.01) 
Hispanic 274,657  72 1.14 (0.88, 1.48) 1.02 (0.79, 1.33) 
Other non-Hispanic 180,900  54 1.35 (1.01, 1.80) 1.27 (0.95, 1.70) 
      
Geographic region      
West 1,080,253  254 0.62 (0.49, 0.77) 0.67 (0.53, 0.84) 
South 329,879  144 1.09 (0.85, 1.40) 0.83 (0.64, 1.07) 
Northeast 290,801  112 1 1 
Midwest 330,698  121 1.01 (0.78, 1.31) 0.84 (0.65, 1.10) 
      
% of persons below poverty      
Q1 956,002  275 1 1 
Q2 465,338  115 0.81 (0.65, 1.01) 0.81 (0.65, 1.01) 
Q3 398,929  168 1.33 (1.09, 1.61) 1.06 (0.86, 1.30) 
Q4 272,731  95 1.15 (0.91, 1.46) 0.98 (0.76, 1.25) 
      
% persons with <HS education      
Q1 995,397  287 1 1 
Q2 436,400  133 0.96 (0.78, 1.19) 1.02 (0.82, 1.27) 
Q3 332,767  152 1.43 (1.17, 1.74) 1.14 (0.92, 1.40) 
Q4 328,435  81 0.74 (0.58, 0.96) 0.77 (0.59, 1.01) 
      
Rural-urban continuum code b     
Metro 1,091,102  316 1 1 
Urban 77,613  20 0.90 (0.57, 1.41) 0.92 (0.59, 1.45) 
Rural 35,037  15 1.48 (0.88, 2.48) 1.62 (0.96, 2.74) 
      
            
a Adjusted for race/ethnicity, calendar year; cancer type and age are stratification variables 




Table 6.17 Hazard ratios for all noncancer deaths according to patient characteristics among AYA men with 
cancers other than Non-Hodgkin lymphoma, 1985-2015 
  
 Total person-years  
  
Deaths Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) a 
Race/ethnicity      
Non-Hispanic White 903,333  3311 1 1 
Non-Hispanic Black 73,023  853 3.09 (2.86, 3.33) 2.38 (2.20, 2.57) 
Hispanic 150,011  728 1.28 (1.18, 1.39) 1.26 (1.16, 1.37) 
Other non-Hispanic 73,717  287 1.04 (0.92, 1.17) 0.90 (0.79, 1.01) 
      
Geographic region     
West 645,009  2533 1.03 (0.94, 1.12) 1.07 (0.98, 1.17) 
South 169,763  983 1.50 (1.35, 1.65) 1.36 (1.22, 1.50) 
Northeast 165,616  634 1 1 
Midwest 186,245  878 1.23 (1.11, 1.36) 1.14 (1.03, 1.26) 
      
% of persons below poverty      
Q1 557,071  2070 1 1 
Q2 273,435  1150 1.13 (1.05, 1.22) 1.17 (1.09, 1.26) 
Q3 218,900  1154 1.39 (1.29, 1.49) 1.29 (1.20, 1.39) 
Q4 150,258  803 1.49 (1.37, 1.62) 1.41 (1.30, 1.54) 
      
% persons with <HS education      
Q1 581,538  2276 1 1 
Q2 252,910  1039 1.07 (0.99, 1.15) 1.12 (1.04, 1.21) 
Q3 180,340  979 1.37 (1.27, 1.48) 1.23 (1.14, 1.33) 
Q4 184,876  883 1.22 (1.13, 1.32) 1.25 (1.15, 1.37) 
      
Rural-urban continuum code b     
Metro 618,108  2356 1 1 
Urban 43,895  201 1.21 (1.04, 1.39) 1.25 (1.08, 1.45) 
Rural 19,943  125 1.64 (1.37, 1.96) 1.76 (1.47, 2.11) 
      
            
a Adjusted for race/ethnicity, calendar year; cancer type and age are stratification variables 




Table 6.18 Hazard ratios for cardiovascular disease death according to patient characteristics among AYA men 
with cancers other than Non-Hodgkin lymphoma, 1985-2015 
  
 Total person-years  
  
Deaths Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) a 
Race/ethnicity      
Non-Hispanic White 903,333  744 1 1 
Non-Hispanic Black 73,023  183 3.22 (2.73, 3.79) 2.37 (2.00, 2.80) 
Hispanic 150,011  131 1.18 (0.98, 1.42) 1.20 (0.99, 1.46) 
Other non-Hispanic 73,717  65 1.13 (0.87, 1.45) 0.98 (0.76, 1.26) 
      
Geographic region      
West 645,009  482 0.84 (0.70, 1.01) 0.89 (0.73, 1.07) 
South 169,763  218 1.54 (1.25, 1.90) 1.41 (1.14, 1.75) 
Northeast 165,616  147 1 1 
Midwest 186,245  239 1.31 (1.06, 1.60) 1.24 (1.01, 1.52) 
      
% of persons below poverty      
Q1 557,071  495 1 1 
Q2 273,435  227 1.04 (0.89, 1.22) 1.08 (0.92, 1.27) 
Q3 218,900  250 1.45 (1.25, 1.70) 1.34 (1.14, 1.57) 
Q4 150,258  151 1.38 (1.15, 1.67) 1.34 (1.10, 1.63) 
      
% persons with <HS education      
Q1 581,538  536 1 1 
Q2 252,910  204 1.08 (0.92, 1.28) 1.12 (0.95, 1.34) 
Q3 180,340  220 1.53 (1.30, 1.79) 1.35 (1.15, 1.60) 
Q4 184,876  163 1.24 (1.03, 1.49) 1.28 (1.05, 1.57) 
      
Rural-urban continuum code b     
Metro 618,108  421 1 1 
Urban 43,895  45 1.51 (1.11, 2.05) 1.58 (1.16, 2.15) 
Rural 19,943  27 1.99 (1.35, 2.93) 2.12 (1.43, 3.14) 
      
            
a Adjusted for race/ethnicity, calendar year; cancer type and age are stratification variables 




Table 6.19 Hazard ratios for infectious disease death according to patient characteristics among AYA men with 
cancers other than Non-Hodgkin lymphoma, 1985-2015 
  
 Total person-years  
  
Deaths Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) a 
Race/ethnicity      
Non-Hispanic White 903,333  584 1 1 
Non-Hispanic Black 73,023  296 5.44 (4.73, 6.26) 3.97 (3.43, 4.59) 
Hispanic 150,011  164 1.41 (1.19, 1.68) 1.57 (1.31, 1.88) 
Other non-Hispanic 73,717  54 1.01 (0.76, 1.34) 0.92 (0.69, 1.22) 
      
Geographic region     
West 645,009  542 1.12 (0.92, 1.36) 1.20 (0.99, 1.47) 
South 169,763  242 1.73 (1.39, 2.15) 1.46 (1.17, 1.82) 
Northeast 165,616  125 1 1 
Midwest 186,245  153 1.23 (0.97, 1.55) 0.94 (0.74, 1.20) 
      
% of persons below poverty      
Q1 557,071  383 1 1 
Q2 273,435  267 1.26 (1.08, 1.47) 1.43 (1.22, 1.68) 
Q3 218,900  272 1.50 (1.28, 1.75) 1.43 (1.22, 1.69) 
Q4 150,258  176 1.50 (1.25, 1.79) 1.50 (1.24, 1.82) 
      
% persons with <HS education      
Q1 581,538  477 1 1 
Q2 252,910  218 0.87 (0.74, 1.02) 1.04 (0.88, 1.24) 
Q3 180,340  218 1.20 (1.02, 1.42) 1.09 (0.92, 1.29) 
Q4 184,876  185 0.93 (0.78, 1.10) 1.12 (0.92, 1.36) 
      
Rural-urban continuum code b     
Metro 618,108  496 1 1 
Urban 43,895  33 0.94 (0.66, 1.34) 1.04 (0.73, 1.49) 
Rural 19,943  21 1.31 (0.84, 2.02) 1.61 (1.04, 2.51) 
      
            
a Adjusted for race/ethnicity, calendar year; cancer type and age are stratification variables 






CHAPTER 7. DISCUSSION 
7.1 Main findings 
 For our first aim, we examined noncancer mortality after AYA cancer among patients 
identified in the SEER database. Overall, mortality from noncancer causes among AYAs with 
cancer was 1.84 (95% CI: 1.80-1.87) times that in the general population, with adjustment for 
age, sex, race, and calendar year. Across cause-specific categories of noncancer death, 
standardized mortality ratios comparing AYAs with cancer to the general population were 
particularly elevated for infectious diseases, cardiovascular diseases, and renal diseases, and 
remained significantly increased for more than 20 years after cancer diagnosis. Cancer types 
associated with the highest SMRs for all noncancer mortality included leukemias, Hodgkin 
lymphoma, non-Hodgkin lymphoma, central nervous system tumors, head and neck cancers, and 
cervical/uterine cancers. 
 For our second aim, we investigated long-term patterns of noncancer mortality after AYA 
cancer and evaluated disparities according to race/ethnicity and other patient characteristics. For 
all cancer types combined, the 10-year cumulative incidence of noncancer death after AYA 
cancer was 2% and 5% among women and men, respectively. With adjustment for cancer type, 
all noncancer mortality was increased among non-Hispanic Black AYAs and those in the South 
or in rural counties. In analyses focused on mortality from cardiovascular and infectious 
diseases, Non-Hispanic Black race/ethnicity was associated with elevated mortality from both 
cardiovascular diseases and infectious diseases, while living in the South or in a rural county was 




 Taken together, these analyses suggest that AYAs with cancer have an elevated burden of 
mortality from noncancer causes, and identify subgroups at particularly increased risk. AYAs 
with hematologic malignancies, central nervous system tumors, head and neck cancers, and 
cervical/uterine cancers, and those who are non-Hispanic Black or diagnosed with cancer in the 
South or in rural areas may be priority groups for increased surveillance and/or behavioral 
interventions throughout survivorship. 
7.2 Strengths and limitations 
 This research utilized freely and publicly available data from SEER, the largest source of 
cancer incidence and mortality data in the U.S., to investigate noncancer deaths among AYAs 
with cancer. The long history of the SEER program, with data available from as early as the 
1970s, allowed us to evaluate whether the risk of death from noncancer causes remains elevated 
among AYA cancer survivors relative to the general population long after the cessation of cancer 
treatment. With information on race and county-level socioeconomic status, we were able to 
highlight potential disparities in noncancer mortality within a national sample of AYAs with 
cancer. 
 These analyses have several limitations, including those inherent to the use of data from 
cancer registries such as those in SEER. Cause of death information in SEER is ascertained from 
death certificates, and may be subject to misclassification. However, for several causes of death, 
including suicide[131] and coronary heart disease,[132] prior studies have suggested moderate to 
high concordance between cause of death codes abstracted from the death certificate and the gold 
standard measure of cause of death determination by a physician review panel.[131-133] In Aim 
1, we investigated the robustness of our SMR estimates to potential cause of death 




deaths to noncancer causes, AYAs with cancer would still experience a significantly elevated 
burden of noncancer deaths relative to the general population. An additional limitation is the lack 
of information on lifestyle factors, comorbidities, and individual-level socioeconomic status. 
These characteristics are not available in registry data, so we were unable to consider their 
impact on noncancer mortality risk in our analyses. Treatment information available in SEER is 
limited to crude categories indicating whether chemotherapy and/or radiation was received as 
part of the first course of therapy, thus precluding any analysis of associations between specific 
chemotherapeutic agents or targeted therapies, or radiation doses, and noncancer causes of death. 
Furthermore, prior research has suggested that the chemotherapy and radiation data that is 
available in SEER is of moderate validity,[143] and therefore we elected not to use this 
information in our analyses. However, though an imperfect proxy, our site-specific analyses 
according to cancer stage and time period of diagnosis may be informative for considering 
potential treatment-related effects on mortality, given fairly standardized treatment protocols for 
cancers of a particular stage within a given time period. 
7.3. Public health implications 
With >80% five-year relative survival for all cancer types combined, the vast majority of 
AYAs with cancer will go on to become long-term survivors, prompting the need for research on 
survivorship issues for patients diagnosed in this age range. This research estimated the extent to 
which mortality from cardiovascular diseases, infectious diseases, and other causes is greater 
among AYA cancer survivors than the general population, an important consideration for 
patients and physicians planning long-term follow-up care. We considered variability in 
noncancer mortality according to cancer type, time since diagnosis, and other factors to identify 




indicated. Our findings of long-term excess mortality for certain cancer types diagnosed at the 
older end of the AYA age range—particularly colorectal cancer, head and neck cancers, and 
cervical/uterine cancers—provide critical information for patient groups that have seldom been 
the focus of survivorship research. Additionally, our analyses according to race, county-level 
socioeconomic status, and other factors highlighted mortality disparities among AYA cancer 
survivors, with the potential to help motivate the direction of resources toward vulnerable patient 
subgroups. 
7.4 Future Directions 
Few large cohort studies to date have examined long-term health outcomes among AYA 
cancer survivors, and current guidelines for follow-up care for this age group continue to be 
based largely on findings from studies of patients diagnosed as children.[4] While our findings 
describe the burden of excess mortality from noncancer causes experienced by AYAs with 
cancer, we were unable to evaluate the potential contribution of cancer treatment-related 
exposures to this excess risk. Future AYA studies, with access to detailed cancer treatment 
information and long-term follow-up, should investigate patterns of noncancer morbidity and 
mortality from particular causes according to receipt of specific chemotherapeutic agents and 
chemo- and radiotherapy doses. For cancer types that span both the childhood and AYA age 
range, such as hematologic malignancies and central nervous system tumors, this would enable 
comparisons with findings from the Childhood Cancer Survivor Study and other large childhood 
cancer cohorts, and further our understanding of potential age-related differences in late effects 
of cancer treatments. For cancer types nearly exclusive to the older end of the AYA age range, 
such as breast cancer, colorectal cancer, and head and neck cancers, long-term health outcomes 




the development of age-appropriate guidelines for AYAs with these cancers. Such studies should 
also consider potential modification of noncancer morbidity and mortality risk according to 
patient factors such as race/ethnicity, comorbidities, family history, and health behaviors to 









Recode Primary Site ICD-O-3 Histology 
1 Leukemias 
   1.1 Acute lymphoid leukemia 3 C000-C809 9826,9835-9836 
  3 C420-C421,C424 9811-9818,9837 




   1.3 Chronic myeloid leukemia 3 C000-C809 9863,9875-9876,9945-9946 
   1.4 Other and unspecified     





  3 C420-C421,C424 98,239,827 
2 Lymphomas 







  3 C000-C419,C422-C423,C425-C809 9811-9818,9823,9827,9837 
   2.2 Hodgkin lymphoma 3 C000-C809 9650-9655,9659,9661-9665,9667 
3 CNS and Other Intracranial and Intraspinal Neoplasms (all behaviors) 
   3.1. Astrocytoma      
      3.1.1 Specified low-grade  
      astrocytic tumors 0,1,3 C723 9380 
  0,1,3 C000-C809 9410-9411,9420-9421,9424 
      3.1.2 Glioblastoma and  
      anaplastic astrocytoma 0,1,3 C000-C809 9401,9440-9442 
      3.1.3 Astrocytoma, NOS 0,1,3 C000-C809 9400 
   3.2 Other glioma 0,1,3 C000-C722,C724-C809 9380 
  0,1,3 C000-C809 9381-9384,9423,9430,9450-9451,9460 
   3.3 Ependymoma 0,1,3 C000-C809 9391-9394 
   3.4. Medulloblastoma and other  
   PNET 
     
      3.4.1 Medulloblastoma 0,1,3 C716 9470-9474 
      3.4.2 Supratentorial PNET 0,1,3 C000-C715,C717-C809 9470-9474 
   3.5 Other specified intracranial  






  0,1,3 C700-C729,C751-C753 9161,9361-9362,9390,9530-9531,9535,9538,9540,9560,9571 
  0,1,3 C700 9,532,953,495,379,530 
  0,1,3 C753 9360 




  0,1,3 C713 94,809,533 
  0,1,3 C719 9350 
  0,1,3 C714,C717 9480 
  0,1,3 C709 9539 
   3.6 Unspecified intracranial and  
   intraspinal neoplasms 
     
      3.6.1 Unspecified malignant  
      intracranial and intraspinal  
      neoplasms 
3 C700-C729,C751-C753 8000-8005 
      3.6.2 Unspec. ben/border  
      intracran. and intraspin. Neo. 0,1 C700-C729,C751-C753 8000-8005 
4 Osseous & Chondromatous Neoplasms 
   4.1 Osteosarcoma 3 C000-C809 9180-9187,9192-9194 
   4.2 Chondrosarcoma 3 C000-C809 9220-9221,9230-9231,9240,9242-9243 
   4.3 Ewing tumor 3 C000-C809 9260,9364-9365 
   4.4 Other specified and  
   unspecified bone tumors 3 C000-C809 8812,9250,9261,9370-9372 
  3 C400-C419 8000-8005,8800-8803,8805-8806,9200 
5 Soft Tissue Sarcomas 




   5.2 Rhabdomyosarcoma 3 C000-C809 8900-8904,8910,8912,8920-8921,8991 
   5.3 Other soft tissue sarcoma      
      5.3.1 Specified soft tissue  
      sarcoma 
     
         5.3.1.1 Specified (excluding  





  3 C000-C699,C730-C750,C754-C809 954,095,609,571 
         5.3.1.2 Kaposi sarcoma 3 C000-C809 9140 
      5.3.2 Unspecified soft tissue  
      sarcoma 3 C000-C399,C420-C809 8800-8803,8805-8806 
6 Germ Cell and Trophoblastic Neoplasms 
   6.1 Germ cell and trophoblastic  
   neoplasms of gonads 3 C569,C620-C629 
9060-9065,9070-9073,9080-
9085,9090-9091,9100-9102,9105 
   6.2 Germ cell and trophoblastic  
   neoplasms of nongonadal sites 
     
      6.2.1 Intracranial (all  
      behaviors) 0,1,3 C700-C729,C751-C753 
9060-9065,9070-9073,9080-
9085,9090-9091,9100-9102,9105 







7 Melanoma and Skin Carcinomas 
   7.1 Melanoma 3 C000-C809 8720-8723,8726,8728,8730,8740-8746,8761,8770-8774,8780 





   8.1 Thyroid carcinoma 3 C739 8010-8589 
   8.2 Other carcinoma of head  
   and neck 
     
      8.2.1 Nasopharyngeal  
      carcinoma 3 C110-C119 8010-8589 
      8.2.2 Other sites in lip, oral  
      cavity and pharynx 3 C000-C109,C120-C148 8010-8589 
      8.2.3 Nasal cav,mid ear,  
      sinuses, larynx, other ill- 
      defined head/neck 
3 C300-C329,C760 8010-8589 
   8.3 Carcinoma of  
   trachea, bronchus, and lung 3 C330-C349 8010-8589 
   8.4 Carcinoma of breast 3 C500-C509 8010-8589 
   8.5 Carcinoma of genitourinary  
   tract 
     
      8.5.1 Carcinoma of kidney 3 C649 8010-8589 
      8.5.2 Carcinoma of bladder 3 C670-C679 8010-8589 
      8.5.3 Carcinoma of gonads 3 C569,C620-C629 8010-8589 
  3 C000-C809 8590-8593 
      8.5.4 Carcinoma of cervix and  
      uterus 3 C530-C559 8010-8589 
      8.5.5 Carcinoma of other and  
      ill-defined sites, genitourinary  







   8.6 Carcinoma of  
   gastrointestinal tract 
     
      8.6.1 Carcinoma of colon and  
      rectum 3 C180-C218 8010-8589 
      8.6.2 Carcinoma of stomach 3 C160-C169 8010-8589 
      8.6.3 Carcinoma of liver and  
      intrahepatic bile ducts 3 C220-C221 8010-8589 
      8.6.4 Carcinoma of pancreas 3 C250-C259 8010-8589 
      8.6.5 Carc other and ill-def  





   8.7 Carcinoma of other and ill- 
   defined sites 
     
      8.7.1 Adrenocortical  
      carcinoma 3 C740-C749 8010-8589 
      8.7.2 Carcinoma of other and  









  3 C809 9010 
9 Miscellaneous specified neoplasms, NOS 
   9.1 Other pediatric and  
   embryonal tumors, NOS 




      9.1.1 Wilms tumor 3 C000-C809 8959-8960 
      9.1.2 Neuroblastoma 3 C000-C809 94,909,500 
      9.1.3 Other pediatric and  
      embryonal tumors, NOS 3 C000-C809 
8963-8964,8970-
8973,8981,9363,9501-9523 
   9.2 Other specified and  
   embryonal tumors, NOS 
     
      9.2.1 Paraganglioma and  
      glomus tumors 3 C000-C809 8680-8711 
      9.2.2 Other specified gonadal  
      tumors 3 C000-C809 8600-8650,9000 
  3 C569 8670,9013-9015,9054 
      9.2.3 Myeloma, mast cell,  
      misc. lymphoreticular neo.,  





      9.2.4 Other specified  






  3 C000-C699,C730-C750,C754-C809 9161 










APPENDIX 2. NONCANCER CAUSE OF DEATH CLASSIFICATION IN SEER 
 
Noncancer Causes of 
Death ICD-8 (1968-1978) ICD-9 (1979-1998) ICD-10 (1999+) 
Infectious diseases 
Tuberculosis 010-018 010-018 A15-A19 
Syphilis 090-097 090-097 A50-A53 
Septicemia 38 38 A40-A41 
Other Infectious and  
Parasitic Diseases  
(including Human  
Immunodeficiency  
Virus [HIV] [1987+]) 
001-009, 020-037, 039-








A00-A08, A20-A33, A35-A39, 
A42-A49, A54-B19, B25-B99; 
 
B20-B24 (HIV) 
Pneumonia and  
Influenza 
470-474, 480-486 480-487 J09-J18 
Cardiovascular diseases 
Diseases of Heart 390-398, 402, 404, 410-
429 
390-398, 402, 404, 410-
429 
I00-I09, I11, I13, I20-I51 
Hypertension without  
Heart Disease 
400-401, 403 401, 403 I10, I12 
Cerebrovascular  
Diseases 
430-438 430-438 I60-I69 
Atherosclerosis 440 440 I70 
Aortic Aneurysm and  
Dissection 
441 441 I71 
Other Diseases of  
Arteries, Arterioles,  
Capillaries 
442-448 442-448 I72-I78 
Respiratory 
Chronic Obstructive  
Pulmonary Disease  
and Allied Cond 
490-493, 519.3 490-496 J40-J47 
Gastrointestinal and liver 
Stomach and  
Duodenal Ulcers 
531-533 531-533 K25-K28 
Chronic Liver Disease  
and Cirrhosis 
571 571 K70, K73-K74 
Renal 
Nephritis, Nephrotic  




580-589 N00-N07, N17-N19, N25-N27 
External causes 
Accidents and  





Suicide and Self- 
Inflicted Injury 950-959 950-959 
U03, X60-X84, Y87.0 
Homicide and Legal  
Intervention 960-978 960-978 
U01-U02, X85-Y09, Y35, 
Y87.1, Y89.0 
Other  
Diabetes Mellitus 250 250 E10-E14 
Alzheimers (ICD-9  
and 10 only) 
N/A 331 G30 
Complications of  
Pregnancy, Childbirth,  
Puerperium 
630-678 630-676 A34, O00-O95, O98-O99 
Congenital Anomalies 740-759 740-759 Q00-Q99 
Certain Conditions  
Originating in  
Perinatal Period 
760-779 760-779 P00-P96 
Symptoms, Signs and  
Ill-Defined Conditions 
780-796 780-799 R00-R99 
Other Cause of Death -- -- -- 
In situ, benign or  
unknown behavior  
neoplasm 
208-239 210-237, 238.0-238.5, 
238.7-238.9, 239 
D00-D48 
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